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ABSTRACT 
 
Bcl-xL is an anti-apoptotic protein that is frequently found to be overexpressed in lung 
adenocarcinoma leading to an inhibition of apoptosis and associated with poor 
prognosis of this disease. Recently, the roles of microRNAs (miRNAs) in regulating 
apoptosis and cell survival during tumorigenesis have become evident, with cancer cells 
showing perturbed expression of various miRNAs. In this project, we utilized miRNA 
microarrays to determine if miRNA dysregulation in bcl-xL silenced A549 lung 
adenocarcinoma cells could be involved in apoptotic behavior. Data from qRT-PCR and 
Western blotting indicated that a siRNA-based transfection induced a decrease of bcl-xL 
expression in A549 cells at both the gene and protein level, resulting in a decrease in 
cell viability. MiRNA microarray revealed that a total of 10 miRNAs were found to be 
significantly differentially expressed between bcl-xL silenced A549 cells and non-
transfected cells. qRT-PCR validation of the miRNA microarray results indicated that 
there was a strong positive correlation between the two sets of data. Bioinformatics 
analysis demonstrated that the differentially expressed miRNAs were found to be 
involved in several signaling pathways, primarily the PI3K/AKT, intrinsic and extrinsic, 
WNT, TGF-, and the MAPK pathway. Based on this, a hypothetical pathway 
illustrating the interactions between these miRNAs with their specific targets were 
generated describing the effects of bcl-xL silencing on initiation of apoptosis in A549 
cells. In conclusion, this study demonstrated that bcl-xL silencing in A549 lung 
adenocarcinoma cells leads to the occurrence of apoptosis through the dysregulation of 
specific miRNAs. With further studies carried out to determine the true targets and 
functions of these miRNAs, our study provided a platform for antisense treatment 
whereby miRNA expression can be exploited to increase the apoptotic properties in 
lung adenocarcinoma cells.  
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ABSTRAK 
 
Bcl-xL merupakan protein anti-apoptosis yang kerap didapati dalam sel-sel 
adenokarsinoma peparu yang menyebabkan perencatan apoptosis serta prognosis tidak 
baik. MicroRNAs (miRNAs) telah dilaporkan untuk memainkan peranan dalam 
pengawalan apoptosis dalam tumorigenesis, dan sel-sel kanser berkeupayaan untuk 
memanipulasi miRNAs untuk mengawal selia penghidupan sel dalam oncogenesis. 
Dalam projek ini, kami menggunakan miRNA microarray untuk menentukan peranan 
yang dimainkan oleh miRNAs dalam aspek apoptosis sel-sel adenokarsinoma peparu, 
A549, sebagai tindak balas terhadap pendiaman bcl-xL. Data daripada qRT-PCR dan 
pemblotan Western menunjukkan bahawa transfeksi dengan siRNA mengurangkan 
ekspresi bcl-xL dalam sel-sel A549 ditahap gen dan protein. MiRNA microarray 
mendedahkan bahawa sejumlah 10 miRNAs yang diekspreskan berlainan signifikan 
antara sel-sel A549 di mana bcl-xL-nya didiamkan dan sel-sel A549 yang tidak 
ditransfect. Keputusan miRNA microarray disahkan dengan qRT-PCR dan ia 
menunjukkan korelasi positif yang kukuh antara dua set data ini. Analisis bioinformatik 
menunjukkan bahawa miRNAs yang diekspreskan berlainan didapati terlibat dalam 
beberapa laluan; terutamanya laluan PI3K/AKT, intrinsik dan extrinsik, WNT, TGF-, 
dan MAPK. Satu laluan hipotetikal telah dibentuk untuk menerangkan interaksi antara 
miRNAs dengan sasaran gen mereka. Laluan hipotetikal ini menggambarkan kesan 
mendiamkan ekspresi bcl-xL ke atas apoptosis di dalam sel-sel A549. Kesimpulannya, 
kajian ini telah menunjukkan bahawa pendiaman ekspresi bcl-xL dalam sel-sel 
adenokarsinoma peparu membawa kepada kejadian apoptosis melalui perancatan 
pengawal aturan miRNAs. Kajian kami telah menyediakan dataran untuk rawatan 
antisense, dimana ekspresi miRNA boleh dieksploitasikan untuk meningkatkan 
apoptosis dalam sel-sel adenokarsinoma peparu.  
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CHAPTER 1: INTRODUCTION 
 
Lung cancer remains a major health problem worldwide. In 2008, lung cancer 
was the most commonly diagnosed cancer as well as the leading cause of cancer deaths 
in males worldwide (Jemal et al., 2011). Among females, lung cancer was the fourth 
most commonly diagnosed cancer and the second leading cause of cancer death (Jemal 
et al., 2011). 13% (1.6 million) of the total cases and 18% (14 million) of the deaths in 
2008 was caused by lung cancer (Jemal et al., 2011). In Malaysia, lung cancer accounts 
for 10.2% of all cancer deaths, making it the most common cancer followed by colon 
and then breast cancer (Zainal and Nor Saleha, 2011) with adenocarcinoma being the 
most common cell type (Liam et al., 2006).  
 In contrast to normal cells, cancer cells have the ability to disrupt the balance 
between pro- and anti-apoptotic factors to promote cell survival under the conditions of 
environmental stress. In terms of molecular events occurring in tumors, evasion of 
apoptosis is an important hallmark of tumor progression. Members of the evolutionarily 
conserved B-cell lymphocyte 2 (Bcl-2 family) are thought to be the central regulators of 
apoptosis. The expression level of Bcl-2 differs for different cell types, however high 
levels and aberrant patterns of Bcl-2 expression have been reported in a wide variety of 
human cancers (Hockenberry et al., 1991). Elevation of Bcl-2 protein expression 
contributes not only to the development of cancer but also to resistance against a wide 
variety of anti-cancer agents (Miyashita and Reed, 1993; Fisher et al., 1993; Tang et al., 
1994). However, studies conducted on non-small cell lung cancer (NSCLC), which 
accounts for the majority of lung cancer cases (Liam et al., 2006), have shown that the 
expression of Bcl-2 is either very low or even absent (Daniel and Smith, 2004). Instead, 
the expression of B-cell lymphocyte xL (bcl-xL), the other major prototype of the anti-
apoptotic Bcl-2 gene, is shown to be over-expressed in NSCLC (Soini et al., 1999). 
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Over-expression of Bcl-xL inhibits apoptosis in NSCLC and has been coupled with 
poor prognosis of this disease (Soini et al., 1999).  
 Over-expression of Bcl-xL has been shown to counteract the pro-apoptotic 
functions of Bcl-2-associated X protein (Bax) and Bcl-2-associated death promoter 
(Bad) by preventing their translocation from the cytosol to the mitochondria. This 
inhibits apoptosis by maintaining the permeabilization status or stabilization of the outer 
mitochondrial membrane, which subsequently prevents cytochrome c release and pro-
caspase-9 activation (Gottlieb et al., 2000). 
MicroRNAs (miRNAs) are small non-coding RNA of about 19-23 nucleotides 
long that regulate gene expression post-transcriptionally, by either inhibiting mRNA 
translation or by inducing mRNA degradation (Bartel, 2004). These regulatory elements 
play a role in a wide range of biological processes including cell proliferation 
(Hayashita et al., 2005), differentiation (Shivdasani, 2006) and apoptosis (Mott, 2007). 
Therefore a disturbed miRNA function or altered miRNA expression may disorganize 
cellular processes and eventually cause or contribute to disease, including cancer 
(Weimer, 2007).  
 MiRNAs are critical apoptosis regulators in tumorigenesis, and cancer cells are 
able to manipulate miRNAs to regulate cell survival in oncogenesis. For example, miR-
133 acts as a regulator of survival in cardiac cells by repressing caspase-9 expression at 
both protein and mRNA levels (Xu et al., 2007), while the miR-17-92 cluster, which is 
amplified in B-cell lymphomas, is capable of inhibiting apoptosis by negatively 
regulating the tumor suppressor phosphatase and tensin homolog (PTEN) and the pro-
apoptotic protein B-cell lymphocyte 11 (Bim) (Xiao et al., 2008).  
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While many miRNAs have been identified to be dysregulated in cancers, their 
specific functions remain unclear due to the nonspecific binding properties of each 
individual miRNA. As the miRNA field continues to evolve and develop it is important 
to gain a better understanding of miRNA biogenesis and function, as it will certainly 
affect the development of miRNA-based therapies. Therefore, this study describes the 
siRNA-based silencing of the anti-apoptotic bcl-xL gene, followed by the establishment 
of a global miRNA expression profile through the comparison between silenced and 
non-silenced cells. It is hypothesized that bcl-xL silencing in A549 cells would result in 
different miRNA expression patterns which could potentially be used for antisense gene 
therapeutic applications in NSCLC.  
 
1.1 Study Objectives 
 
i. To investigate the apoptotic effects of bcl-xL silencing in A549 cells.  
 
ii. To observe the global miRNA expression profile in bcl-xL silenced A549 cells. 
 
iii. To predict and identify the target genes of selected miRNAs dysregulated in bcl-
xL silenced A549 cells.  
 
iv. To identify the potential role(s) of the dysregulated miRNAs in various signaling 
pathways in bcl-xL silenced A549 cells.  
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CHAPTER 2: LITERATURE REVIEW 
 
2.1 Cancer 
 
Cancer is a genetic disease that occurs when various mutations take place in 
specific genes. These mutations may enhance the effects of normal genes that control 
cell growth, survival and spread, while the genes that suppress these effects may be 
inhibited. Dysregulated gene expressions leads to a number of important changes in the 
fundamental biological processes within cancer cells, termed the hallmarks of cancer 
(Hannahan & Weinberg, 2011). The “hallmarks of cancer” are traits that are acquired by 
cancer cells to enable them to become tumorigenic and ultimately malignant. These 
hallmarks of cancer include growth factor independence, insensitivity to anti-growth 
signals, avoidance of apoptosis, sustained angiogenesis, cellular immortalization, and 
tissue invasion and metastasis (Hannahan & Weinberg, 2011).  
 
Figure 2.1: The hallmarks of cancer (Figure adapted from Hanahan & Weinberg, 2000). 
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2.1.1 Hallmarks of Cancer 
 
Growth factor independence: Independence of growth factors allows the cells to have 
sustained signaling in pathways that control essential biological functions such as 
growth, apoptosis, angiogenesis, invasion and DNA damage repair (Harrington, 2007). 
Cancer cells use three main strategies to attain self-sufficiency in growth factors. The 
first strategy is to produce and release growth factors that stimulate their own receptors 
(autocrine signaling) and those of neighboring cells (paracine signaling). Secondly, they 
can alter the number, structure or function of the growth factor receptors on their 
surface, thus making them more likely to send a growth signal to the nucleus. Thirdly, 
cancer cells can deregulate signaling pathways downstream of the growth factor 
receptor, making them permanently turned on (Hanahan & Weinberg, 2011; Harrington, 
2007).  
 
Insensitivity to anti-growth signals: Anti-growth signals function by forcing the cells 
into quiescence (G0 stage of the cycle) or by inducing terminal differentiation so that the 
cells are unable to enter the cell cycle (Hanahan & Weinberg, 2011). Ligands mediate 
anti-growth signaling and these pathways are involved in controlling the cell cycle 
clock. Their effects are mediated through various proteins, which include 
retinoblastoma protein (Rb), cyclins, cyclin-dependant kinase (CDK) and their 
inhibitors (CDKI) (Hannon and Beach, 1994;). Dysregulation of the anti-growth 
signaling pathways play a role in aiding the cancer cells to progress through the cell 
cycle.  
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Avoidance of apoptosis: The balance between anti-apoptotic and pro-apoptotic signals 
are continually assessed in normal cells. In normal cells, DNA damage will lead to cell 
cycle arrest while the potential for repair is evaluated.  If the amount of damage 
surpasses the ability of the cells to repair, the balance of the anti- and pro-apoptotic 
signals will tip and the cell undergo apoptosis (Harrington, 2007). Dysregulation of 
normal apoptotic pathway signaling is common in cancer (Ker et al., 1972). Due to their 
ability to ignore signals that are sent through the extrinsic pathway, cancer cells are able 
to avoid apoptosis. Also, cancer cells have the ability to re-set the balance of 
intracellular pro- and anti-apoptotic molecules in favor of inhibition of apoptosis 
(Hannahan and Weinberg, 2011; Harrington, 2007).  
 
Sustained angiogenesis: A good source of blood supply is essential to the survival and 
growth of cancer cells. Cancer cells can grow to 60-100m by obtaining a supply of 
oxygen and nutrients through direct diffusion (Hannahan and Weinberg, 2011). 
However, beyond this size the tumor must obtain its own dedicated blood supply 
(Bouck et al., 1996; Hanahan and Folkman, 1996) By overthrowing the balance 
between pro- and anti-angiogenic factors, cancer cells can acquire the ability to grow a 
new blood supply. For example, this can be carried out through up-regulation of the 
production of pro-angiogenic proteins such as vascular endothelial growth factor 
(VEGF) and downregulation of the production of anti-angiogeneic proteins such as 
thrombospondin-1 (Bull et al., 1994).   
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Cellular immortalization:  Malignant cells can acquire immortality through the 
maintenance of the length of their telomeres. In contrast, normal cells can only undergo 
a finite number of cell division before they enter a period of permanent growth arrest, 
due to their inability to replicate their telomeres fully at each division (Hanahan and 
Weinberg, 2011). Cancer cells do this through either the up-regulation of the enzyme 
telomerase or by a mechanism called alternative lengthening of the telomeres (ALTs) 
(Harrington, 2007).  
 
Invasion and metastasis: Dissemination of cancer cells into the circulation involves 
various biological processes. At the local site, the cells must first undergo detachment 
from their immediate neighbors and stroma (Hannahan and Weinberg, 2011). Cohesion 
to the primary tumor mass is mediated by active homotypic cell adhesion molecules 
(CAMs) (Aplin et al., 1998). Downregulation of the cadherin family of cell surface 
receptors results in the loss of tissue integrity and is responsible for the breakdown of 
tissue architecture and allows for the escape of individual cells (Hart, 2004). Once the 
cancer cells have penetrated into the blood of lymphatic vessels, they must survive in 
the circulation until they arrive at the metastatic site. At its destination, they will adhere 
to the endothelium of blood cells and extravasate from the vessel. At this site, the cancer 
cells will begin to proliferate and set about constructing a new blood supply (Hannahan 
& Weinberg, 2011).  
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2.1.2 Cancer Statistics 
 
 Cancer is a major burden of disease worldwide. Yearly, tens of millions of 
people are diagnosed with cancer, and eventually more than half of the patients would 
die from it. Worldwide, cancer ranks as the second most common cause of death 
following cardiovascular diseases (Ma & Yu, 2006). However due to the vast 
improvement in the treatment and prevention of cardiovascular diseases, cancer has or 
will become the number one killer in the world (Ma & Yu, 2006).  
 GLOBOCAN, a Windows based software, provides access to a global cancer 
incidence and mortality rates data (International Agency for Research on Cancer, 2008). 
Based on the GLOBOCAN database, there were about 12,662,600 new cancer cases in 
the world in 2008. Of these, 52.3% were male and 47.7% were female (International 
Agency for Research on Cancer, 2008). For males and females combined, the most 
common cancer site worldwide was lung. The second most common site was breast, 
followed by colon. For women, the number one cancer site was breast followed by 
colon and cervix. Among men, the three most common cancer sites were lung, prostate 
and colon (Jemal et al., 2011). In Malaysia, for males and females combined, the most 
common cancer site, for the year 2008, was lung followed by colon and then breast 
(International Agency for Research on Cancer, 2008). 
The number of deaths caused by cancer worldwide in 2008 was 7,564,800 
among which 4,219,600 were males and 3,345,200 were females. Lung cancer led to the 
most cancer deaths in the world. The second on the list was breast followed by 
colorectum. Similarly, in Malaysia, lung cancer led to the most cancer deaths in the 
country. This was followed by colon cancer and then breast cancer (International 
Agency for Research on Cancer, 2008). 
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Figure 2.2: Worldwide incidence and mortality of cancers in males and females 
combined, in 2008 (Figure adapted from International Agency for Research on Cancer, 
2008).  
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Figure 2.3: Malaysian population’s incidence and mortality of cancers in males and 
females combined, in 2008 (Figure adapted from International Agency for Research on 
Cancer, 2008).  
 
2.2 Lung Cancer 
 
 Lung cancer is a disease that is associated with the uncontrolled cell growth in 
tissues of the lung (Collins et al., 2007). The vast majority of primary lung cancers are 
carcinomas, which are derived from epithelial cells (The Merck Manuals Online 
Medical Library, 2009). Lung cancer can be characterized into two main groups based 
upon the size and appearance of malignant cells: small cell lung cancer (SCLC) and 
non-small cell lung cancer (NSCLC) (The Merck Manuals Online Medical Library, 
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2009). NSCLC includes squamous cell carcinoma, adenocarcinoma, large-cell 
undifferentiated carcinoma, as well as some rare subtypes such as adenosquamous cell 
carcinoma, coepidermoid carcinoma, and adenoid cystic carcinoma (The Merck 
Manuals Online Medical Library, 2009).  
 
2.2.1 Lung Cancer Subtypes 
 
 SCLC accounts for 20% of lung cancer and it is highly aggressive and is most 
strongly associated with smoking (The Merck Manuals Online Medical Library, 2009). 
SCLC usually grows in the submucosa of the airways. It is rapidly growing and about 
60% of patients have widespread metastatic disease at the time of diagnosis cancers 
(The Merck Manuals Online Medical Library, 2009). 
NSCLC has a more variable clinical behavior and depends on histologic type. 
About 40% of patients have metastatic disease outside of the chest at the time of 
diagnosis. NSCLC accounts for approximately 75-80% of all lung cancers (The Merck 
Manuals Online Medical Library, 2009). Lung adenocarcinoma normally begins in the 
tissues near the outer parts of the lungs and is usually present for a long time prior to the 
onset of symptoms. Lung adenocarcinoma is the most common form of lung cancer 
found in women, and is largely associated with non-smokers. As lung adenocarcinoma 
occurs in the outer parts of the lung, common symptoms of this type of cancer include 
chronic cough and coughing up of blood (The Merck Manuals Online Medical Library, 
2009). 
Squamous cell cancer of the lung occurs in about a quarter of all lung cancer 
patients and is normally located near the central bronchus. Squamous cell carcinomas 
are strongly linked with smoking. However, the incidence of this type of cancer has 
decreased since filtered cigarettes have become available and the smoke is inhaled more 
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deeply into the lungs, the region where adenocarcinoma begins (The Merck Manuals 
Online Medical Library, 2009). Squamous cell lung cancer is less aggressive and grows 
more slowly. Due to the location of this type of cancer, it is often found earlier than 
other forms of lung cancer (The Merck Manuals Online Medical Library, 2009). 
Large cell carcinoma is the least common form of NSCLC, occurring in 10-15% 
of patients, and can start in any part of the lung (The Merck Manuals Online Medical 
Library, 2009). This type of carcinoma occurs in the outer regions of the lungs and 
tends to grow and spread quickly (The Merck Manuals Online Medical Library, 2009). 
Because large cell carcinomas are often found in the outer regions of the lungs, they can 
cause fluid to develop in the space between the tissues that line the lung, invading into 
the chest wall. This can cause pain in the chest or side, which worsens with a deep 
breath (The Merck Manuals Online Medical Library, 2009).  
 
2.2.2 Etiology of Lung Cancer  
 
 There are numerous risk factors for lung cancer, and these risk factors can be 
grouped into two broad categories: factors that are inherent to the individual (intrinsic 
factors) and factors that are extraneous to the individual (extrinsic or environmental 
factors). The former category includes intrinsic features such as genetic susceptibility, 
family history of cancer, sex, race, age and previous respiratory diseases, while the 
latter category includes extrinsic aspects such as tobacco use, diet, occupation and 
environmental pollution (Ruano-Ravina et al., 2003).  
The most important environmental carcinogen that has been linked to lung 
cancer is tobacco smoke (Miller, 2005). Tobacco was used for many centuries prior to 
the modern epidemic of lung cancer. However, tobacco products only become more 
widely and intensively used with the development of machines for the commercial 
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production of cigarettes in the late nineteenth century (Miller, 2005). As early as the 
1920s, tobacco smoke was suspected to cause lung cancer, when physicians began to 
see an increase in the number of patients with lung cancer, and discovered that nearly 
all were cigarette smokers (Witschi, 2001). Today, the most important cause of lung 
cancer is still cigarette smoking, which accounts for 85% of lung cancer cases (Hecht, 
1999). Due to the complexity of tobacco smoke, the mechanism by which it causes lung 
cancer is still unknown. Among the many components of tobacco smoke, there have 
been about 55 carcinogens that have been closely linked to lung tumors in laboratory 
animals or humans and are therefore likely to be involved in lung cancer induction 
(Hecht, 1999). 
The risk of cancer differs by age, smoking intensity and smoking duration. 
However, about 15% of people who develop lung cancer have never smoked. Studies 
have reported that lung cancer patients who have never smoked have genetic mutations 
in the epidermal growth factor gene (EGF) (Miller, 2005).  
Various other environmental carcinogens include pollution from motor vehicle 
exhaust fumes, heating systems, power stations and other industrial emissions, such as 
asbestos, radiation, arsenic chromates, nickel, chloromethyl ethers, mustard gas or coke-
oven emissions (Ruano-Ravina et al, 2003; The Merck Manuals Online Medical Library, 
2009). The respiratory epithelial becomes neoplastic only after prolonged exposure to 
cancer-promoting agents and accumulation of multiple genetic mutations. Mutations in 
genes that stimulate cell growth may cause abnormalities in growth factor receptor 
signaling inhibit apoptosis and contributes to the proliferation of abnormal cells. In 
addition, mutations that inhibit the tumor suppressor genes can also lead to cancer (The 
Merck Manuals Online Medical Library, 2009).  
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In terms of intrinsic factors, the highest incidence of lung cancer occurs at 
around 65 years of age (Ruano-Ravina et al., 2003). This finding allows for a strong 
link to be made between lung cancer and tobacco use, as it takes into account the 
required induction time for the habit of smoking to exert its effects (Ruano-Ravina et al., 
2003). Studies have shown that incidence of lung cancer declines after the age of 80 
years. This can be due to two possible reasons: a lower prevalence of smoking habit 
amongst the older age group; or a bias of survival effect due to the fact that people who 
reach such ages are in some way genetically resistant to certain risk factors (Parkin et 
al., 1996). 
 
2.2.3 Epidemiology of lung cancer 
 
 In 2008, lung cancer was the most commonly diagnosed cancer as well as the 
leading case of cancer deaths in males worldwide. Among females, lung cancer was the 
fourth most commonly diagnosed cancer and the second leading cause of cancer death 
(Jemal et al., 2011). 13% (1.6 million) of the total cases and 18% (14 million) of the 
deaths in 2008 was caused by lung cancer. The highest lung cancer incidence rates in 
males occurs in Eastern and Southern Europe, North America, Micronesia and 
Polynesia, and Eastern Asia, while the rates in sub-Saharan Africa are low (Jemal et al., 
2011). On the other hand, for females, the highest lung cancer incidence rates are found 
in North America, Northern Europe, and Australia/New Zealand (Jemal et al., 2011). 
The differences in lung cancer rates and trends that are observed across countries or 
between males and females within each country are largely due to the differences in the 
stage and degree of the tobacco epidemic. Smoking accounts for 80% of the worldwide 
lung cancer burden in males and 50% of the lung cancer burden in females (Jemal et al., 
2011).  
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In Malaysia lung cancer is the leading cause of cancer deaths, accounting for 
19.8% of all cancer deaths. Lung cancer accounts for 13.8% of all cancers in males and 
3.8% of all cancers in females (National Cancer Registry, 2008). In a study conducted 
by Liam et al., a comparison was made between patients with lung cancer diagnosed at 
the University of Malaya Medical Centre, Kuala Lumpur, Malaysia, from October 1991 
to September 1999, with another group of lung cancer patients diagnosed at the same 
hospital during an earlier period of 1967-1976 (Liam et al., 2006; Menon & Saw, 1979). 
This study was conducted to determine whether there had been a change in the 
distribution of lung cancer types. It was found that in the recent period, the percentage 
of patients with adenocarcinoma had increased significantly to 34.2% from 25.2%, 
while that of the large cell carcinoma had decreased to 3.3% from 11.9% (Liam et al., 
2006). The percentage of patients with squamous cell carcinoma (SCC) and SCLC 
remained stable. In the period of 1967-1976, SCC was the predominant cell type in men, 
while adenocarcinoma was the main cell type in women. In the period of 1991-1999, it 
was found that adenocarcinoma was the most common cell type in both men and 
women (Liam et al., 2006).  
 
2.2.4 Pathogenesis of Lung Cancer 
 
 Lung cancer is the end result of a multi-step carcinogenesis, that is, in most 
cases driven by the genetic and epigenetic damage that is caused by prolonged exposure 
to tobacco smoke carcinogens (Fong et al., 1999). There are two levels of genetic 
instability that can be seen in human cancers: the chromosomal level, which includes 
large-scale losses and gains, and the nucleotide level, which includes single or several 
base changes (Fong et al., 1999). In lung cancer, many numeric chromosome 
abnormalities (aneuploidy) and structural cytogenetic abnormalities, which include 
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deletions and nonreciprocal translocations, occur. The chromosomal instability that 
leads to aneuploidy is strongly associated with the loss of function of a mitotic 
checkpoint (Fong et al., 1999). However, how exactly this loss occurs in lung cancer is 
not known.  
There are at least three classes of cellular genes involved in cancers: proto-
oncogenes, tumor suppressor genes (TSGs), and DNA repair genes (Fong et al., 1999). 
Studies have shown alterations in simple repeat sequences in lung cancer. The 
phenotype that is seen in lung cancers appears to be different from the typical 
replication error repair (RER+) phenotype that is seen in tumors with mutations in DNA 
mismatch repair genes. This instability affects a small proportion of markers, which 
causes a single “shift” of individual allelic bands, and is thus referred to as 
“microsatellite alteration” (Fong et al., 1999). These microsatellite alteration 
frequencies have been reported in around 35% of SCLCs and 22% of NSCLCs (Sekido 
et al., 1998), and have been reported to be associated with reduced survival and 
advanced tumor stage (Rosell et al., 1997). 
There are various specific molecular alterations that occur in lung cancer. For 
example, NSCLC demonstrate abnormalities of the neuregulin receptors ERBB2 
(human epidermal growth factor receptor 2) and ERBB1 (epidermal growth factor 
receptor), which are a family of transmembrane receptor tyrosine kinases (Weiner et al., 
1990). Upon ligand binding, the ERBB receptors homodimerize or heterodimerize, 
thereby inducing intrinsic kinase activities which in turn initiate intracellular signal 
transduction cascades including the mitogen-activated protein (MAP) kinase pathway 
(Weiner et al., 1990; Rachwal et al., 1995). High levels of ERBB2 levels have been 
associated with the multiple drug resistance phenotype and increased metastatic 
potential (Yu et al., 1994). The ERBB1 regulates epithelial proliferation and 
differentiation, and studies have shown ERBB1 to be activated in lung cancer cells 
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(Tateishi et al., 1990; Damstrup et al., 1992). Activated ERBB1 has been shown to be 
related to tumor stage and differentiation.  
The RAS proto-oncogene family (KRAS, HRAS, and NRAS) has also been shown 
to be altered in lung cancer. The RAS proto-oncogene family encodes for plasma 
membrane proteins and is activated in some lung cancers by point mutations. Mutations 
in RAS expression will result in inappropriate prolonged signaling for cell division 
(Fong et al., 1999). The most frequently activated RAS gene in lung cancers is KRAS, 
and this usually occurs by mutations at codon 12 and occasionally codons 13 and 61. 
Mutations of KRAS affect approximately 20-30% of lung adenocarcinomas and 15-20% 
of all NSCLC, but rarely SCLCs (Richardson and Johnson, 1993). 
A tumor suppressor gene that has been shown to be altered in lung cancer is p53. 
When challenged with  ultraviolet radiation and carcinogens, DNA damage occurs, p53 
expression is increased and it acts as a sequence-specific transcription factor regulating 
downstream genes including p21, MDM2, GADD45, and Bax, thereby helping to 
regulate the G1/S cell cycle transition, G2/M DNA damage checkpoint, and apoptosis 
(Fong et al., 1999). Therefore, a dysfunction of p53 will allow for inappropriate survival 
of genetically damaged cells, thus leading to accumulation of multiple mutations and 
the subsequent evolution of a cancer cell (Fong et al., 1999). In lung cancer, p53 plays 
an integral role. Its chromosome 17p13 locus is frequently hemizygously deleted, and 
mutational inactivation of the remaining allele occurs in 75% or more of SCLCs and 
about 50% of NSCLCs (Greenblatt et al., 1994).  
There are many other molecular alterations that occur in lung cancer.  The 
potential of molecular epidemiology is increasingly recognized as it allows for the 
identification of individual genetic susceptibility factors to lung cancer as well as the 
identification of individuals at the highest risk for development of lung cancer (Fong et 
al., 1999).   
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2.2.5 Lung Adenocarcinoma Cell Line (A549) 
 
 The A549 lung adenocaricnoma cell line was first initiated in 1972 by Giard et 
al., and is derived from type II alveolar epithelial cells from a 58-year-old Caucasian 
male (Giard et al., 1972). This male presented with a brief history of chest pain, blood-
streaked productive cough and loss of weight. When X-rays and tomography were 
carried out, a mass lesion in the right lower lobe of the lung was observed. Histologic 
examination showed the alveoli lined with epithelial carcinoma cells in clumps and 
acini (Lieber et al., 1976).  
When examined by electron microscopy at both the early and late passage levels, 
A549 cells contain multilamellar cytoplasmic inclusion bodies that are characteristic of 
those found in type II alveolar epithelial cells of the lung (Lieber et al., 1976). At the 
early and late passage levels, A549 cells synthesize lecithin with a high percentage of 
disaturated fatty acids utilizing the cytidine diphosphocholine pathway (Lieber et al., 
1976).  
A549 cell line is maintained as a monolayer culture in culture flasks in 
Dulbecco’s Modified Eagles medium (DMEM) with 10% heat-inactivated fetal bovine 
serum (FBS). The culture is incubated in 37°C with high relative humidity (95%), stable 
temperature (37°C) with controlled CO2 levels (5.0%). 
 
2.3 Apoptosis 
 
 Apoptosis plays an important role during development and in the maintenance of 
multicellular organisms through the removal of damaged, aged or autoimmune cells 
(Sorenson, 2004). Apoptosis allows for organisms to control cell number and tissue size, 
thus protecting itself from cells that threaten homeostasis (Hengartner, 2000). 
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Dysregulation of apoptosis contributes to half of all human diseases. Excessive 
apoptosis occurs in various neurodegenerative disorders including Alzheimer’s, 
Parkinson’s, autoimmune disorders, heart disease, as well as infectious diseases (Singh 
& Anand, 1994). Apoptosis dysregulation can also lead to abnormal accumulation of 
cells thus contributing to tumor growth. There are many ways by which cell death via 
apoptosis can be induced; including growth factor deprivation, cytokine interactions, 
cell-cell interactions, irradiation, glucocorticoids or treatment with various cytotoxic 
agents (Cohen et al., 1992). 
 
2.3.1 Extrinsic Pathway of Apoptosis 
 
 The extrinsic pathway, also known as the death receptor pathway, is initiated by 
cell surface-expressed death receptors of the tumor necrosis factor (TNF) family. Once 
activated, for example by Fas ligands, the receptors oligomerize and recruit intracellular 
adaptor proteins, the Fas-associated death domains (FADD), to form scaffolding 
complexes (Strasser et al., 2009). 
 The complexes recruit members of the caspase family of cell death protease, most 
commonly caspase-8. Caspase-8 will in turn be cleaved leading to the formation of an 
active enzyme, comprising of p20 and p10 heterotetramer (Engel and Henshall, 2009). 
This activated initiator caspase will then cleave downstream effector caspases, such as 
caspase-3. Caspase-3 in turn cleaves a large number of intracellular substrates (Taylor et 
al., 2008). 
 Most of the morphological changes that occur in cells undergoing apoptosis are 
caused by caspases (Alnemri et al., 2000). As caspases bring about the most visible 
changes that characterize apoptotic death, caspases are thought to be the central 
executioners of the apoptotic pathway (Hengartner, 2000). Caspases selectively cleave a 
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restricted set of target proteins, usually at one or more positions in the primary sequence 
(Hengartner, 2000).  Cleavage of specific substrates by caspase explains several of the 
characteristic features of apoptosis, such as the cleavage of the nuclear lamins that are 
required for nuclear shrinking and budding (Buendia et al., 1999; Rao et al., 1996). 
Also, cleavage of the cytoskeletal proteins such as fodrin and gelsolin cause loss of the 
overall cell shape. Lastly, cleavage of PAK2, a member of the p21-activated kinase 
family, by caspases mediates active blebbing, which is observed in apoptotic cells 
(Hengartner, 2000).  
 
2.3.2 Intrinsic Pathway of Apoptosis 
 
 The intrinsic pathway, commonly known as the mitochondrial pathway, is 
activated in response to disturbances within the cell, which may include DNA damage, 
endoplasmic reticulum stress, calcium overload, and withdrawal of survival factors 
(Engel and Henshall, 2009). Cytochrome c will be released into the cytosol, as a result 
of this activation. Cytochrome c then binds to the apoptotic protease-activating factor 1 
(APAF1) and pro-caspase-9, leading to the assembly of a heptamere protein ring called 
an apoptosome, This apoptosome catalyzes the activation of caspase-9, an initiator 
caspase, which in turn activates effector caspases that cleave multiple cellular proteins 
(Singh, 2007). The central regulators of this mitochondrial pathway are the Bcl-2 family 
of proteins.  
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Figure 2.4: Scheme depicting intrinsic and extrinsic pathways of apoptosis. (Figure 
adapted from Youle and Strasser, 2008). 
 
2.3.3 Bcl-2 Family Members 
 
 The B-cell lymphoma-2 (Bcl-2) gene was first discovered at the t(14;18) 
chromosome translocation breakpoint in follicular lymphomas where the transcription 
of the gene was excessively driven by the immunoglobulin heavy chain promoter and 
enhancer of chromosome 14 (Tsujimoto et al., 1985; Bakshi et al., 1985; Cleary et al., 
1986). Additionally homologs of Bcl-2 were later discovered. Members of the Bcl-2 
gene family encode proteins that function to either promote or inhibit apoptosis.  
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 The Bcl-2 protein contains four conserved domains (BH1, BH2, BH3 and BH4) 
that can be found in the other family members. The members can be categorized into 
three functional groups, as found in Table 2.1. The first group is made up of the anti-
apoptotic proteins, which generally contain all four BH domains, and are responsible for 
protecting the cells from apoptotic stimuli (Dewson et al., 2010). The second comprises 
of the BH3-only proteins. The sequence homology of this group with other members of 
the family is restricted to the BH3 domain. The BH3-only proteins are activated in 
response to various cellular stresses to initiate apoptosis, such as DNA damage, growth 
factor deprivation and endoplasmic reticulum stress. The third group also contains all 
four BH domains, however they are pro-apoptotic. Activation of this group of proteins 
is downstream to BH3-only proteins and thus they are ultimately responsible for the 
death of the cell (Dewson et al., 2010).  
 The pro-apoptotic proteins Bax and Bcl-2-antagonist killer (Bak) can induce cell 
death via mitochondrial membrane permeabilization. The activation of Bax/Bak occurs 
in response to DNA damage and is facilitated by the translocation of Bax/Bak from the 
cytoplasm to the mitochondria. This will induce the oligomerization of Bax/Bak and the 
oligomer will then be inserted into the mitochondrial outer membrane for the release of 
cytochrome c, which then activates caspases to induce cell death (Green and Kroemer, 
2004; Khosravi-Far and Esposti, 2004; Debatin, 2004).  
 The pro-apoptotic BH3-only proteins function by activating the multidomain 
proapoptotic Bax/Bak either through direct binding or by indirectly binding to the anti-
apoptotic proteins (Engel and Henshall, 2009). The anti-apoptotic proteins function to 
sequester the activation of the pro-apoptotic proteins and thereby binding of pro-
apoptotic proteins will antagonize the activity of the anti-apoptotic proteins thus 
favoring cell destruction (Engel and Henshall, 2009). Therefore, the concentration, or 
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balance of expression, of the various members of the family is largely responsible for 
cellular apoptotic homeostasis (Daniel and Smith, 2004). 
 
Table 2.1: Functional categories of the Bcl-2 family of proteins  
Anti-apoptotic proteins BH-3 only proteins Pro-apoptotic proteins 
Bcl-2 
Bcl-xL 
Mcl-1 
Bcl-w 
Bfl-1 
Bcl-B 
Bid 
Bim 
Puma 
Noxa 
Bad 
Bmf 
Hrk 
Bik 
Bax 
Bak 
Bok/Mtc 
 
(Table adapted from Daniel and Smith, 2004). 
 
2.3.4 Bcl-2 Expression in Cancer 
 
 The expression level of Bcl-2 differs for different cell types, however high levels 
and aberrant patterns of Bcl-2 expression have been reported in a wide variety of human 
cancers. The elevation of Bcl-2 protein expression contributes not only to the 
development of cancer but also to resistance against a wide variety of anti-cancer agents 
(Baffy et al., 1993; Miyashita and Reed, 1993; Walton et al., 1993; Kamesaki et al., 
1993; Fisher et al., 1993; Tang et al., 1994). However, studies have shown that in 
NSCLC the expression of Bcl-2 is either very low or even absent (Daniel and Smith, 
2004). Instead, the expression of bcl-xL, the other major prototype of the anti-apoptotic 
bcl-2 gene, is shown to be over-expressed. Over-expression of Bcl-xL protein inhibits 
apoptosis in NSCLC and has been coupled with poor prognosis of this disease (Soini et 
al., 1999).  
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2.3.5 Bcl-xL Overexpression in Lung Cancer 
 
 Over-expression of Bcl-xL can counteract the pro-apoptotic functions of Bax and 
Bad. Bcl-xL can prevent the translocation of Bax from the cytosol to the mitochondria 
thus inhibiting apoptosis by maintaining the permeabilization status or stabilization of 
the outer mitochondrial membrane. Such stabilization of the membrane prevents 
cytochrome c release and resulting pro-caspase-9 activation (Grad et al., 2000; Groeger 
et al., 2004; Gottlieb et al., 2000). Bad is a BH3-only, pro-apoptotic Bcl-2 family 
member, and is a cytosolic protein in healthy cells. In the cytosol, Bad is normally 
phosphorylated at a number of serine residues. This will allow the phosphorylated Bad 
to be sequestered by the cytosolic scaffold protein 14-3-3. An apoptotic signal that 
triggers Bad dephosphorylation will then result in the binding of the phosphorylated 
Bad to Bcl-xL and the inactivation of Bcl-xL’s pro-survival function (Zha et al., 1996). 
However, when Bcl-xL is present in large quantities it will have a higher affinity for 
Bad than 14-3-3, thus sequestering Bad to the mitochondria, leaving the excess of 
uncomplexed Bcl-xL to perform its pro-survival function (Cheng et al., 2001; Jeong et 
al., 2004). As research has shown that the Bcl-xL gene is an anti-apoptotic gene that is 
over-expressed in lung adenocarcinoma cancer, this project will concentrate upon how 
this gene effects the expression of microRNAs. 
 
2.3.6 Phosphatidylinositol 3-Kinase (PI3K)/AKT Pathway  
 
 The PI3K/AKT pathway is a crucial regulator of mammalian cell survival and 
proliferation (Vivanco and Sawyers, 2002). P13K catalyzes the phosphorylation of 
inositol-containing lipids, known as phosphatidylinositols (PtdIns). Activation of PI3K 
leads to the generation of PtdIns(4,5)P2 (PIP2), which is converted to PtdIns(3,4,5)P3 
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(PIP3). The PIP3 will then act as a ligand to recruit plekstrin homology (PH) domain 
containing proteins to the inner surface of the cell membrane (Vivanco and Sawyers, 
2002). 
One target of PIP3 is the serine/threonine kinase Akt, the cellular homologue of 
the retroviral oncogene v-Akt, also known as protein kinase B (PKB) (Vivanco and 
Sawyers, 2002; Datta et al., 1997). At the membrane, another PH-domain containing 
serine/threonine kinase named 3-phosphoinositide-dependent protein kinase-1 (PDK1) 
will phosphorylate Akt on threonine-308 (Thr-308). Phosphorylation at Thr-308 and 
direct binding by PIP3 is necessary for the activation of Akt (Vivanco and Sawyers, 
2002).  
  Akt signaling plays an important role in various processes that are critical to 
tumorigenesis including inhibition of apoptosis, aberrant cell proliferation, promotion of 
angiogenesis and tumor cell invasiveness (Testa and Bellacosa, 2001). Various studies 
have shown that aberrant expression of Akt plays an important role in human 
malignancy. Akt has been demonstrated to be amplified and overexpressed in various 
tumor types, including ovarian, breast, prostate, pancreatic, and human gastric cancer 
(Bellacosa et al., 1995; Cheng et al., 1998; Staal, 1987). In lung cancer Akt has been 
suggested to contribute to resistance to chemotherapy, radiation and tyrosine kinase 
inhibitors through mediation of survival signals that guard the cells from undergoing 
apoptosis (Brognard et al., 2001; Hill and Hemmings, 2002; Janmaat et al., 2003).  
 Akt promotes survival through various mechanisms as Akt directly 
phosphorylates several components of the cell-death machinery.  For example, Akt can 
phosphorylate Bad, a pro-apoptotic member of the Bcl-2 family of proteins (Datta et al., 
1997). Bad promotes cell death through the formation of a non-functional heterodimer 
with the anti-apoptotic protein Bcl-xL. Phosphorylation of Bad by Akt would prevent 
interaction of Bad with Bcl-xL and promote its association with 14-3-3 proteins in the 
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cytosol instead. Thus Akt inhibits apoptosis by reinstating Bcl-xL’s anti-apoptotic 
function and preventing cytochrome c release from the mitochondria (Vivanco and 
Sawyers, 2002; Zhou et al., 2001). Similarly, Akt phosphorylates the pro-death protease, 
caspase-9, thus inhibiting its catalytic activity (Cardone et al., 1998).  
 Akt is also able to influence the activity of the pro-apoptotic tumor suppressor 
p53 (Vivanco and Sawyers, 2002). Mdm2 is an oncoprotein that promotes cell survival 
and cell cycle progression through the inhibition p53. However, regulation of p53 can 
only occur once Mdm2 enters the nucleus. Phosphorylation by Akt on serine-166 and 
serine-186 is necessary for the translocation of Mdm2 from the cytoplasm into the 
nucleus. Once Mdm2 is in the nucleus, p53 will be targeted for degradation by the 
proteasome through its E3 ubiquitin ligase activity (Mayo and Donner, 2001).  
 Akt also has the ability to influence survival through indirect effects on nuclear 
factor of light polypeptide gene enhancer in B cells (NFB). The NFB transcription 
factor complex can promote cell survival in response to various apoptotic stimuli 
(Vivanco and Sawyers, 2002). Akt carries out its positive effect by phosphorylation and 
activation of the inhibitor of kappa light polypeptide gene enhancer in B cells (IB) 
kinases (IKK), a kinase that directly phosphorylates the NFB inhibitor, thus leading to 
its ubiquitination and degradation. Degradation of IB will allow for the release of 
NFB from the cytoplasm into the nucleus, and activation of its target genes (Vivanco 
and Sawyers, 2002).  
Akt plays a role in proliferation through signals to the cell machinery. The cell 
cycle is controlled by the organized action of CDK complexes and CDK inhibitors. 
Cyclin D1 levels are important in the G1/S phase transition, and its levels are regulated 
at the transcriptional, post-transcriptional and post-translational level by various 
mechanisms (Vivanco and Sawyers, 2002). Akt prevents cyclin D1 degradation through 
its regulation of the activity of cyclin D1 kinase glycogen synthase-kinase-3 (GSK3). 
 27 
Akt directly phosphorylates GSK3 thus inhibiting its kinase activity, thereby leading 
to cyclin D1 accumulation (Diehl et al., 1998). 
 
Figure 2.5: PI3K Signaling (Figure adapted from Vivanco and Sawyers, 2002).  
 
2.3.7 Wingless-Type MMTV Integration Site Family (WNT) Pathway 
 
 The Wnt ligands are a family of secreted glycoproteins that have varying 
expression patterns and a variety of roles (Tennis et al., 2007). These ligands play a role 
in the activation of signal transduction pathways and elicit changes in gene expression, 
cell behavior, adhesion and polarity (Mazieres et al., 2005). Three pathways have been 
elucidated to demonstrate Wnt protein signaling. The pathway best understood, known 
as the canonical Wnt-catenin pathway, involves Wnt binding to two distinct families of 
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cell receptors: the Frizzled (Fzd) receptor family and the low density lipoprotein 
receptor related proteins (LRP) family (Mazieres et al., 2005).  
In the situation of an unstimulated canonical pathway, GSK3 phosphorylates -
catenin in a complex that includes adenomatous polyposis coli (APC) and axin. 
Phosphorylation would cause -catenin to be targeted for ubiquitin-mediated 
degradation, thereby decreasing levels of cytosolic -catenin (Tennis et al., 2007).  
In active Wnt signaling, Wnt ligands are bound to the Fzd receptors complexed 
with LRP, which leads to the phosphorylation of Dishevelled (Dvl), a family of 
cytosolic transducer molecules (Noordermeer et al., 1994). Activated Dvl inhibits the 
GSK3/APC/axin complex, which in turn prevents GSK3 from phosphorylating -
catenin. Thus free -catenin is stabilized and accumulates in the cytosol where it will be 
translocated into the cell nucleus forming an active transcription complex with T-cell 
factor (TCF) and lymphoid enhancer factor (LEF) (Tennis et al., 2007; Mazieres et al., 
2005). Assembly of the transcription complex leads to target gene activation of various 
genes including matrix metalloproteinases (MMP2, MMP3, MMP7 and MMP9) 
(Tamamura et al., 2005), cyclin D1 (Shtutman et al., 1999; Tetsu and McCormick, 
1999), Cox-2 (Longo et al., 2002), c-myc (He et al., 1998), c-jun, Fra-1 (Mann et al., 
1999), and VEGFR (Zhang et al., 2001).  
 Studies have reported aberrant activation of the Wnt signaling pathway in 
various human cancers, including colorectal cancer, head and neck carcinoma, 
melanoma and leukemia (Mazieries et al., 2005). To date, Wnt signaling has been 
reported to be occasionally involved in lung carcinogenesis (Sunaga et al., 2001; 
Hommura et al., 2002; Winn et al., 2002). In lung cancer, the canonical Wnt signaling 
has been found to be excessively active. In studies of lung cancer cell lines and primary 
tumors, Wnt7a has been found to be frequently lost (Calvo et al., 2000), while Wnt1 
(He et al., 2004) and Wnt2 (You et al., 2004) have been reported to be overexpressed in 
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NSCLC cells. Cells with an overexpression of Wnt1 have been shown to be resistant to 
therapies that mediate apoptosis (Mazieres et al., 2002). Furthermore, expression of Dvl 
has also been shown to be overexpressed in NSCLC tumors and cell lines, and is 
involved in lung carcinogenesis (Kazutsugu et al., 2003).  
 
 
Figure 2.6: Canonical Wnt/-catenin signaling pathway (Figure adapted from Tennis et 
al., 2007).  
 
 
 
 30 
 
 
2.3.8 Transforming Growth Factor (TGF-) Signaling Pathway 
 
TGF- is part of a superfamily, which comprise of a large number of structurally 
related polypeptides, including TGF-2, TGF-3, Activins, Nodals and bone 
morphogenetic (BMP) proteins (Massagué, 1998). They are produced by a variety of 
cell types, and are capable of regulating numerous cellular processes including cell 
proliferation, lineage determination, differentiation, motility, adhesion and death 
(Massagué, 1998).  The TGF- family members are multifunctional, and their effects 
depend upon the responsiveness of the target cell (Massagué and Wotton, 2000).  
TGF- signaling is initiated when two different serine/threonine kinase 
transmembrane proteins, known as receptor I and II, are brought together by the TGF- 
ligand (Massagué, 1998). The TGF- ligand is a receptor assembly factor which 
complexes with receptor I, thus phosphorylating the guanidine specificity (GS) region, 
resulting in the activation of receptor I. TGF- receptor I is then recruited to the 
heteromeric complex of TGF- receptor II (Massagué, 1998).   
 The TGF- receptor I will phosphorylate the receptor activated Smads (R-
Smads), which are comprised of Smad2 and 3 (Massagué and Wotton, 2000). 
Phosphorylation by the TGF- receptor, initiates R-Smad activation and accumulation 
in the nucleus. Prior to translocation into the nucleus, the activated Smad2 and 3, binds 
with the common-mediated Smad (Co-Smad), Smad4 (Massagué and Wotton, 2000). 
The R-Smad and Co-Smad complex now move into the nucleus, and both participates in 
DNA binding and recruitment of transcriptional co-factors (Massagué and Wotton, 
2000; Massagué, 1998) (Refer to Figure 2.7). 
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 TGF- negatively regulates cell proliferation through the induction of G1 arrest, 
promotion of termination differentiation, or activation of cell death mechanisms  
(Alexandrow and Moses, 1995). For example p15 and p21, which are cyclin-dependent 
kinase inhibitors, are rapidly induced in response to TGF-, which in turn mediates cell 
cycle arrest (Hannon and Beach, 1994). Also, inhibition of gene transcription can occur 
through the downregulation of c-myc and the Cdk-activating phosphatase cdc25A, thus 
resulting in antiproliferative effects (Iavarone and Massagué, 1997).  
 Studies have shown that alterations in TGF- signaling have been associated 
with a variety of human diseases, including cancer (Jeon and Jen, 2010; Massagué and 
Wotton, 2000). It has been shown that the ligand along with downstream elements, 
including the receptors as well as the Smad proteins, are essential in suppressing 
primary tumorigenesis in many tissue types (Markowitz and Roberts, 1996).  
 Lung cancer has been shown to often overexpress TGF- (Roberts and 
Wakefield, 2003).  While most lung cancer cells secrete TGF-, the malignant 
transformation that occurs in lung cancer leads to a loss of the tumor suppressor effects 
of TGF-. The loss of this TGF- response will in turn result in a loss of the inhibitory 
effects on proliferation, which has been associated with tumor development and 
progression in several cancers (Yanagisawa et al., 1998; Kim et al., 2000).  
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Figure 2.7: TGF- Signaling pathway. (Figure adapted from Massague, 1998.)  
2.3.9 Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway 
 
The mitogen-activated protein kinase (MAPK) cascades are intracellular signal 
transduction pathways that are triggered by various extracellular and intracellular 
stimuli, which include peptide growth factors, cytokines, hormones and diverse cellular 
stresses such as oxidative stress and endoplasmic reticulum stress (Kim and Choi, 2010). 
There are three well described pathways: the extracellular signal-regulated kinases 1 
and 2 (ERK1/2), c-Jun N-terminal kinases/ stress-activated protein kinases 
(JNK/SAPK) and the p38 pathway (Raman et al, 2007). Each cascade is composed of 
three core components: a MAPK kinase kinase (MAP3K), a MAPK kinase (MAP2K), 
and a MAPK. Additional upstream MAP4K and downstream MAPKAPK components 
also exist (Plotnikov et al., 2011). Within the cascade, one or more kinase component 
will phosphorylate and activate components in the next tier, eventually leading to the 
phosphorylation of the target regulatory molecules by the MAPK, thus initiating various 
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cellular processes (Raman et al., 2007). The MAPK pathway regulates numerous 
essential cellular activities including growth, proliferation, differentiation, motility, 
stress response, survival and apoptosis (Lewis et al., 1998). Aberrant MAPK signaling 
have been associated with the development of several human diseases including 
Alzheimer’s disease (Wang and Liu, 2008; Perez et al., 2008), Parkinson’s disease 
(Levy et al., 2009), amyotrophic lateral sclerosis (Bendotti, 2005), and many types of 
cancer (Dhillon, 2007; Boutros et al., 2008; Schubbert et al., 2007).  
 
2.3.9.1 ERK 1/2 Cascade 
 
The ERK cascade is the best characterized MAPK pathway, and it is composed 
of two genes, the ERK1 (p44) and ERK2 (p42), which are 83% identical (Chen et al., 
2001) and are likely functionally redundant although they may have different substrate 
specificities (Greenberg et al., 2002). The signaling via the ERK cascade is initially 
activated by mitogenic stimuli such as peptide growth factors EGF or PDGF. The 
binding of the growth factors to its cell surface receptor tyrosine kinase, will lead to 
dimerization and autophosphorylation of the receptor (Mercer and D’Armiento, 2006). 
Phosphorylation of the intracellular domain of the receptor will activate guanine 
nucleotide exchange factors (GEFs) such as such as Son of Sevenless (Sos), which will 
facilitate the activation of GTPase Ras (Plotnikov, 2011). Ras-GTP will activate the 
MAP3K tier of the cascade, the Raf isoforms (A-Raf, B-Raf or Raf-1), leading to Raf-
mediated phosphorylation of the dual-specificity MAP kinase kinase-1 and -2 (MEKs), 
MEK1/2 (Mercer and D’Armiento, 2006; Malumbres and Barbacid, 2003). MEK1/2 
will in turn phosphorylate ERK1/2, thus transmitting ERK1/2 through the nuclear 
membrane pore allowing for the phosphorylation and activation of various transcription 
factors including TCF-member ELK-1 (Gille et al., 1992), c-Fos (Murphy et al., 1992), 
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p53 (Milne et al., 1994), Ets1/2 (Yang et al., 1996) and c-Jun (Morton et al., 2003), all 
of which are important for the initiation and regulation of cell proliferation and 
oncogenic transformation (Shaul and Seger, 2007).  Various studies have been 
conducted to analyze the ERK pathway and its role in tumorigenesis. Correlation 
between incidence of cancer and increased Ras activiation, ERK1/2 activity, or binding 
of DNA by ERK1/2 transcription factor targets (Mercer and D’Armiento, 2006), have 
been made in vitro (Vincent et al, 2004), animal (Sebolt-Leopold, 1999) and human 
(Han et al., 2005) studies. 
 
2.3.9.2 JNK/SAPK Cascade 
 
The JNK-family of kinases was initially identified as protein kinases involved in 
the activation of the transcription factor c-Jun, in response to UV irradiation (Hibi et al., 
1993). They were also found to be mediators of intra- or extra-cellular stresses, thus 
giving them their other name, stress-activated protein kinase (SAPKs) cascade (Davis, 
1994). Initial studies show that JNK can be activated by various stimuli including 
growth factors (Hibi et al., 1993), cytokines (Westwick et al., 1994), and stress factors 
(Cano et al., 1994).  Later studies indicated that inflammatory cytokines and many 
different cytotoxic as well as genotoxic reagents stimulate JNK, leading to the discovery 
of the critical role JNKs played in mediating apoptotic signaling (Sluss et al., 1994; 
Cano and Mahadevan, 1995; Dai et al., 1995).   
Activated stress, or other, stimuli transmits their signal to small GTPases such as 
CDC42 and Rac1, which in turn activates the MAP3K level kinases either directly or 
through the MAP4Ks (Plotnikov et al., 2011). The MAP3Ks can also, alternatively, be 
activated by interaction with adaptor proteins such as TRAF (Bradley and Pober, 2001). 
The MAP3Ks include members of the MEKK group (MEKK1-4), apoptosis signal-
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regulating kinase group (ASK1 and ASK2), mixed lineage kinase (MLK1, MLK2, 
MLK3, DLK, and LZK), and transforming growth factor-beta activated kinase 1 
(TAK1) (Davis, 2000). The kinases at the MAP3K tier will then transmit the signals 
further by phosphorylating the kinases of the MAPKK level, MEK4 (MKK4) and 
MEK7 (MKK7), which in turn activate the three components at the MAPK level 
(JNK1-3) (Davis, 2000). 
Activated JNKs phosphorylate a large number of substrates, including 
transcription factors c-Jun, c-Myc ATF2, ATF3, p53, Elk-1 and nuclear factor of 
activated T cells (NFAT) (Raman et al, 2007; Johnson and Nakamura, 2007). These 
phosphorylated targets would further regulate the transcription of many genes, thus 
mediating cellular processes such as apoptosis (Dhanasekaran and Reddy, 2008), 
immunological effects (Rincon Davis, 2009), neuronal activity (Haeusgen et al., 2009), 
insulin signaling (Haeusgen et al., 2009) and more. For example, JNKs can activate 
apoptotic signaling through the up-regulation of pro-apoptotic genes, via activation of c-
Jun. The phosphorylation of c-Jun will lead to the formation of AP-1, which is involved 
in the transcription of a wide range of proteins, including known pro-apoptotic proteins 
(Dhanasekaran and Reddy, 2008). The JNK-AP-1 pathway has been shown to be 
involved in the increased expression of pro-apoptotic genes such as TNF-alpha, Fas-L 
and BAK (Fan and Chambers, 2001).  
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2.3.9.3 p38 Cascade 
 
The p38 cascade is also an SAPK pathway and shares many components with 
the other SAPK pathway, the JNK cascade (Kyriakis and Avruch, 2001). This cascade 
is primarily induced by stress related stimuli, however it can also be activated by 
various growth factors including insulin-like growth factor (IGF) (Cheng and Feldman, 
1998), vascular endothelial growth factor (VEGF) (Rousseau et al., 1997) and platelet-
derived growth factor (PDGF) (Pyne and Pyne, 1997) and many more. Upon activation 
of the receptors by the stimuli, the signals will be transmitted via adaptor proteins, small 
GTPases, MAP4Ks and MAP3K, similar to those functioning in the JNK cascade 
(Plotnikov et al., 2011). The MAP3K will in turn phosphorylate and activate the 
MAPKK components, which include the MKK3 and MKK6 (Whitmarsh and Davis, 
2007). Activation of MKK3 and MKK6 would lead to signal transmission to the four 
isoforms at MAPK tier of the cascade, p38 α-δ (Plotnikov et al., 2011). The p38s can 
additionally be mediated by autophosphorylation in a MAPKK-independent manner. 
This autophosphorylation is is induced by stimulated interaction with adaptor proteins 
Tab1 (Ge et al., 2002), or by interaction with lipidic phosphatidyl inositol analogues 
(Gills et al, 2007). The signals are then finally transmitted, via p38s, or MAPKAPKs to 
target molecules, such as ATF-2, c-Fos, c-Myc, c-Jun, p53, and Elk-1, which are 
responsible for various processes that are stimulated and regulated by the cascade 
(Plotnikov et al., 2011).  
Studies have shown that the p38s play a central role in the regulation of 
immunological effects (Huang et al., 2009), apoptosis (Sohn et al., 2007), cell cycle 
checkpoint and even survival (Thornton and Rincon, 2009). Therefore a dysregulation 
of the cascade may have pathological manifestations (Plotnikov et al., 2011). p38 has 
been shown to act as a tumor suppressor via the downregulation of Ras-dependent and 
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independent transformation, invasion and also by inducing apoptosis (Plotnikov et al., 
2011). 
 
2.4 MicroRNA (miRNA) 
 
 In 1993, microRNAs (miRNAs) were first discovered in the worm 
Caenorhabdotis elegans (C. elegans) by Ambros and colleagues. By identifying the C. 
elegans mutants that were disturbed in developmental timing, they discovered that a 22-
nucleotide transcript of lin-4 regulated developmental timing by acting as a negative 
regulator of the protein coding gene lin-14 (Lee et al., 1993; Wightman et al., 1993). 
Lin-4 showed a partial sequence complementarity to a sequence repeat in the 3’UTR of 
lin-14, which lead the authors to hypothesize that lin-4 functions by interacting with 
these 3’UTR elements, thus inhibiting the translation of lin-14. Originally miRNAs 
were considered to be unique to nematodes, until it was found that the sequence and 
temporal expression pattern of another miRNA involved in developmental timing in C. 
elegans, let-7, was phylogenetically conserved in a wide variety of animals including 
humans (Pasquinelli et al., 2000). This observation lead to the construction and 
characterization of several large-scale cDNA libraries enriched for small miRNAs, in 
turn leading to the identification of many additional miRNAs from plants, C. elegans, 
Drosophila and mammals (Lagos-Quintana et al., 2001; Lagos-Quintana et al., 2003).  
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 MiRNAs are defined as small non-coding RNA of about 19-23 nucleotides long 
that regulates gene expression post-transcriptionally, by either inhibiting mRNA 
translation or by inducing mRNA degradation. MiRNAs play a role in a wide range of 
biological processes including cell proliferation, differentiation, apoptosis, 
developmental timing, fat metabolism, insulin secretion, stem cell maintenance, 
neuronal patterning, and hematopoietic differentiation (Ruan et al., 2009; Weimer, 
2007). MiRNAs are an integral part of the regulatory networks in cells, therefore a 
disturbed miRNA function or altered miRNA expression may disorganize cellular 
processes and eventually cause or contribute to disease (Weimer, 2007).  
 
2.4.1 MiRNA Biogenesis 
 
 MiRNA genes can be found distributed across the genome as either single genes 
or as gene clusters. Gene clusters give rise to large polycistrone transcripts, from which 
the individual miRNAs are processed. Some miRNAs can be found in intergenic 
regions, but at least 50% are found in defined transcription units (in introns and exons) 
of both protein coding and non-coding transcripts and are therefore co-transcribed with 
the gene in which they reside (Kim and Nam, 2006; Rodriguez et al., 2004; Weber, 
2005). 
 MiRNAs are initially transcribed by RNA polymerase II, forming long primary 
miRNA (pri-miRNA), which contains a 5’CAP structure and are polyadenylated at their 
3’end. These pri-miRNA can be up to several kilobases in length and contains one or 
more stem-loop or hairpin structures of about 70 nucleotides. These hairpin structures 
are recognized and cleaved in the nucleus by the 650 kDa microprocessor complex 
which consists of a dsRNA specific RNase III endonuclease Drosha and the dsRNA 
binding proteins, the Di-George syndrome critical region gene 8 (DGCR8) (Han et al., 
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2004). The resulting precursor miRNA (pre-miRNA) which is a 60-100 nucleotide 
RNA hairpin intermediate with a two nucleotide 3’overhang, is then transported to the 
cytoplasm by the nuclear export factor Exportin-5 and its co-factor Ran-GTP. In the 
cytoplasm, the pre-miRNA is further cleaved by a second RNase endonuclease Dicer 
with its dsRNA binding partner, the immunodeficiency virus (HIV) transactivating 
response DNA binding protein (TRBP), resulting in a mature product of 19-24 
imperfect nucleotide duplex (Lund et al., 2004; Yi et al., 2003).  
 The TRBP will then recruit the human agronaute protein hAgo2 to the Dicer 
complex, thus forming a minimal RNA-induced silencing complex (RISC). The core 
components of the RISC are members of the agronaute family of proteins, which 
contain the conserved RNA-binding domains: the PAZ domain, which binds to the 
single stranded 3’ end of the miRNA, and the PIWI domain, which interacts with the 5’ 
end of the miRNA guide strand (Filipowicz, 2005; Sontheimer, 2005). 
 The strand of the duplex, which has the weakest base-pairing at its 5’ terminus, is 
selected as the guide strand. This guide strand will direct the RISC to the 3’UTR of the 
target mRNA on the basis of sequence complementarity between the guide miRNA and 
target mRNA (Matranga et al., 2005; Rand et al., 2005). The passenger strand will later 
be removed. 
 The mature miRNA can regulate their targets by direct cleavage of mRNA or by 
inhibition of protein synthesis, according to the degree of complementarities with their 
target 3’UTR. Target mRNA cleavage can only take place if the miRNA has a near 
perfect complementarity to its target sequence. Imperfect base-pairing cannot bring 
about mRNA cleavage but instead induces transcriptional silencing (Bartel, 2004). 
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Figure 2.8: The current model for the biogenesis and post-transcriptional suppression 
of microRNAs (Figure adapted from Applied Biosystems, 2009).   
 
2.4.2 MiRNA and Cancer 
 
 As mentioned previously, miRNAs play a key role in an assortment of biological 
processes including development, cell proliferation, differentiation and apoptosis. 
Therefore, an altered miRNA expression is likely to contribute to human disease 
including cancer. When human miRNAs were first discovered it was noticed that many 
miRNA genes reside in genomic regions that are involved in cancers, including minimal 
regions of loss of heterozygocity (LOH), minimal regions of amplification (minimal 
amplicons), or breakpoint cluster regions (Calin et al., 2004). Overexpressed oncogenic 
miRNAs are located in amplified regions and the down-regulated suppressor miRNAs 
in deleted regions in cancer (Calin et al., 2004). 
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 The proof that chromosomal rearrangements are fundamental to the inducement of 
cancer, was an early report of a masked t(8;17) translocation that resulted in an 
aggressive B-cell leukemia by overexpressing c-myc oncogene by an unknown 
mechanism at the moment of identification (Calin et al., 2004). Later it was discovered 
that miR-143 was located at chromosome 17 breakpoint, and that the c-myc was 
rearranged under the control of the promoter of miR-143 with consequent 
overexpression (Calin et al., 2004).  
 Compared to normal tissues, malignant tumors and tumor cell lines have been 
found to have widespread deregulated miRNA expression (Sassen et al., 2008). A 
global decrease in miRNA levels has been observed in human cancers, demonstrating 
that small RNAs may have an intrinsic function in tumor suppression (Sassen et al., 
2008). Lu and colleagues were the first to show that the expression levels of many 
miRNAs were significantly reduced in cancers compared to the corresponding normal 
tissues. The authors hypothesized that miRNAs can function to drive terminal 
differentiation and prevent cell division (Lu et al., 2005). Cancer specific fingerprints 
have since been identified in various cancers including B-cell chronic lymphocytic 
leukemia (B-CLL), breast carcinoma, primary glioblastoma, hepatocellular carcinoma, 
papillary thyroid carcinoma, lung cancer, gastric carcinoma, colon carcinoma and 
endocrine pancreatic tumors (Calin et al., 2004).  
 
 
 
 
 
 
 
 42 
2.4.3 MiRNA As Oncogenes and Tumor Suppressors 
 
 MiRNAs can be either up-regulated or down-regulated in various human cancers. 
MiRNAs whose expressions are increased in tumors are considered as oncogenes 
(Zhang et al., 2007). These oncogenic miRNAs, called oncomirs, promote the 
development of tumors by negatively inhibiting tumor suppressor genes and/or genes 
that control cell differentiation or apoptosis (Zhang et al., 2007). MiRNAs 
overexpressed in human cancers may result from amplification, deregulation of a 
transcription factor or demethylation of CpG islands in the promoter regions of the gene 
(Croce, 2008). 
 An example of an oncomir is the miR-17-92 cluster, which is a miRNA 
polycistron located at chromosome 13q31, a genomic locus that is amplified in lung 
cancer and other kinds of lymphomas including diffuse large B-cell lymphoma 
(Hayashita et al., 2005; He et al., 2005). In comparison to normal tissue the expression 
of miR-17-92 is significantly increased in several cancer types. The miR-17-92 cluster 
appears to enhance lung cancer cell growth (Hayashita et al., 2005).  
 MiRNAs that are down-regulated are considered tumor suppressor genes. Tumor 
suppressor miRNAs usually prevent tumor development by negatively regulating 
oncogenes and/or genes that control cell differentiation or apoptosis (Zhang et al., 2007). 
MiRNAs that act as tumor suppressors can be down-regulated as a result of deletions, 
epigenetic silencing, or loss of the expression of transcription factors (Ruan et al., 2009).  
 Let-7 is an example of a tumor suppressor miRNA. Inappropriate expression of 
let-7 results in oncogenic loss of differentiation. In let-7 mutants, stem cells are unable 
to exit the cell cycle and terminally differentiate at the correct time, which is a hallmark 
of cancer (Reinhart et al., 2000). Let-7 is located at a chromosome region that is usually 
deleted in human cancer. Let-7 is found to be poorly expressed in lung cancers, and the 
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reduced let-7 expression has been shown to be significantly associated with shortened 
post-operative survival (Takamizawa et al., 2004).  
 
2.5 MiRNA and Apoptosis 
 
 In contrast to normal cells, cancer cells have the ability to disrupt the balance 
between pro- and anti-apoptotic factors to promote cell survival under the conditions of 
environmental stress. In terms of molecular events occurring in tumors, apoptosis is an 
important hallmark of tumor progression. MiRNAs are critical apoptosis regulator in 
tumorigenesis, and cancer cells are able to manipulate miRNAs to regulate cell survival 
in oncogenesis. 
 
2.5.1 Pro-Apoptotic miRNAs 
 
 MiRNAs can participate in tumorigenesis by directly targeting anti-apoptotic 
genes.  
 
miR-15 & miR-16: miR-15 and miR-16 are two examples of pro-apoptotic miRNAs, 
and they function by targeting and inhibiting the pro-survival molecule Bcl-2 to disrupt 
tumor development by promoting apoptosis through the mitochondrial pathway (Calin 
et al., 2002). Deletions and translocations involving miR-15a and miR-16-1 are located 
in a cluster at 13q14.3, and their downregulation can be found in B-cell CLL patients. 
Bcl2 overexpression by downregulation of miR-15a and miR-16-1 seems to be the main 
regulatory mechanism involved in the pathogenesis of the major fraction of human B 
cell CLL (Cimmino et al., 2005). Downregulation of miR-15a and miR-16-1 have also 
been reported in cases of diffuse large BCLs. Therefore it can be assumed that the 
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significance of this mechanism may be extended to other human malignancies. 
 
miR-29: miR-29 regulates myeloid cell leukemia-1 (Mcl-1) protein expression and 
induces apoptosis. Mcl-2 is an important multidomain anti-apoptotic protein of the Bcl-
2 family, which contains the Bcl-2-homology domains BH1-3, and heterodimerizes 
with other Bcl-2 family members (Mott et al., 2007). When miR-29b expression is 
increased, the cellular protein levels of Mcl-1 can be reduced, which in turn leads to an 
increase of BH3-only domain proteins Bim and Puma and sensitizes the cancer cells to 
tumor necrosis-factor-related apoptosis inducing ligand (TRAIL) cytotoxicity. This will 
activate the Bak/Bax dependent apoptotic cascade and death ligand-induced apoptosis 
(Mott et al., 2007; Han et al., 2006).  
 
miR-34 family members: miR-34a, miR-34b, and miR-34c, members of the miR-34 
family, are down-regulated in various human cancers. The expression of miR-34 is 
associated with the expression of p53 and is strongly induced by genotoxic and 
oncogenic stress in a p53-dependent manner (He et al., 2007). When miR-34 expression 
is reduced, p53-mediated cell death is weakened, whereas an overexpressed expression 
of miR-34 leads to apoptosis or cellular senescence through the direct repression of 
several targets genes, such as Bcl-2, Cdk4 and hepatocyte growth factor receptor (Met), 
which promotes cell cycle arrest, apoptosis and senescence (He et al., 2007). 
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2.5.2 Anti-apoptotic miRNAs 
 
 miR-133 and miR-24a: During initiation of the intrinsic pathway of apoptosis, 
cytochrome c is released from the mitochondrial intermembrane space after BAX and/or 
BAK oligomerisation forms a caspase-9 activating complex of apoptosome with 
APAF1 and pro-caspase 9. miR-133 and miR-24a have been shown to inhibit the 
expression of Caspase-9, thus leading to a block of the intrinsic pathway of apoptosis. 
MiR-133 acts as a regulator of survival in cardiac cells by repressing Caspase-9 
expression at both the protein and mRNA levels (Xu et al., 2007). miR-24 is capable of 
repressing apoptosis by directly inhibiting Caspase-9, and prevents apoptosis of the 
retina during eye morphogenesis of Xenophus, thus playing a pivotal role in controlling 
the eye size (Walker and Harland, 2009).  
 
miR let-7a: miR let-7 inhibits the executioner caspase-3, thus antagonizing drug-
induced apoptosis. Let-7 has been shown to play a role in modifying the sensitivity of 
cells to therapeutic drugs including duxorubicon, paclitaxel and interferon-gamma 
(Tsang and Kwok, 2008). A dysregulated expression of let-7 decreases the extent of 
drug induced apoptosis as well as apoptotic cell population.  
 
miR-17-92 cluster: The miR-17-92 cluster has been reported to negatively regulate the 
expression of E2F1 and shift the E2F transcriptional balance away from the pro-
apoptotic E2FI and toward the proliferative E2F3 transcriptional network (Woods et al., 
2007). The miR-17-92 cluster is amplified in B cell lymphomas and shows an altered 
expression in many tumor types. This cluster is also capable of inhibiting apoptosis by 
negatively regulating the tumor suppressor PTEN and the pro-apoptotic protein Bim. 
Downregulation of Bim by the miR-17-92 cluster may contribute to this miRNAs 
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ability to increase the severity of disease progression (Xiao et al., 2008). 
 
miR-21: mir-21 expression is up regulated in human breast, colon, lung, pancreas, 
prostate and stomach cancers (Volinia et al, 2006). Direct targets of miR-21 include 
PTEN, tropomyosin 1, and programmed cell death 4 (PDCD4). Up-regulation of miR-
21 will reduce cell death and promotes angiogenesis and invasion of hepatocellular 
carcinoma (Loffler et al., 2007). Overexpression of miR-21 provides a significant 
survival advantage to cancer cells.  
 
2.6 MiRNA in Cancer Diagnosis and Treatment 
 
2.6.1 MiRNA Signatures in Cancer Diagnosis 
 
 Through the use of transcriptional profiling, it has been found that the 
expression of miRNAs is highly standardized in specific tissues. Therefore, it has been 
suggested that these miRNA signatures can be used for the detection and classification 
of various cancers as well as to predict the severity of disease (Garzon et al., 2010). 
These include chronic lymphocytic leukemia, chronic myeologenous leukemia, and 
prostate, testicular, lung, breast, ovarian, pancreatic, and gastric cancer (Tricoli and 
Jacobson, 2007). For example, in a study conducted by Yanaihara and colleagues, in 
2006, it was found that the genome-wide expression profiling of miRNAs was 
significantly different among primary lung cancers and the corresponding non-
cancerous lung tissues. The correlation between miRNA expression profiles and lung 
adenocarcinoma patient survival were also investigated and it was found that lung 
adenocarcinoma patients with either high hsa-mir-155 or reduced hsa-let-7a expression 
had a poorer survival than patients with low hsa-mir-155 or high hsa-let-7a-2 expression, 
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respectively (Yanaihara et al., 2006). Furthermore, studies have shown that the miRNA 
signatures characterize the developmental origins of tumors more effectively than 
mRNA signatures, thus providing a more useful tool for diagnosis and prognosis of 
human cancer (Tricoli and Jacobson, 2007). 
 
2.6.2 MiRNA as a Target For Cancer Treatment 
 
 Experimental studies have shown that targeting miRNA expression can modify 
cancer phenotypes, thus miRNAs have become targets of novel anticancer gene therapy. 
Targeting of miRNA is based on either selective inhibition of miRNA expression or 
binding or selective overexpression (Nana-Sinkan and Croce, 2011). Using miRNAs as 
therapeutic agents have become very appealing due to their ability to target multiple 
genes, thus making them extremely efficient in regulating distinct biological cell 
processes that are involved in normal and malignant cell homeostasis (Garzon et al., 
2010).  
 There are a number of different strategies for miRNA targeting. Direct strategies 
involve the use of oligonucleotides or virus-based constructs to either block the 
expression of an oncogenic miRNA or to substitute for the loss of expression of tumor 
suppressor miRNA (Garzon et al., 2010). Some examples of direct strategies include 
anti-miRNA oligonucleotide (AMOs), antagomirs, miRNA sponges (Nana-Sinkan and 
Croce, 2011) and miR-masking antisense oligonucleotide technology (miR-mask) 
(Garzon et al., 2010). AMOs are single-stranded molecules that form direct 
complementarity and thus inhibiting specific miRNA. Antagomirs are also single 
stranded molecules that form direct complementarity, thus inhibiting specific miRNAs. 
However they have been modified with a cholesterol conjugated 2’-O-methyl in order 
to maintain stability, thus minimizing degradation (Nana-Sinkan and Croce, 2011). 
 48 
MiRNA sponges function by using multiple complementary 3’UTR mRNA sites for a 
specific miRNA. These sponges will competitively bind to miRNA, thus interfering 
with normal targeting of miRNA. The advantage of using miRNA sponges include its 
ability to target and inhibit a whole family of miRNAs as opposed to single miRNA 
targeting that occurs with antisense oligonucleotides (Nana-Sinkan and Croce, 2011). 
MiRNA-mask consist of single-stranded 2’-O-methyl-modified antisense 
oligonucleotides that are fully complementary to the predicted miRNA binding sites in 
the 3’UTR of the target mRNA. This will allow the miR-mask to cover up the miRNA-
binding site, thus blocking the oncogenic miRNA deleterious functions at the target 
level, and activating the translation of target mRNA (Garzon et al., 2010). 
 In a study conducted by Tuschl and colleagues, targeting of miR-122 in the 
mouse liver using an anti-miR-122 antagomir resulted in the complete degradation of 
miR-122 in a dose-dependent manner. These antagomirs were highly specific and long 
lasting, with little or no short-term toxicity (Tricoli and Jacobson, 2007). In another 
study, conducted by Blenkiron and Miska, the oncogenic miR-17-92 cluster was also 
successfully down-regulated, through the use of 2’-O-methyl oligoribonucleotides (2’-
O-Me-RNA) antagomir in mouse tissues following intravenous injection in vivo 
(Blenkiron and Miska, 2007). These studies suggested that targeting of specific 
miRNAs for the purpose of attaining a therapeutic advantage might be possible through 
the use of antagomirs (Tricoli and Jacobson, 2007). 
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Figure 2.9: Oncogenic miRNAs can be blocked through the use of antisense 
oligonucleotides, miRNA (Figure adapted from Garzon et al., 2010).  
 
The expression of miRNAs that function as tumor-suppressors can be lost or 
down-regulated in cancer. This issue can be overcome through the introduction of 
synthetic oligonucleotides that are identical to the selected miRNA, known as miRNA 
mimics (Garzon et al., 2010). Various studies have shown that synthetic miRNA 
mimics with tumor-suppressor functions in cancer cells induced cell death and as well 
as blocking proliferation (Bonci et al., 2008; Akao et al., 2006). For example, mimics of 
miR-15a in prostate cell lines induce apoptosis. These miRNA mimics are small, 
usually double stranded and are chemically modified, 2’-O-methyl with 
phosphorothioate modifications (Bonci et al., 2008).  
 Another strategy that is utilized to increase the expression of tumor-suppressor 
miRNAs in cancer is the adenovirus-associated vectors (AAV). An advantage of these 
AAV is that they do not integrate into the genome and are eliminated efficiently with 
minimal toxicity. Also, AAV vectors have efficient transduction of target cells. In a 
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study conducted by Kota and colleagues, it was found that the expression of miR-26 
was lost in human liver cancers, while expressed at high levels in normal tissue (Kota et 
al., 2009). The decreased levels of miR-26 in liver cancer cells were shown to induce 
cell-cycle arrest. Kota and colleagues then cloned miR-26 into an AAV, and 
intravenous injection of this miRNA into liver cancer mouse models resulted in the 
suppression of tumorigenicity by inducing tumor apoptosis and repressing cell growth, 
without any signs of toxicity (Kota et al., 2009). Many serotypes of AAV are available 
which allow for efficient targeting of many tissues of interest. Therefore through use of 
this technology, it would be possible to target cancers that arise from different tissues 
(Garzon et al., 2010). 
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CHAPTER 3: MATERIALS AND METHODS 
 
3.1 Cancer Cell Lines 
 
3.1.1 Cell Lines and Culture Conditions 
 
The human lung adenocarcinoma cell line (A549) and the normal human 
nasopharyngeal epithelial cell line (NP69) was obtained from Cancer Research 
Initiative Foundation (CARIF), Sime Darby Medical Centre, Malaysia. A549 cells were 
cultured in Roswell Park Memorial Institute 1640 (RPMI 1640) (Thermo Scientific 
Hyclone, USA) culture medium, supplemented with heat inactivated 10% (v/v) fetal 
bovine serum (FBS) (JR Scientific Inc. USA), while NP69 was cultured in keratinocyte 
serum-free medium (KSFM) (Gibco, USA) supplemented with 1×2.5μg recombinant 
epidermal growth factor (rEGF) (Gibco, USA) and 1×2.5mg bovine pituitary extract 
(Gibco, USA). Both cell lines were grown as a monolayer and maintained in a carbon 
dioxide (CO2) incubator (Memmert, Germany) with high relative humidity (95.0%), 
stable temperature (37°C), controlled CO2 levels (5.0%) and controlled pH (7.2-7.4).  
 
3.1.2 Subculturing Cell Line Monolayers: Harvesting a Cell Monolayer 
 
 A549 was split every two to three days, or when 80-90% confluency was 
achieved on the culture flask surface. The spent culture medium was removed and 
discarded using a serological pipette. The cell monolayer was rinsed with sterile 
autoclaved 1× phosphate- buffered saline (1×PBS) to remove any residual serum that 
could inactivate trypsin activity. The PBS was removed and discarded using a 
serological pipette. 3ml of dissociating agent, 0.25% trypsin (Sigma-Aldrich, USA) 
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ethylenediaminetetraacetic acid (EDTA) (Gibco, USA), was added to the culture flask. 
The culture flask was incubated in 37°C in the CO2 incubator for approximately 10 
minutes to allow the cells in the culture flask to detach from the flask. The progress of 
cell detachment was checked every five minutes using an inverted fluorescence 
microscope (Nikon, Japan).  
 Once the cells were detached, equal volume of culture medium, supplemented 
with 10% (v/v) FBS, was added to the culture flask to inactivate trypsin activity. Any 
remaining cells were washed from the bottom of the culture flask and a quick check was 
done under the inverted microscope to look for single cells in the suspension. If mostly 
single cells were observed, more vigorous pipetting was performed on the suspension. 
All the suspension was then transferred to a labeled 15ml Falcon tube and the tube was 
centrifuged for 5 minutes at 1,200 RPM using the Eppendorf Centrifuge 5702 
(Eppendorf, Germany). The supernatant in the tube was then discarded and the cell 
pellet was resuspended in fresh culture medium. The cell suspension was then collected 
for cell counting or divided into prepared culture flasks for routine maintenance of cell 
lines. For routine maintenance of cell lines, approximately 2ml of cell suspension was 
transferred to a new T-25cm
2
 culture flask with 3 ml of new growth medium. The 
culture flask was then stored at 37°C in the 5.0% CO2 incubator.  
 
3.1.3 Cell Counting 
 
A dye exclusion viability assay using a haemocytometer was used to determine 
the number of cells present in a specific population. The cell suspension was gently 
mixed and 20μl of the suspension was aliquoted into a 1.5ml microcentrifuge tube, and 
20μl of 0.08% tryphan blue stain (Sigma-Aldrich, USA) was then added to this aliquot 
and mixed well. The tube was left to stand for about 3 minutes. After 3 minutes, 10μl of 
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the mixture was removed and loaded on to a clean haemocytometer (Resistance, 
Germany) chamber to be counted. The counting was conducted under the inverted 
fluorescence microscope at 100 magnification. Dead cells appeared blue, while viable 
cells appeared as unstained bright spheres. The number of cells in each of the four 
square grid corners was counted and the average number of cells was obtained. Each 
square grid represents a 0.1mm
3
 or 10
-4
ml volume, and the concentration of cells was 
determined according to the following formula, with a dilution factor of two. 
 
                              
                           
                   
                  
 
From the concentration, the volume of suspension required for cell plating was 
calculated. 
 
3.2 Short Interfering RNA (siRNA) Transfection 
 
3.2.1 Stealth RNAi™ siRNA Duplex Oligonucleotides (Invitrogen, USA) 
 
Table 3.1: Stealth RNAi™ siRNA Duplex Oligonucleotides used for transfection 
Primer Name Sequence Length 
BCL2L1-
HSS141361 
Forward (RNA) – UCA CUA AAC UGA CUC CAG CUG UAU C 25 
Reverse (RNA) – GAU ACA GCU GGA GUC AGU UUA GUG A 25 
BCL2L1-
HSS141362 
Forward (RNA) – AUG GGU UGC CAU UGA UGG CAC UGG G 25 
Reverse (RNA) – CCC AGU GCC AUC AAU GGC AAC CCA U 25 
BCL2L1-
HSS141363 
Forward (RNA) – AUC ACC UCC CGG GCA UCC AAA CUG C 25 
Reverse (RNA) – GCA GUU UGG AUG CCC GGG AGG UGA U 25 
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3.2.2 Transfection of siRNA  
 
 siRNA silencing of the Bcl-xL gene was performed using the Stealth RNAi™ 
siRNA Duplex Oligonucleotides (Table 3.1.), according to a modified version of the 
manufacturer’s protocol. One day prior to transfection, 1.125×106 A549 cells were 
plated in 15ml of RPMI 1640 medium without antibiotics in a T-75cm
2
 culture flask 
(Corning, USA). Cells were 60% confluent at the time of transfection. For each 
transfection sample, a Stealth RNAi™-Lipofectamine™ 2000 complex was prepared as 
follows: 10μl of 20μM of Stealth RNAi™ oligonucleotide was diluted in 1990μl of 
Opti-MEM
® I Reduced Serum Medium (Invitrogen, USA) and mixed gently. 37.5μl of 
Lipofectamine™ 2000 Transfection Reagent (Invitrogen, USA) was diluted in 1875μl 
of Opti-MEM
® 
I Reduced Serum Medium and mixed gently. Both solutions were left to 
incubate for 15 minutes at room temperature. After the 15 minute incubation, the diluted 
Stealth RNAi and the diluted Lipofectamine™ 2000 (total volume ≈4ml) was combined 
and mixed gently. The combined solution was incubated for 15 minutes at room 
temperature to allow complexes to form. The ≈4ml of Stealth RNAi™-Lipofectamine™ 
2000 complexes was added to the 75cm
2
 flask containing cells and growth medium. The 
flask was mixed gently by rocking back and forth. The cells were then incubated at 
37°C in the humidified CO2 incubator for 24 hours.  
 The same procedure was carried out with the Stealth RNAi™ siRNA Negative 
Control Low GC (Invitrogen, USA) and Stealth RNAi™ siRNA Negative Control High 
GC (Invitrogen, USA) as well as the BLOCK-iT™ Alexa Fluor® Red Fluorescent Oligo 
(Invitrogen, USA). 
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3.3 RNA isolation using TRIzol® Reagent (Invitrogen, USA) 
 
3.3.1 Homogenization 
 
 The spent culture medium in the flask was removed and discarded using a 
serological pipette. The remaining cells were washed with sterile autoclaved 1×PBS to 
remove any remaining culture medium. The solution in the culture flask was removed 
and discarded. 5ml of dissociating agent 0.25% trypsin EDTA was added to the culture 
flask. The flask was then incubated at 37°C in the CO2 incubator for approximately 10 
minutes to allow the cells in the culture flask to detach. The progress of cell detachment 
was checked every five minutes using the inverted fluorescence microscope.  
 Once the cells were detached 5ml of RPMI 1640 culture medium was added to the 
flask. The suspension was then transferred from the culture flask to a labeled 15ml 
Falcon tube, and the tube was centrifuged for 10 minutes at 1200RPM. The supernatant 
in the tube was discarded and the pellet was resuspended in 1ml of TRIzol® reagent. 
The cell lysate was passed through a pipette several times. 
 
3.3.2 Phase Separation 
 
The homogenized sample was transferred to a 1.5ml microcentrifuge tube and 
incubated for 5 minutes at room temperature to allow for the complete dissociation of 
nucleoprotein complexes. 0.2ml of chloroform (J.T Baker, USA) was added and the 
caps capped securely. The tubes were shaken vigorously by hand for 15 seconds and 
incubated at room temperature for 3 minutes. The tubes were then centrifuged at 
12,000×g for 10 minutes at 4°C in the Sorvall Legend Micro 17R (Thermo Scientific, 
USA) centrifuge. Following centrifugation, the mixture separated into a lower red, 
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phenol-chloroform phase, an interphase, and a colorless upper aqueous phase. RNA 
remains exclusively in the aqueous phase. The volume of the aqueous phase was about 
60% of the volume of TRIzol-reagent used for homogenization.  
 
3.3.3 RNA Precipitation 
 
 The aqueous phase was transferred to a fresh tube. The RNA was precipitated 
from the aqueous phase by mixing with 0.5ml of isopropanol (Merck, Germany). The 
samples were incubated at room temperature for 10 minutes and then centrifuged at 
12,000×g for 10 minutes at 4°C. 
 
3.3.4 RNA Wash 
 
 The supernatant was removed and the pellet washed once with 1ml of 75% 
ethanol (J.T Baker, USA). The sample was mixed by vortexing and then centrifuged at 
7,500×g for 5 minutes at 4°C. 
 
3.3.5 Re-Dissolving the RNA 
 
 After centrifugation, the supernatant was removed and the RNA pellet was air-
dried for about 5 to 10 minutes. The RNA samples was then dissolved in nuclease-free 
water (Qiagen, Germany) by passing the solution a few times through a pipette tip, and 
incubating for 10 minutes in the water bath incubator (Memmert, Germany) at 58°C. 
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3.4 Quantitation of RNA 
 
 The concentration and purification of extracted RNA for transfected and non-
transfected cells were analyzed using the NanoDrop 2000 (Thermo Scientific, USA). 
When the arm was open, 1μl of distilled water was pipetted directly on the pedestal and 
used as a blank for the NanoDrop. When the measurement was complete, the surfaces 
were wiped with a lint-free KimWipe before going on to the next sample. The RNA 
concentration, OD260, OD280, A260/280, and A260/230 ratio of the samples were measured 
 
3.5 Agarose Gel Electrophoresis 
 
 In the casting tray 1.0 × 10-2 g/ml gel solution was prepared. In other words 1% 
Low EEO Agarose (Amresco, USA) in 40.0ml 1×Tris/Borate/EDTA (TBE), prepared 
from 10X TBE liquid concentrate (Bio-Rad, USA), was measured and prepared using 
the Analytical Balance CP224S (Sartorius, Germany). The solution was heated in the 
microwave oven (Pensonic, Malaysia) at medium heat for 2 minutes. Meanwhile an 
attached 6 well 1.0mm gel comb was placed in the 5.5×12.0cm gel-casting tray 
(BayGene, China). After the agarose powder was dissolved completely, the mixture was 
cooled under running water before being poured into the prepared casting tray. When 
the gel was completely solidified, after approximately 30 minutes, the gel comb was 
carefully removed without damaging the gel’s sample wells and the gel was placed in 
the gel buffer tank, BG-Submidi Submarine Unit (BayGene, China). 1×TBE 
electrophoresis buffer was then added into the tank until it covered the gel’s surface to a 
depth of 1-2mm.  
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 For RNA sample loading, 2 volumes of 2×RNA loading dye (Fermentas, Canada) 
was mixed with 2 volumes of RNA sample. This mixture was boiled for 10 minutes at 
70°C using a water bath, and then cooled to room temperature. 3μl of RiboRuler™ High 
Range RNA Ladder (Fermentas, Canada), was also boiled for 10 minutes at 70°C. After 
boiling, 3μl of the RiboRuler™ High Range RNA Ladder was loaded into the well of 
the gel.  3μl of each RNA sample was also loaded into the gel. After all the RNA 
samples had been loaded, the lid was assembled onto the electrophoresis chamber 
correctly so that the RNA can be migrated towards the positive lead. The electric 
sources were provided by Power Supply-PowerPac (Bio-Rad, USA). The gel 
electrophoresis was run at 80.0 volts and 400.0 mA of free running current for 
approximately 60 minutes or until the dye front was 1.0-2.0cm from the bottom of the 
gel.  
 
3.5.1 Detection of RNA Bands 
 
 The gel was stained for 15 minutes in 0.5μg/ml ethidium bromide (EtBr) (Sigma-
Aldrich, USA) solution and de-stained for 10 minutes in distilled water to remove any 
residual staining solution. The gel was then visualized under UV transillumination and 
analyzed by the Imager Kit Digital, AlphaImager™ 2000 (Alpha Innotech, USA) at 
320nm wavelength. 
 
 
 
 
 
 59 
3.6 Protein Isolation Using NE-PER Nuclear and Cytoplasmic Extraction Kit 
(Pierce, USA) 
 
 The A549 cells were plated on a 75.0cm2 culture flask and grown to 80% 
confluency. The confluency of the cells was assessed through use of an inverted 
microscope. Once the desired confluency was achieved, the spent culture medium in the 
flask was removed and discarded using a serological pipette. The remaining cells were 
washed with sterile autoclaved 1×PBS to remove any remaining culture medium. The 
solution in the culture flask was removed and discarded. 5 ml of dissociating agent 
0.25% trypsin was added to the culture flask. The flask was then incubated in 37°C and 
5% CO2 incubator for approximately 10 minutes to allow the cells in the culture flask to 
detach. The progress of cell detachment was checked every five minutes using an 
inverted microscope.  
 Once the cells were detached, 5 mL of the RPMI-1640 culture medium was added 
to the flask. Any remaining cells were washed from the bottom of the culture flask and a 
quick check was conducted under the inverted microscope to ensure that the suspension 
was made up of single cells. If they are not mostly single cells, vigorous pipetting of the 
mixture was done on the suspension. The suspension was then transferred from the 
culture flask to a labeled 15 ml Falcon tube, and the tube was centrifuged for 10 minutes 
at 1500 RPM using a Centrifuge 502 (Eppendorf, USA). 
 NE-PER® Nuclear and Cytoplasmic Extraction Kit was used to extract the 
cytoplasmic protein from the whole cell lysate. The NE-PER® Nuclear and Cytoplasmic 
Extraction Kit contains three reagents, Cytoplasmic Extraction Reagent I (CER I), 
Cytoplasmic Extraction Reagents II (CER II) and Nuclear Extraction Reagent (NER). 
1×Halt™ Protease (Thermo Scientific, USA) and 1×Phosphatase inhibitor cocktails 
(Thermo, USA) were freshly prepared and added to the CER I in 1:1000 dilution to 
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prevent proteolysis and dephosphorylation.  
 The supernatant in the tube was discarded and the pellet was resuspended in 200μl 
of ice cold CER I and vortexed vigorously for 15 seconds to fully resuspend the pellet. 
The tube was then incubated on ice for 10 minutes. 11μl of ice cold CER II was added 
to the tube and vortexed for 5 seconds. The tubes were incubated on ice for 1 minute 
and then vortexed again for 5 seconds. The tubes were then centrifuged at 16,000×g for 
5 minutes and the supernatant, containing the cytoplasmic extract, was transferred to a 
new pre-chilled tube. The protein solution was used immediately for Western blotting, 
otherwise, the solubilized proteins was stored at -20°C and the heating, centrifugation 
steps performed at the time of use. 
 
3.7 Bradford Assay Protein Quantification 
 
 The Quick Start Bradford Protein Assay Kit was used to determine the protein 
concentration of extracted protein samples. The Quick Start™ Bradford Dye Reagent 
(Bio-Rad, USA) was removed from the 4°C fridge and allowed to cool to room 
temperature. The Quick Start™ Bovine Serum Albumin (BSA) Standard Set (Bio-Rad, 
USA), containing seven known concentrations of BSA (2.000, 1.500, 1.000, 0.750, 
0.500, 0.250, and 0.125 mg/ml) was used to create a standard curve. This allows for the 
determination of the unknown sample’s concentration. Blank, standards and samples 
were diluted with a dilution factor of 100. 10.0μl of each BSA standards and protein 
samples were added into separate 10.0mm×10mm disposable cuvettes, followed by 
990μl 1×dye reagent and mixed well. Blank sample was prepared using 10.0μl of 
distilled water and 990.0μl 1×dye reagent. The blank, standards and samples were 
incubated at least 5 minutes at room temperature.  
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The parameter of the spectrophotometer was set to 595nm wavelength. This 
instrument was zeroed by the blank sample. Absorbance of each standards and samples 
were then measured. A standard curve was created by plotting the 595nm values (y-
axis) against the standard concentration in mg/ml (x-axis). After obtaining the samples 
concentration, samples were then normalized to the same concentration with distilled 
water. All samples were kept at -20.0°C freezer until further use. 
 
3.8 Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR) 
 
The oligonucleotides used for qRT-PCR was obtained from 1
st
 Base, Singapore.   
 
Table 3.2: Oligonucleotides used for qRT-PCR 
Synthesis 
ID 
Oligo 
Name 
Sequence Length 
782265 
Bcl-xL 
Forward 
5’-CGT GGA AAG CGT AGA CAA GGA-3’ 21 
782266 
Bcl-xL 
Reverse 
5’-ATT CAG GTA AGT GGC CAT CCA A-3’ 22 
782267 
β-Actin 
Forward 
5’-AAG CCA CCC CAC TTC TCT CTA A-3’ 22 
782268 
β-Actin 
Reverse 
5’-ACC TCC CCT GTG TGG ACT TG-3’ 20 
 
First strand cDNA was synthesized for use in real-time quantitative RT-PCR, 
using the SuperScript III First-Strand Synthesis SuperMix (Invitrogen, USA).  The 
following kit components were combined on ice. For multiple reactions, a master mix 
without RNA was prepared.  
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Table 3.3: Kit components used to prepare cDNA samples 
Component Volume 
2 RT Reaction Mix 10μl 
RT Enzyme Mix 2μl 
RNA (up to 1μg)  μl 
DEPC-treated water to 20μl 
 
 The tube contents was gently mixed and incubated at 25°C for 10 minutes. The 
tubes were then incubated at 50°C for 30 minutes and the reaction then terminated at 
85°C at 5 minutes. The tubes were then chilled on ice and 1μl of E. coli RNase H was 
added and the tubes incubated at 37°C for 20 minutes. The cDNA was then used in 
qPCR.  
 The Platinum SYBR Green qPCR SuperMix-UDG with ROX (Invitrogen, USA) 
was used to carry out qPCR. For each qPCR reaction the following components were 
added to a 0.2-ml microcentrifuge tube. The volumes for a single 50μl reaction are 
listed below. For multiple reactions, a master mix of common components was prepared 
and the appropriate volume added to each tube, and the unique reaction components (eg. 
template) was then added. 
 
Table 3.4: Kit components used to prepare qPCR samples 
Component Volume 
Platinum

 SYBR
 
Green qPCR SuperMix-UDG with ROX 25μl 
Forward primer, 10μM 1μl 
Reverse primer, 10μM 1μl 
Template (cDNA generated from 10pg to 1μg of total RNA) ≤ 10μl 
DEPC-treated water to 50μl 
 
 The reaction tubes were capped and gently mixed. The reactions were then placed 
into a preheated real-time instrument, the CFX96 Real-Time PCR Detection System 
(Bio-Rad Laboratories, USA), and programmed as described below.  
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Table 3.5: Real-time PCR instrument conditions 
50C for 2 minutes hold (UDG incubation) 
90C for 2 minutes 
40 cycles of: 95C, 15 seconds 
                       60C, 30 seconds 
Melting curve analysis.  
 
3.9 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
 
 The SDS-PAGE is a technique for separating proteins according to their 
molecular weight. The separation of protein molecules within a gel is determined by 
relative size of the pores formed within the gel. 12.0% resolving gel was used to 
separate proteins ranging from 14-70kDa. 4.0% stacking gel and 12.0% resolving gel 
was prepared by mixing the reagents listed in Table 2.4 together. Freshly prepared 
10.0% (w/v) APS and TEMED were added last to the mixture to initiate gel 
polymerization. Bromophenol blue, an anionic small molecule, was added to the 
stacking gel and functioned as a tracking dye, which monitored the migration front of 
the proteins.  
 18.0cm×16.0cm, with 0.75mm thickness, glass plates (Bio-Rad, USA) were 
aligned and clipped to the casting tray (Bio-Rad, USA). The resolving gel was prepared 
and loaded until 75% of the glass plate was filled. The remaining resolving gel solution 
was kept in a tube rack as an indicator of complete gel polymerization, which usually 
takes approximately 45 minutes. Immediately after adding the resolving gel, 0.1% (v/v) 
SDS was added gently on top of the resolving gel to prevent oxidization and 
dehydration of the gel, which can slow down the polymerization process. After 
polymerization was complete, the 0.1% SDS solution was rinsed out by tilting the 
casting tray and blotting out the solution with Kim-wipe (Kimberly-Clark, Canada).  
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The desired volume of 10% APS was added into the stacking solution. The 
solution was mixed well and straight away added to the cast above the resolving gel. 
The stacking solution was ensured to completely fill 100% of the glass plate until it 
overflows. The 10-well gel comb, with a 0.75mm thickness, was inserted at an angle to 
prevent formation of air bubbles. The remaining stacking gel solution was kept in a tube 
rack as an indicator of complete gel polymerization (approximately 45 minutes). 
 
Table 3.6: Reagents for preparation of 4.0% stacking gel and 12.0% resolving gel for 
SDS-PAGE 
Reagents 
Stacking Gel 
(4.0%) 
Resolving gel 
(12.0%) 
40.0% (w/v) Acrylamide (Promega, USA) 360μl 4320μl 
2.0% (w/v) Bis-Acrylamide (Promega, USA) 195μl 2400μl 
0.5M Tris HCl (pH6.8) 945μl - 
1.5M Tris HCl (pH 8.8) - 3750μl 
10.0% (w/v) SDS 37.5μl 150μl 
Distilled H2O 2175μl 4280μl 
N,N,N’,N’ – Tetramethyl-ethylenediamine 
(TEMED) (Acros, USA) 
3.8μl 7.5μl 
10.0% (w/v) APS 18.8μl 75.0μl 
Bromophenol Blue (Fisher Scientific, USA) 7.5μl - 
Total Volume 3.75ml 15.0ml 
 
3.9.1 Sample Preparation 
  
 Antibodies typically recognize a small portion of the protein of interest (epitope), 
and this domain may reside within the three dimensional conformation of the protein. 
To enable access of the antibody to this portion it is necessary to denature the protein. 
Lane Marker Reducing Sample Buffer (5×) (Thermo Scientific, USA) contained 
dithiothreitol (DTT) as a reducing agent to reduce disulphide bridges within tertiary 
protein structures to produce primary protein structures. The sample buffer also 
contained SDS, which binds to the polypeptides to form complexes with fairly constant 
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negative charge to mass ratios. The electrophoretic migration rate through a gel is 
therefore determined only by the size of the complexes.  
First, protein samples and the Lane Marker Reducing Sample Buffer (5×) was 
equilibrated to room temperature. One volume of sample buffer was mixed with four 
volumes of protein samples in a microcentrifuge tube. These mixtures were vortexed 
before and after boiling for 5 minutes at 95°C using a thermal cycler, and then cooled to 
room temperature. 
 
3.9.2 Sample Loading and Running the Gel 
 
 The glass plates were transferred to the Mini PROTEAN Tetra System (Bio-Rad, 
USA) and placed in the holder facing each other. The space between the gels was filled 
fully with 1×Tris/Glycine/SDS (TGS) running buffer. The comb was gently removed 
and the wells were flushed with this buffer to allow the wells to form properly and to 
rinse off traces of unpolymerized gel. The tank was then filled with sufficient amount of 
buffer according to the number of gels being run. 5.0μl of Spectra Multicolor Broad 
Range Protein Ladder (Fermentas, Canada) was loaded into the first well followed by 
5.0μl of Biotinylated Protein Ladder (Cell Signaling Technology, USA) (Protein ladder 
sizes are listed in Appendix 2. 15.0μl of protein samples pre-mixed with sample buffer 
was then added to subsequent wells. Gel was run at 110 volts until the sample front 
reached the resolving gel, followed by 120 volts until the end of the gel. Power supply 
was provided by the Power Pack (Bio-Rad, USA).  
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3.10 Western Blotting 
 
3.10.1 Protein Transfer 
 
 The 2μm nitrocellulose membrane (Bio-Rad, USA) and the Extra Thick Blot 
Paper (Bio-Rad, USA) were cut to the same size as the gel or slightly larger than the gel. 
The membrane and filter papers were soaked in 1×TGS transfer buffer with 20.0% (v/v) 
methanol for 10 minutes. Once the SDS-PAGE finished running, the glass was removed 
from the tank carefully. The upper glass plate was removed using a plastic spatula. 
Using a delicate task wiper, the stacking gel was carefully torn away from the resolving 
gel. The glass plate was then inverted over the transfer buffer and then lifted so that the 
surface tension will peel the gel from the glass plate. The gel was soaked in transfer 
buffer for at least 10 minutes. The “transfer sandwich” was then placed in the Trans-
Blot SD Semi-Dry Transfer Cell (Bio-Rad, USA). Each layer of the sandwich was 
rolled out to ensure no air bubbles were formed. The gels were then transferred at 50mA 
at 25 volts for 90 minutes using the MP-2AP Power Supply (Major Science, Taiwan).  
 
Transfer sandwich: 
 Cathode ( - ) 
 Blot paper 
 PAGE gel 
 Nitrocellulose membrane 
 Blot paper 
 Anode ( + ) 
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3.10.2 Visualization of Proteins on Membrane Using Ponceau S Stain (Sigma, 
USA) 
 
 After transferring, the membrane was stained with 0.1% (w/v) Ponceau S Stain 
in 5.0% (v/v) to check the efficiency of proteins transferred. The membrane was soaked 
in Ponceau S staining solution for 5 minutes. After observation, the membrane was 
washed twice with aqueous solution with 5.0% (v/v) acetic acid (Merck, Germany) 
followed by washing twice with distilled water by shaking slowly on the Reciprocal 
Shaker MS-RC (Major Science, Taiwan) for 5 minutes each. After washing, membrane 
was continued to blocking step.  
 
3.10.3 Blocking the Membrane 
 
 The membrane was blocked to prevent non-specific binding of the primary and 
secondary antibodies to the membrane. Two blocking buffers, blocking buffer A and 
blocking buffer B, were used for non-phosphorylated proteins and phosphorylated 
proteins respectively.  Blocking buffer A consisted of consisted of 5.0% (w/v) non-fat 
skim milk powder (Merck, Germany), 0.05% (v/v) Tween 20 (Promega, USA) in 
1×TBS, while blocking buffer B consisted of consisted of 5.0% Bovine Serum Albumin 
(BSA) (Calbiochem, USA), 0.05% Tween 20 and 1×TBS. The membrane was soaked in 
blocking buffer A or B for one and a half hours at room temperature under agitation. 
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3.10.4 Incubation With Primary Antibody 
 
 Equal amounts of cytoplasmic protein extracts were probed against two 
antibodies: Bcl-xL and β-actin. The Bcl-xL rabbit monoclonal antibody (Cell Signaling 
Technology, USA) and β-actin rabbit monoclonal antibody (Cell Signaling Technology, 
USA) was diluted in blocking buffer A and blocking buffer B, respectively, at a dilution 
of 1:1000. The blocked membrane was incubated in primary antibody at 4° overnight in 
a petri dish sealed with parafilm. The following day the membrane was incubated at 
room temperature for 3 hours with agitation. The membrane was then washed 3 times 
with 1×TBST buffer for 5 minutes each with agitation and then incubated with 
secondary antibody.  
 
3.10.5 Incubation With Secondary Antibody 
  
 Anti-rabbit IgG HRP-linked antibody (Cell Signaling Technology, USA) and 
anti-biotin HRP-linked antibody (Cell Signaling Technology, USA) was added at a 
dilution of 1:1000 to blocking buffer B. The membrane was then incubated for 2 hours 
with agitation at room temperature. The membrane was then washed 3 times with 
1×TBST buffer for 5 minutes each, with agitation, followed by a 1×TBS buffer wash 
for 5 minutes, with agitation. The membrane was then blotted dry with Kim-wipes. 
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3.10.6 Exposure of Membrane to Electrochemiluminescence (ECL) 
 
SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific, USA) is 
a high-sensitivity substrate that reacts with horseradish peroxidase (HRP) conjugated to 
the secondary antibodies on the membrane by releasing chemiluminescence signal. This 
kit contained two solutions; the Enhance Solution (hydrogen peroxide) and the Stable 
Peroxide Solution. The working solution was prepared by mixing equal parts of the 
stable peroxide solution and enhancer solution. The membrane was incubated in the 
working solution for 5 minutes. The excess substrate on the membrane was blotted 
away and the membrane wrapped in cling wrap and carefully pressed to get rid of any 
air bubbles. The light emission was most intense during the first 5-30 minutes after 
substrate incubation and decreased with time. Therefore, to protect the membrane, it 
was placed in a Medical X-Ray Cassette (Kodak, USA) in order to prevent light 
exposure.  
 In the darkroom, a piece of General Purpose Green X-Ray film (Kodak, USA) 
was cut to the size of the membrane and carefully placed on top of the membrane inside 
the Medical X-Ray Cassette. The cassette was closed and the film was exposed to the 
chemiluminescence signal for 30 seconds. The exposure time was varied to achieve 
optimal results. The film was then washed in Kodak RP X-OMAT Developer and 
Replenisher (Kodak, USA) to allow the exposed areas of the film to become dark. After 
development, the film was washed with distilled water to remove excess chemical. The 
film was then placed in the Kodak RP X-OMAT Fixer and Replenisher (Kodak, USA). 
The film was subsequently washed with running tap water to remove fixing chemicals 
and allowed to completely dry. Film was then scanned with CanonScan LiDE600F 
Scanner (Canon, Vietnam) and the results analyzed.  
 
 70 
3.11  MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenltetrazolium bromide] 
Cell Viability Assay 
 
A549 cells were harvested by trypsinization and centrifugation, and then re-
suspended with RPMI 1640 culture medium. Using a dye exclusion viability assay, 
viable A549 cells were counted and 1.0 × 10
4
 A549 cells in 100μl of RPMI 1640 
medium were plated in triplicates onto a 96 well microtiter plate. The plate was then 
incubated at 37°C overnight in a CO2 incubator to allow for cell attachement to the well 
surface. Commencement of siRNA transfection was carried out at 100nM at various 
incubation periods (12 hrs, 24hrs and 48hrs). Wells containing Stealth RNAi siRNA 
Negative Control Low GC were used as negative controls and solvent controls using 
Opti-MEM

 I Reduced Serum Medium and Lipofectamine 2000 Transfection 
Reagent were conducted to ensure that decrease in cell viability was not solvent induced. 
Wells containing cells at descending concentrations (10,000 cells, 5,000 cells, 2,500 
cells, 1,250 cells and 0 cells) via a serial dilution was used to constructstandard curves 
for quantification purposes. After incubation,  
Following incubation, 20.0μl MTT reagent (5.0mg/ml) (Calbiochem, USA) was 
added to each well and incubated in the dark at 37°C for one hour. Periodically the cells 
were viewed under an inverted microscope for the presence of the purple formazon 
crystals at the bottom of each well. When the purple formazon crystals were clearly 
visible under the microscope, the media containing excessive MTT reagent was 
aspirated and 200μl of dimethyl sulfoxide (DMSO) (Merck, Germany) was added to 
dissolve the purple formazon precipitates. After a few minutes at room temperature, to 
allow for complete colour stabilization of the formazon compound, results were 
obtained using a microtiter plate reader (Tecan Sunrise

, Switzerland) at 570nm 
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absorbance wavelength and 650nm reference wavelength. The results were then 
quantified using the Magellan Version 6.3 (Tecan, Switzerland) software. 
 
3.12 BioAnalyzer Quantification of Total RNA 
 
 The Agilent RNA 6000 Nano Kit  (Agilent, Germany) was used with the Agilent 
2100 BioAnalyzer (Agilent, Germany) to determine the RNA integrity number (RIN 
value).   
 
3.12.1 Setting Up Chip Priming Station 
 
 The plastic cap of the syringe was removed and the syringe inserted into the clip. 
The syringe was slid into the hole of the lock adaptor and screwed tightly to the chip 
priming station.  
 
3.12.2 Preparing the Gel 
 
550l of RNA 6000 Nano gel matrix was pipetted into a spin filter and 
centrifuged at 1500g for 10 minutes at room temperature. 65l of the filtered gel was 
aliquoted into 0.5ml RNase-free microfuge tubes.  
 
3.12.3 Preparing the Gel-Dye Mix 
 
The RNA 6000 Nano dye concentrate was allowed to equilibrate to room 
temperature for 30 minutes. The dye was then vortexed for 10 seconds, spun down, and 
1l of the dye was added to the 65l aliquot of filtered gel. The solution was vortexed 
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and the tube centrifuged at 13000g for 10 minutes at room temperature. The prepared 
gel-dye mix was used within one day.  
 
3.12.4 Loading the Gel-Dye Mix 
 
 A new RNA 6000 Nano chip was placed on the chip priming station. 9.0l of 
gel-dye mix was pipetted into the well marked       .  The plunger was positioned at 1ml 
and the chip priming station closed. The plunger was pressed until it was held by the 
clip. After 30 seconds the clip was released. After 5 seconds the plunger was pulled 
back to the 1ml position. The chip priming station was opened and 9.0l of gel-dye mix 
was pipetted into the well marked       . The remaining gel-dye mix was discarded.  
 
3.12.5 Loading the Agilent RNA Nano Marker 
 
 5l of RNA Nano marker was pipetted into all 12 sample wells and in the wells 
marked        . 
 
3.12.6 Loading the Ladder and Samples 
 
 1l of prepared ladder was pipetted into the well marked      . .1l was pipetted 
into each of the sample wells. 1l of RNA 6000 Nano marker was pipetted into each 
unused sample. The chip was placed horizontally in the adaptor of the IKA vortexer and 
vortexed for 1 minute at 2400rpm. The chip was then run in the Agilent 2100 
bioanalyzer (Agilent, Germany) within 5 minutes.  
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3.13 MiRNA Microarray – Global miRNA Expression 
 
The microRNA microarray analysis allowed for the examination of the global 
expression pattern of miRNAs in the transfected and non-transfected A549 cells, using 
the Affymetrix GeneChipmiRNA Arrays (Affymetrix, USA) with the FlashTag Biotin 
HSR RNA Labeling Kit (Genisphere, USA).  
 
3.13.1 Poly (A) Tailing 
 
 The volume of RNA was adjusted to 8l with nuclease-free water in a 
microcentrifuge tube, and transferred to ice. 2l of RNA Spike Control Oligos 
(Affymetrix, USA) was added and the tube returned to ice. The ATP mix was diluted in 
1mM Tris (Applied Biosystems, USA) at a dilution of 1:500. The following 
components were then added to the 10l RNA/Spike Control Oligos, to make a final 
volume of 15l. If at least 5 labeling reactions are run simultaneously, a master mix was 
prepared. 5l of master mix was added to the 10l RNA/Spike Control Oligos, for a 
volume of 15l.  
 
Table 3.7: Components used to prepare Poly (A) tail 
Component Volume (l) 
10 Reaction Buffer 1.5 
25mM MnCl2 1.5 
Diluted ATP mix 1.0 
PAP Enzyme 1.0 
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3.13.2 FlashTag Biotin HSR Ligation 
 
 The FlashTag Biotin HSR RNA Labeling Kit (Genisphere, USA) contains the 
following components: 10 Reaction Buffer, 25mM MnCl2, ATP Mix, PAP Enzyme, 
5 FlashTag Biotin HSR Ligation Mix, T4 DNA Ligase, HSR Stop Solution, RNA 
Spike Control Oligos, ELOSA Spotting Oligos, ELOSA Positive Control, Nuclease-free 
water, and 27.5% Formamide.  
The 15l of tailed RNA was briefly centrifuged and placed on ice. 4l of 5 
FlashTag Biotin HSR Ligation Mix was added. 2l of T4 DNA Ligase was then added. 
The mixture was gently mixed and centrifuged. The tubes were then incubated at 25C 
for 30 minutes. The reaction was then stopped by adding 2.5l of HSR Stop Solution. 
The 23.5l of ligated sampled was then mixed and centrifuged. 2l of biotin-labeled 
sample was removed and ELOSA QC Assay was carried out. The remaining biotin-
labeled sample may be stored on ice for up to 6 hours, or at -20C for up to 2 weeks, 
prior to hybridization on Affymetrix GeneChip miRNA Arrays.  
 
3.13.3 Hybridization of Affymetrix Arrays 
 
 The reagents in table 2.6 were first allowed to cool to room temperature. The 
20 Eukaryotic Hybridization Controls (bioB, bioC, bioD, cre from the 
GeneChipEukayotic Hybridization Control Kit (Affymetrix, USA)) was completely 
thawed and then heated for 5 minutes at 65C. The following components were then 
added to the 21.5l biotin-labeled sampled in the order listed below, to prepare the array 
hybridization cocktail: 
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Table 3.8: Components used to prepare array hybridization cocktail 
Component 
Volume 
(l) 
Hybridization Mix (from GeneChip Hyb, Wash and Stain Kit) 50 
Nuclease-free water 10 
Deionized formamide, molecular biology grade 5 
DMSO (from GeneChip Hyb, Wash and Stain Kit) 10 
20 Eukaryotic Hybridization Controls 5 
Control Oligonucleotide B2, 3nM (From GeneChip Eukaryotic Hyb Control 
Kit) 
1.7 
 
The resulting final volume was 103.2l. The samples were then incubated at 
99C for 5 minutes and then 45C for 5 minutes. 100l of the sample was aspirated and 
injected into an array. The pipet tip was removed from the upper right septum of the 
array and both septa covered with 1/2” Tough-Spots to minimize evaporation and/or 
prevent leaks. The arrays were placed into the hybridization oven trays and loaded into 
the hybridization oven. The arrays were incubated at 48C and 60rpm for 16 hours.  
 
3.13.4 Washing and Staining 
 
 The GeneChip Hybridization, Wash & Stain Kit (Affymetrix, USA) was used 
for the washing and staining producedure. The GeneChip Hybridization, Wash & Stain 
Kit contains the components listed in table 3.9.  
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Table 3.9: Components of GeneChip Hybridization, Wash & Stain Kit 
Component Volume (mL) 
Box 1 of 2 
Hybridization Module  
Pre-hybridization mix 6 
2 Hybridization mix 4.5 
DMSO 0.9 
Nuclease-free water 4 
Stain Module  
Stain cocktail 1 18 
Stain cocktail 2 18 
Array holding buffer 30 
Nuclease-free water 4 
Box 2 of 2 
Wash buffer A (3 bottles) 800mL/bottle 
Wash buffer B (1 bottle) 600mL/bottle 
 
After the 16 hours of hybridization, the arrays were removed from the oven and 
the Tough-Spots removed. The hybridization cocktail was extracted from each array 
and transferred to a new tube or well of a 96-well plate in order to save the 
hybridization cocktail. The hybridization cocktail was stored on ice during the 
procedure, or at -80C for long-term storage. Each array was then filled completely with 
Array Holding Buffer, and the arrays allowed to equilibrate to room temperature before 
washing and staining.  
 
The following vials were placed into sample holders on the fluidics station: 
1. One amber vial containing 600l Stain Cocktail 1 was placed in sample 
holder 1.  
2. One clear vial containing 600l Stain Cocktail 2 was placed in sample 
holder 2.  
3. One clear vial containing 800l Array Holding Buffer was placed in sample 
holder 3. 
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The arrays were then washed and stained with Fluidics Station 450 using fluidics script 
FS450_0003. 
 
Table 3.10: Fluidic station protocol summary for the staining of each Affymetrix 
GeneChip

miRNA Arrays 
Protocol Description of Protocol 
Post Hyb Wash #1 10 cycles of 2 mixes/cycle with Wash Buffer A at 25C. 
Post Hyb Wash #2 8 cycles of 15 mixes/cycle with Wash Buffer B at 50C. 
1
st
 stain Probe array stained for 10 minutes with Stain Cocktail 1 (Vial 
position 1) at 25C. 
Post Stain Wash 10 cycles of 4 mixes/cycle with Wash Buffer A at 30C. 
2
nd
 stain Probe array stained for 10 minutes with Stain Cocktail 2 (Vial 
position 2) at 25C. 
3
rd
 stain Probe array stained for 10 minutes with Stain Cocktail 1 (Vial 
position 1) at 25C. 
Final Wash 15 cycles of 4 mixes/cycle with Wash Buffer A at 35C. 
Array Holding 
Buffer 
Probe array filled with Array Holding Buffer (Vial position 3). 
 
The arrays were checked for air bubbles. If air bubbles were observed, the arrays 
were filled manually with Array Holding Buffer.  If no air bubbles were observed, both 
septa were covered with 3/8” Tough-Spots. The array glass surface was observed for 
dust and/or other particulates, and if necessary, the surface was carefully wiped with a 
clean lab wipe before scanning.  
 
3.14 ELOSA QC Assay 
 
3.14.1 Washing and Blocking for ELOSA 
 
 The following steps were completed prior to or during the FlashTag Labeling 
procedure. The ELOSA Spotting Oligos were removed by expelling the liquid into the 
sink. The wells were washed 2 times with 1PBS, 0.02% Tween-20, and blot dry. 150l 
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of 5% BSA in 1PBS was added to each well. The wells were covered and incubated 
for 1 hour at room temperature.  
 
3.14.2 Sample Hybridization 
  
 2.0l of each biotin-labeled reaction was used in the ELOSA. The following 
components were added and gently vortexed until the dextran sulfate was in solution.  
 
Table 3.11: Components used to prepare for ELOSA sample hybridization 
Component Volume (l) 
FlashTag Biotin-labeled RNA sample or 
negative control labeling reaction 
2.0 
5 SSC, 0.05% SDS, 0.005% BSA 48.0 
25% Dextran sulfate 2.5 
 
For the positive and negative control the following components were added and 
gently vortexed until the dextran sulfate was in solution. The mixture was then briefly 
centrifuged.  
 
Table 3.12: Components used to prepare negative and positive controls for ELOSA 
sample hybridization 
Positive Control Negative Control 
Component Volume (l) Component Volume (l) 
ELOSA Positive Control 2.0 
5 SSC, 0.05% SDS, 
0.005% BSA 
50 
5 SSC, 0.05% SDS, 
0.005% BSA 
48.0 
Dextran sulfate 2.5 
25% Dextran sulfate 2.5 
 
The BSA blocking solution was then removed by expelling the liquid into a sink, 
and the wells blotted dry. 52.5l of hybridization solution was then added to the 
designated wells. The wells were covered and incubated at room temperature for 1 hour.  
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3.14.3 SA-HRP Binding 
  
 SA-HRP was diluted in 5% BSA in 1PBS at a dilution of 1:4000. The 
hybridization solution was removed from the wells by expelling the liquid into the sink. 
The wells were washed vigorously 3-4 times with 1PBS, 0.02% Tween 20, and then 
blotted dry. 75l of the diluted SA-HRP was then added to each well. The wells were 
covered and incubated for 30 minutes at room temperature.  
 
3.14.4 Signal Development 
 
 The SA-HRP was removed from the wells by expelling the liquid into a sink. 
The wells were washed vigorously 3-4 times with 1PBS, 0.02% Tween 20, and blotted 
dry. Any bubbles in the wells were removed with a forced air duster or equivalent 
device. 100l of TMB Substrate was then added to the wells. The wells were covered 
and incubated at room temperature for 30 minutes in the dark (or covered with 
aluminum foil).  A blue substrate color indicated a positive result and was used as 
qualitative results. After a successful ELOSA QC assay, Affymetrix GeneChip miRNA 
array procedure was carried out. 
 
3.15 MiRNA Microarray Analysis 
 
 Statistical and gene expression analyses were carried out using the GeneSpring
 
GX (Agilent Technologies, USA) and Partek

 Genomics Suite (Partek Incorporated, 
USA) software. Following scanning of each array, a CEL file containing probe intensity 
readings and a library file specifying the location of each probe on the array was 
generated and input into the software.  Microarray images were analyzed and the 
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average values of the replicate spots of each miRNA were background subtracted, 
normalized and subjected to further analysis. The microarray raw data were normalized 
using per chip median normalization method and the summarization algorithm Robust 
Multichip Average (RMA). The differentially expressed miRNAs were then filtered 
with p-value of <0.05, using two-way ANOVA, and fold change thresholds, between 
siRNA-transfected and non-transfected samples, of more than 1.5.   
 
3.16 MiRNA Microarray Validation 
 
 The microRNA microarray results were validated with qRT-PCR, using the 
TaqMan® MicroRNA Assays (Applied Biosystems, USA).  
 
3.16.1 TaqMan® MicroRNA Assays 
 
The primers used for qRT-PCR was obtained from Applied Biosystems, USA.  
 
Table 3.13: TaqMan
®
 MicroRNA Assays used for qRT-PCR.  
Assay ID Ascension Number Assay Name 
000480 MIMAT0000256 hsa-miR-181a 
001998 MIMAT0003886 hsa-miR-769-5p 
000554 MIMAT0000703 hsa-miR-361-5p 
002874 MIMAT0005892 hsa-miR-1304-5p 
001571 MIMAT0003276 hsa-miR-608 
001093 - U6 
 
Reverse transcription was performed using the TaqMan® MicroRNA Reverse 
Transcription Kit (Applied Biosystems, USA) according to a modified version of the 
manufacturer’s protocol. The components of the kit were first allowed to thaw on ice. 
The RT master mix was then prepared by combining the following components.  
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Table 3.14. Kit components used to prepare RT master mix 
Component 
Master mix volume per 10l 
reaction* 
100nM dNTPs (with dTTP) 0.10l 
MultiScribe Reverse Transcriptase, 50 U/l 0.67l 
10× Reverse Transcription Buffer 1.00l 
RNase Inhibitor, 20 U/l 0.13l 
Nuclease-free water 2.78l 
Total Volume 4.68l 
* Each 10l RT reaction consists of 4.68l master mix, 2.0l of 5× RT primer, and 
3.3l RNA sample.  
 
The components were mixed gently and centrifuged to bring solution to the bottom 
of the tupe. The RT master mix was then placed on ice until the RNA reaction was 
prepared.  
The 5× RT primer and RNA template was thawed on ice. The RT primer tubes were 
then vortexed to mix and then briefly centrifuged. For each 10l RT reaction, the RT 
master mix was combined with 10ng of total RNA in the ratio of 4.68l RT master 
mix : 3.3l total RNA. The mixture was then mixed gently and gently centrifuged 
briefly to bring the solution to the bottom of the tube. 2.0l of RT primer from each 
assay set was added to the corresponding RT reaction tube. The reaction tube was 
sealed and mixed gently, followed by a brief centrifugation. The reactions were 
incubated on ice for 5 minutes and then loaded into the thermal cycler, and run 
according to the following conditions: 
 
Table 3.15: Thermal cycler conditions for cDNA synthesis 
Time Temperature 
30 minutes 16°C 
30 minutes 42°C 
5 minutes 85°C 
 4°C 
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Quantitative PCR (qPCR) amplification was then carried out. The following 
components were placed on ice and gently mixed. The volumes required, based upon 
the number of reactions and a reaction volume of 20l, was calculated.  
 
Table 3.16: Components used to prepare qPCR master mix 
Component Master mix volume per 10l reaction 
TaqMan
® 
Fast Advanced PCR Master Mix  5.00l 
Nuclease-free water 3.84l 
TaqMan
® 
MicroRNA Assay (20) 0.50l 
Product from RT reaction 0.67l 
Total Volume 10.01l 
 
The reaction components were combined in a microcentrifuge tube and gently 
mixed by inversion and then centrifugation. 10l was transferred into low-profile 
microcentrifuge tubes and the tubes were sealed and briefly centrifuged. The reactions 
were then loaded into the real-time PCR instrument, and run according to the following 
conditions: 
 
Table 3.17: Real-time PCR instrument conditions for qPCR. 
Step 
 
 
Optional 
AmpErase 
UNG Activity 
Enzyme 
Activation 
PCR 
HOLD HOLD 
CYCLE (40 Cycles) 
Denature Anneal/Extend 
Temperature 50C 95C 95C 60C 
Time 2 minutes 10 minutes 15 seconds 60 seconds 
 
 
 
 
 
 
 83 
3.17 Bioinformatic Analyses of MiRNA Gene Targets 
 
 An in silico approach was used to identify the putative miRNA targets by using 
TargetScan Human v5.2 (Lewis et al, 2005) (Whitehead Institute for Biomedical 
Research, USA), the database of conserved 3’UTR miRNA targets, found at 
http://www.targetscan.org/. Gene-annotation enrichment analyses of the predicted 
miRNA targets, with total context scores below 0, were then performed using the web 
tool Database for Annotation, Visualization and Integrated Discovery (DAVID) v6.7 
(Huang et al, 2009) (SAIC-Frederick, Inc., USA) at http://david.abcc.ncifcrf.gov 
/summary.jsp, using default parameters.  
 
3.18 Statistical Analysis 
 
 All experiments were performed in triplicate independent experiments. All data 
were presented as mean  standard deviation (SD). Student’s t-test was used to 
determine the statistical significance of results, where a p-value of ≤ 0.05 was 
considered significant. Pearson’s correlation coefficient (r) value was used to determine 
the association between miRNA microarray and qRT-PCR data. 
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CHAPTER 4: RESULTS 
 
4.1 Selection Process of siRNA 1, 2 & 3 
 
4.1.1 siRNA Silencing Of Bcl-xL 
  
4.1.1.1 siRNA Targets on Bcl-xL mRNA 
 
The expression of Bcl-xL in A549 cells was transiently silenced through the 
transfection of Stealth RNAi™ siRNA Duplex Oligonucleotides. Using a set of three 
siRNAs, the siRNAs were compared to determine which siRNA had the greatest 
silencing efficiency in A549 cells. 
 
Table 4.1: Hybridization sites of the Stealth RNAi™ siRNA Duplex Oligonucleotides 
on bcl-xL mRNA. 
 siRNA Sequences Target Site on Bcl-xL (nucleotide number) 
siRNA 
1 
(RNA)-
UCACUAAACUGACUCCAGCUGUAUC 
452…5’-TCACTAAACTGACTCCAGCTGTATC-3’…428 
siRNA 
2 
(RNA)-
AUGGGUUGCCAUUGAUGGCACUGGC 
532…5’-ATGGGTTGCCATTGATGGCACTGGG-3’…508 
siRNA 
3 
(RNA)-
AUCACCUCCCGGGCAUCCAAACUGC 
608…5’-ATCACCTCCCGGGCATCCAAACTGC-3’...584 
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The bcl-xL gene sequence (ascension number NM_138578) was taken from the 
National Center for Biotechnology Information (NCBI)  (http://www.ncbi.nlm.nih.gov/ 
gene?term=NM_138578). The hybridization site of the siRNA oligonucleotides on Bcl-
xL mRNA was determined using the Basic Local Alignment Search Tool (BLAST) 
search algorithm from the NCBI website (http://blast.ncbi.nlm.nih.gov/Blast.cgi).  The 
sequence identity of all three siRNAs to the Bcl-xL mRNA was 100%. 
 
4.1.1.2 siRNA Transfection Efficiency in A549 Cells 
 
 As the siRNA utilized do not fluoresce, A549 cells were transfected with 
BLOCK-iT Alexa Fluor Red Fluorescent Oligo to determine the transfection efficiency 
of the experimental siRNA (Figure 4.2, Figure 4.3, & Figure 4.4). BLOCK-iT
™
 Alexa 
Fluor
®
 Red
 
Fluorescent Oligo is a highly stable, fluorescein-labeled, non-targeted 
dsRNA compound that allows for visual monitoring of transfection efficiency. After 24 
hours, transfection efficiency was assessed by visualizing uptake of BLOCK-iT
™
 Alexa 
Fluor
®
 Red
 
Fluorescent Oligo using fluorescence microscopy. This transfection control 
was carried out for each set of siRNA. The percentage of transfection efficiency shown 
is a representative of mean values from independent triplicate experiments with mean  
S.D. The complete transfection efficiency data for each transfection condition are 
shown in Appendix 4.  
 As shown in Figures 4.2A-C, the siRNA 1 set of A549 cells transfected with 
100nM of BLOCK-iT
™
 Alexa Fluor
®
 Red
 
Fluorescent Oligo showed a transfection 
efficiency of 87.1%  6.5%, while the transfection control for siRNA 2 and 3 had a 
transfection efficiency of 77.4%  10.9% and 84.9%  3.7%, respectively. Cells that 
were not transfected with any siRNAs or BLOCK-iT
™
 Alexa Fluor
®
 Red
 
Fluorescent 
Oligo had a transfection efficiency of 0% (Figure. 4.1). All three siRNA sets had a 
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transfection efficiency of 70% or higher thus allowing for the experiment to proceed to 
determine which of the three siRNA sets had the greatest silencing efficiency. 
 
        (A)          (B)         (C) 
Figure 4.1: Determination of transfection efficiency in non-transfected A549 cells. (A) 
Phase-contrast image of non-transfected A549 cells. (B) Fluorescent image of non-
transfected A549 cells. (C) Merged image of non-trasnfected A549 cells.  Percentage of 
mean transfection efficiency is indicated, and image shown are representative of 
triplicates independent experiments.  
 
 
           (A)            (B)            (C) 
Figure 4.2: Determination of transfection efficiency in siRNA 1 transfected A549 cells. 
(A) Phase-contrast image of siRNA 1 A549 cells transfected with BLOCK-iT
™
 Alexa 
Fluor
®
 Red
 
Fluorescent Oligo. (B) Fluorescent image of siRNA 1 A549 cells transfected 
with BLOCK-iT
™
 Alexa Fluor
®
 Red
 
Fluorescent Oligo. (C) Merged image of siRNA 1 
A549 cells transfected with BLOCK-iT
™
 Alexa Fluor
®
 Red
 
Fluorescent Oligo. 
Percentage of mean transfection efficiency is indicated, and image shown are 
representative of triplicates independent experiments.  
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                     (A)           (B)           (C) 
Figure 4.3: Determination of transfection efficiency in siRNA 2 transfected A549 cells. 
(A) Phase-contrast image of siRNA 2 A549 cells transfected with BLOCK-iT
™
 Alexa 
Fluor
®
 Red
 
Fluorescent Oligo. (B) Fluorescent image of siRNA 2 A549 cells transfected 
with BLOCK-iT
™
 Alexa Fluor
®
 Red
 
Fluorescent Oligo. (C) Merged image of siRNA 2 
A549 cells transfected with BLOCK-iT
™
 Alexa Fluor
®
 Red
 
Fluorescent Oligo. 
Percentage of mean transfection efficiency is indicated, and image shown are 
representative of triplicates independent experiments.  
 
          (A)      (B)            (C) 
Figure 4.4: Determination of transfection efficiency in siRNA 3 transfected A549 cells. 
(A) Phase-contrast image of siRNA 3 A549 cells transfected with BLOCK-iT
™
 Alexa 
Fluor
®
 Red
 
Fluorescent Oligo. (B) Fluorescent image of siRNA 3 A549 cells transfected 
with BLOCK-iT
™
 Alexa Fluor
®
 Red
 
Fluorescent Oligo. (C) Merged image of siRNA 3 
A549 cells transfected with BLOCK-iT
™
 Alexa Fluor
®
 Red
 
Fluorescent Oligo. 
Percentage of mean transfection efficiency is indicated, and image shown are 
representative of triplicates independent experiments.  
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4.1.2 RNA Extraction 
 
4.1.2.1 RNA Quantification Via Spectrophotometry Readings 
 
Upon visual confirmation of siRNA uptake into A549 cells, total RNA was 
extracted from siRNA-transfected and non-transfected A549 cells to determine the 
silencing efficiency of each siRNA set. Spectrophotometric readings of the RNA 
sample were taken to determine the purity and RNA concentration of the samples. The 
ratio of the readings at 260nm and 280nm (A260/A280) was an estimation of the purity of 
RNA with respect to contaminants that absorb in the UV spectrum. When measuring 
RNA in a buffered solution (10nM Tris-HCl (pH 87.5)), pure RNA had an A260/A280 
ratio between 1.8-2.0. A ratio below 1.8 indicated samples contaminated with organic 
solvents. Based on Table 4.2, it can be seen that all RNA samples extracted from the 
A549 cells were pure RNA samples that did not contain any contaminants. 
 
Table 4.2: Spectrophotometric quantification of total RNA extracted from siRNA-
transfected and non-transfected A549 cells.  
Sample μg/ml A260/A280 A260 
RNA 
Concentration 
(μg/ml) 
Total RNA 
(μg) 
siRNA 1 0.982 1.95 0.491 982 49.1 
siRNA 2 0.860 1.94 0.430 860 43.0 
siRNA 3 0.293 1.79 0.146 292 14.6 
Hi GC NC† 0.763 1.65 0.382 794 39.7 
Lo GC NC
‡
 0.843 1.80 0.422 844 42.2 
NTC† 0.606 1.96 0.303 606 30.3 
† Hi GC NC denotes cells transfected with high GC content negative controls 
‡ 
Lo GC NC denotes cells transfected with low GC content negative controls 
NTC denotes non-transfected cells 
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4.1.2.2 Agarose Gel Electrophoresis 
 
 Agarose gel electrophoresis and ethidium bromide staining evaluated the 
integrity and size distribution of total RNA. Intact total RNA run on a denaturing gel 
had sharp, clear 28S and 18S ribosomonal RNA (rRNA) bands. The 28S rRNA band 
was approximately twice as intense as the 18S rRNA band. This 2:1 ratio (28S: 18S) 
was a good indication that the RNA is completely intact. As the rRNA bands in Figure 
4.5 have a 2:1 ratio, it was concluded that the RNA samples are intact and can be used 
for further downstream work.  
 
 
Figure 4.5: Agarose gel electrophoresis image for the total RNA extraction of siRNA 1, 
2, and 3 transfected and non-transfected A549 cells.  
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4.1.3 Protein Extraction 
 
4.1.3.1 Bradford Assay Protein Quantification 
 
 The Bradford protein assay is a spectroscopic analytical procedure used to 
measure the concentration of protein in a solution. This assay is based on an absorbance 
shift of the dye Coomassie Brilliant Blue G-250, in which under acidic conditions the 
red form of the dye is converted into its bluer form to bind to the protein being assayed. 
The biding of protein stabilizes the blue form of the Coomassie dye; thus the amount of 
the complex present in solution is a measure for the protein concentration, and can be 
estimated by the use of an absorbance reading.  
 The bound form of the dye has an absorption spectrum held at 595nm. The 
increase in absorbance at 595nm is proportional to the amount of bound dye, and thus to 
the amount of protein (concentration) present in the sample.  
 
Table 4.3: Spectrophotometric quantification of protein using Bradford Assay.  
siRNA Sample g/mL A595 
1 
siRNA 1827.5 0.892 
Lo GC NC
‡
 1532.7 0.755 
NTC† 1314.3 0.653 
2 
siRNA 2419.5 1.167 
Hi GC NC† 2310.5 1.116 
NTC† 2114.2 1.025 
3 
siRNA 2070.5 1.005 
Hi GC NC† 202.51 0.984 
NTC† 1626.3 0.798 
† Hi GC NC denotes cells transfected with high GC content negative controls 
‡ 
Lo GC NC denotes cells transfected with low GC content negative controls 
NTC denotes non-transfected cells 
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4.1.4 Quantitative Real-Time Reverse Transcribe PCR (qRT-PCR) 
 
4.1.4.1 Determination of PCR Amplification Efficiencies 
 
To determine the silencing efficiency of siRNA, quantitative real-time RT-PCR 
(qRT-PCR) was performed to allow for the evaluation of the bcl-xL expression in 
siRNA-transfected and non-transfected A549 cells. Real-time PCR amplification 
efficiencies and linearity was first determined through the generation of standard curves. 
The real-time PCR efficiencies were calculated from the given slopes generated by the 
Bio-Rad CFX Manager
™
 Software v1.6 (Bio-Rad Laboratories, USA). The 
corresponding real-time PCR efficiency (E) of one cycle in the exponential phase was 
calculated according to the equation: E = 10
-1/slope
. Figure 4.6 indicated that the real-time 
PCR efficiency for bcl-xL primers was 110.0%, while β-actin had an efficiency of 
106.3% (Figure 4.7).  
 
Figure 4.6: Standard curve generated for bcl-xL standards had an efficiency of 2.10.  
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Figure 4.7: Standard curve generated for β-actin standards had an efficiency of 2.06.  
 
4.1.4.2 Evaluation of Bcl-xL Gene Expression 
 
 After normalization to endogenous -actin mRNA expression, the expression of 
bcl-xL in siRNA-transfected A549 cells were expressed in comparison to the levels 
observed in non-transfected cells. All experiments were carried out in triplicates and 
represented as ± S.D. Results indicated that bcl-xL expression levels were lower for all 
siRNA transfected A549 cells in comparison to non-transfected cells (Figure 4.8). The 
fold change in the bcl-xL expression in siRNA-transfected and non-transfected cells was 
calculated using the Pfaffl method (Pfaffl, 2001):  
 
Fold change 
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Figure 4.8: Quantitatitve real-time RT-PCR analysis of bcl-xL expression in siRNA-
transfected and non-transfected A549 cells. All experiments were carried out in 
triplicates, and presented as mean  SD. 
 
Table 4.4: Fold-change in bcl-xL gene expression in siRNA-transfected A549 cells as 
compared to non-transfected A549 cells (p  0.005). 
Sample Fold Change* ± SD p-Value 
siRNA 1 -4.42 ± 0.079 0.009 
siRNA 2 -2.62 ± 0.071 0.003 
siRNA 3 -1.70 ± 0.088 0.013 
Hi GC NC† 1.22 ± 0.093 0.025 
Lo GC NC
‡
 -1.16 ± 0.150 0.013 
*
Positive values denote up-regulation while negative values denote downregulation.  
† Hi GC NC denotes cells transfected with high GC content negative controls 
‡ 
Lo GC NC denotes cells transfected with low GC content negative controls 
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Table 4.5: Percentage of Bcl-xL gene knockdown in siRNA-transfected A549 cells as 
compared to non-transfected A549 cells.  
Sample % Knockdown ± SD 
siRNA 1 75.19 ± 8.32 
siRNA 2 55.52 ± 4.32 
siRNA 3 39.29 ± 8.58 
Hi GC NC† -19.96 ± 8.80 
Lo GC NC
‡
 13.52 ± 14.08 
† Hi GC NC denotes cells transfected with high GC content negative controls 
‡ 
Lo GC NC denotes cells transfected with low GC content negative controls 
 
 As shown in Table 4.4, siRNA 1 had the highest negative fold induction at 4.42; 
followed by siRNA 2 and 3 with negative fold change of 2.62 and 1.70 respectively. 
The percentage of gene knockdown was also calculated (Table 4.5.) and results 
indicated that siRNA 1 had the greatest percentage of knockdown, with 75.19  8.32%, 
followed by siRNA 2 and 3 with a knockdown percentage of 55.52  4.23% and 39.29 
 8.58%, respectively. As siRNA 1 had the greatest bcl-xL gene knockdown, it was 
concluded that siRNA had the greatest silencing efficiency and was chosen to be used 
for further downstream work. As the SYBR Green dye was used to detect PCR product, 
the primer specificity was confirmed using a melting curve analysis as shown in 
Appendix 5. 
 
4.1.5 Western Blot 
 
 Western blot was then carried out to further measure the total Bcl-xL protein 
levels following the transfection experiment. The relative level of Bcl-xL protein in 
siRNA-transfected and non-transfected A549 cells was quantified through densitometry, 
using the ImageJ Analyst software (National Institute of Mental Health, USA), with 
each band being normalized to β-actin. Figure 4.9 shows that the Bcl-xL protein level 
was significantly decreased in A549 cells transfected with siRNA set 1, in comparison 
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to the Bcl-xL protein levels in non-transfected A549 cells. Densitometry analysis of the 
bands illustrated that cells transfected with siRNA 1 had 28.33 ± 6.79% Bcl-xL protein 
level in comparison to the 100.00 ± 0.48% protein level in non-transfected cells. Bcl-xL 
protein levels in cells transfected with siRNA 2 and 3 had proteins levels of 82.01 ± 
1.56% and 84.77 ± 2.16% respectively.  
 
† Hi GC NC denotes cells transfected with high GC content negative controls 
‡ 
Lo GC NC denotes cells transfected with low GC content negative controls 
* NTC denotes non-transfected cells 
 
Figure 4.9: Indication of significantly decreased Bcl-xL (30-kDa) protein levels in 
A549 cells transfected with siRNA 1. β-actin (45-kDa) was used as a normalization 
control to ensure equal protein concentrations across samples.  
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Figure 4.10.  Densitometry analysis of the Western blots using the ImageJ Analyst 
software. The results were standardized against the levels of β-actin and are presented 
as normalized intensities. All experiments were carried out in triplicates, and presented 
as mean  SD. 
 
Table 4.6: Densitometry analysis of the Western blots was carried out using the ImageJ 
Analyst software.  
Sample Bcl-xL Protein Level (%) ± SD p-Value 
siRNA 1 28.33 ± 6.79 0.0001 
siRNA 2 82.01 ± 1.56 0.0003 
siRNA 3 84.77 ± 2.16 0.0031 
Hi GC NC† 99.96 ± 1.46 0.4761 
Lo GC NC
‡
 100.21 ± 3.63 0.4687 
NTC
*
 100.00 ± 0.48 0.0001 
† Hi GC NC denotes cells transfected with high GC content negative controls 
‡ 
Lo GC NC denotes cells transfected with low GC content negative controls 
* 
NTC denotes non-transfected cells 
 
 
0 
20 
40 
60 
80 
100 
120 
N
o
rm
a
li
z
e
d
 B
c
l-
x
L
 I
n
te
n
s
it
y
 (
%
) 
 97 
4.2 A549 Transfection With siRNA 1 
 
Once it was determined that siRNA 1 had the greatest silencing efficiency in 
A549 cells amongst the three siRNAs used, A549 cells were once again transfected with 
siRNA in triplicates for use in miRNA microarray.  
 
4.2.1 Bcl-xL Silencing Using siRNA 1 
 
4.2.1.1 siRNA transfection efficiency in A459 cells 
 
The percentage of transfection efficiency shown is a representative of mean 
values from independent triplicate experiments with mean  S.D. The complete 
transfection efficiency data for each transfection condition are shown in Appendix 4. As 
shown in Figures 4.11 – 4.13, all biological replicates had a transfection efficiency of 
70% or higher, thus allowing for the experiment to proceed for confirmation of efficient 
silencing efficiency.  
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        (A)          (B)          (C) 
Figure 4.11: Determination of transfection efficiency in siRNA 1 biological replicate 1 
transfected A549 cells. (A) Phase-contrast image of siRNA 1 biological replicate 1 
A549 cells transfected with BLOCK-iT
™
 Alexa Fluor
®
 Red
 
Fluorescent Oligo. (B) 
Fluorescent image of siRNA 1 biological replicate 1 A549 cells transfected with 
BLOCK-iT
™
 Alexa Fluor
®
 Red
 
Fluorescent Oligo. (C) Merged image of siRNA 1 
biological replicate 1 A549 cells transfected with BLOCK-iT
™
 Alexa Fluor
®
 Red
 
Fluorescent Oligo had a transfection efficiency of 81.2%  3.57%. Image shown are 
representative of triplicates independent experiments.  
 
         (A)          (B)          (C) 
Figure 4.12: Determination of transfection efficiency in siRNA 1 biological replicate 2 
transfected A549 cells. (A) Phase-contrast image of siRNA 1 biological replicate 2 
A549 cells transfected with BLOCK-iT
™
 Alexa Fluor
®
 Red
 
Fluorescent Oligo. (B) 
Fluorescent image of siRNA 1 biological replicate 2 A549 cells transfected with 
BLOCK-iT
™
 Alexa Fluor
®
 Red
 
Fluorescent Oligo. (C) Merged image of siRNA 1 
biological replicate 2 A549 cells transfected with BLOCK-iT
™
 Alexa Fluor
®
 Red
 
Fluorescent Oligo had a transfection efficiency of 79.0%  4.17%. Image shown are 
representative of triplicates independent experiments.  
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          (A)         (B)                           (C) 
Figure 4.13: Determination of transfection efficiency in siRNA 1 biological replicate 3 
transfected A549 cells. (A) Phase-contrast image of siRNA 1 biological replicate 3 
A549 cells transfected with BLOCK-iT
™
 Alexa Fluor
®
 Red
 
Fluorescent Oligo. (B) 
Fluorescent image of siRNA 1 biological replicate 3 A549 cells transfected with 
BLOCK-iT
™
 Alexa Fluor
®
 Red
 
Fluorescent Oligo. (C) Merged image of siRNA 1 
biological replicate 3 A549 cells transfected with BLOCK-iT
™
 Alexa Fluor
®
 Red
 
Fluorescent Oligo had a transfection efficiency of 81.2%  3.7%. Image shown are 
representative of triplicates independent experiments.  
 
4.2.2 RNA Extraction 
 
4.2.2.1 RNA Quantification Via NanoDrop 
 
Table 4.7: Spectrophotometric quantification of total RNA extracted from siRNA 1 
transfected and non-transfected cells.  
Biological 
Replicate 
Sample 
Concentration 
(ng/μl) 
A260 A280 A260/280 A260/230 
1 
siRNA 408.8 10.221 5.294 1.93 1.55 
Lo GC NC
†
 362.0 9.051 4.680 1.93 1.30 
NTC
‡
 442.2 11.054 5.749 1.92 1.85 
2 
siRNA 327.2 8.180 4.273 1.91 1.86 
Lo GC NC
†
 175.0 4.375 2.339 1.87 1.74 
NTC
‡
 181.2 4.529 2.391 1.89 3.60 
3 
siRNA 258.0 6.449 3.344 1.93 1.96 
Lo GC NC
†
 226.9 5.672 2.998 1.89 2.08 
NTC
‡
 490.9 12.272 6.339 1.94 2.16 
† Lo GC NC denotes cells transfected with low GC content negative controls 
‡ 
NTC denotes non-transfected cells 
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4.2.2.2 Agarose Gel Electrophoresis 
 
 
Figure 4.14: Agarose gel electrophoresis image for the total RNA extraction of siRNA 
1 transfected and non-transfected A549 cells.  
 
4.2.2.3 Quality Check Of Extracted Total RNA Using Agilent 2100 BioAnalyzer 
 
The quality of the extracted total RNA samples were evaluated using the Agilent 
2100 BioAnalyzer prior to running qRT-PCR and miRNA microarray. Analysis using 
the BioAnalyzer allows for an evaluation of the total RNA samples to unsure that all 
samples had acceptable levels of concentration, integrity and purity, in order to increase 
the accuracy of miRNA expression profiles in siRNA-transfected and non-transfected 
cells.  
The RNA integrity number (RIN value) was also determined. The RIN software 
algorithm allows for the classification of total RNA based on a numbering system from 
1 to 10, with 1 being the most degraded profile and 10 being the most intact. Figure 
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4.15 shows the nano gel image of total RNA samples, while the RIN, rRNA ratio and 
RNA concentration data of all replicates and samples types are summarized in Table 4.8. 
RIN of all samples were maintained between 9.0 and 10.0, where samples with RIN 
below 9.0 were discarded due to low RNA integrity levels (Table 4.8). All replicates 
were transfected and extracted independently of one another and at varying time points 
to ensure statistical significance.  
 
 
Figure 4.15: Total RNA Nano Agilent BioAnalyzer gel image of total RNA triplicate 
samples extracted from siRNA 1 transfected and non-transfected A549 cells.  
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Table 4.8: RNA integrity number (RIN value) was determined using the Agilent 2100 
BioAnalyzer.  
Biological 
Replicate 
Sample 
RNA 
Concentration 
(μg/μl) 
RIN Value 
rRNA Ratio 
[28s/18s] 
1 
siRNA 469.0 9.60 1.9 
Lo GC NC
†
 400.0 9.60 1.9 
NTC
‡
 660.0 9.60 1.8 
2 
siRNA 240.0 9.50 2.2 
Lo GC NC
†
 171.6 8.80 1.5 
NTC
‡
 193.9 9.50 2.2 
3 
siRNA 371.0 9.40 2.1 
Lo GC NC
†
 317.0 9.40 2.0 
NTC
‡
 306.4 9.60 2.1 
† Lo GC NC denotes cells transfected with low GC content negative controls 
‡ 
NTC denotes non-transfected cells 
 
4.2.3 Protein Extraction 
 
4.2.3.1 Bradford Assay Protein Quantification 
 
Table 4.9: Spectrophotometric quantification of protein using Bradford Assay.  
Biological 
Replicate 
Sample 
Protein 
Concentration 
(μg/ml) 
A595 
1 
siRNA 1945.000 0.172 
Lo GC NC
†
 1121.343 0.120 
NTC
‡
 1935.751 0.170 
2 
siRNA 1873.882 0.166 
Lo GC NC
†
 784.540 0.099 
NTC
‡
 1599.024 0.149 
3 
siRNA 1645.066 0.152 
Lo GC NC
†
 1604.805 0.149 
NTC
‡
 1542.621 0.146 
† Lo GC NC denotes cells transfected with low GC content negative controls 
‡ 
NTC denotes non-transfected cells 
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4.2.4 Quantitative Real-Time Reverse Transcribe PCR (qRT-PCR) 
 
4.2.4.1 Determination of PCR Amplification Efficiencies 
 
Real-time PCR amplification efficiencies and linearity was determined through 
the generation of standard curves. The real-time PCR efficiencies were calculated from 
the given slopes in the Bio-Rad CFX Manager
™
 Software v1.6 (Bio-Rad Laboratories, 
USA). The corresponding real-time PCR (E) of one cycle in the exponential phase was 
calculated according to the equation: E = 10
-1/slope
.  
 
 
Figure 4.16: Standard curve generated for bcl-xL standards had an efficiency of 1.93. 
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Figure 4.17: Standard curve generated for β-actin standards had an efficiency of 2.04. 
   
4.2.4.2 Evaluation of Bcl-xL Gene Expression 
 
After normalization to endogenous -actin expression, the expression of bcl-xL 
in siRNA-transfected A549 cells was expressed in comparison to the levels observed in 
non-transfected cells. The bcl-xL gene expression levels were lower for siRNA-
transfected A549 cells in comparison to the non-transfected cells. The fold change in 
the bcl-xL expression in transfected and non-transfected cells was calculated using the 
Pfaffl method.  
As shown in Table 4.10, siRNA-transfected A549 cells had a significant 
negative fold induction of 6.15 ± 0.032. The percentage of gene knockdown was also 
calculated (Table 4.11) and results indicated that siRNA-transfected A549 cells had a 
knockdown percentage of 79.90  3.67%. siRNA transfected A549 cells had significant 
knockdown of the bcl-xL gene allowing for the project to proceed to microRNA 
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microarray to determine the miRNA expression profile in siRNA-transfected and non-
transfected A549 cells.  
 
 
Figure 4.18: Quantitative teal-time RT-PCR analysis for Bcl-xL expression in siRNA-
transfected and non-transfected A549 cells.  All experiments were carried out in 
triplicates, and presented as mean  SD. 
 
Table 4.10: Fold-change in bcl-xL gene expression in siRNA-transfected A549 cells as 
compared to non-transfected A549 cells.  
Sample Fold Change
†
 ± SD p-Value 
siRNA 6.15 ± 0.032 0.002 
Lo GC NC
‡
 1.67 ± 0.037 0.008 
† Positive values denote up-regulation while negative values denote downregulation 
‡
 Lo GC NC denotes cells transfected with low GC content negative controls 
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Table 4.11: Percentage of Bcl-xL gene knockdown in siRNA-transfected A549 cells as 
compared to non-transfected A549 cells. 
Sample % Knockdown ± SD 
siRNA  79.90 ± 3.67 
Lo GC NC
†
 22.00 ± 4.32 
† Lo GC NC denotes cells transfected with low GC content negative controls 
 
4.2.5 Western Blot 
 
Western blot was then carried out to further measure the total Bcl-xL protein 
levels following the transfection with siRNA 1. The relative level of Bcl-xL protein in 
siRNA-transfected and non-transfected A549 cells was quantified through densitometry, 
using the ImageJ Analyst software (National Institute of Mental Health), with each band 
being normalized to β-actin. Figure 4.19 shows that the Bcl-xL protein level was 
significantly decreased in A549 cells transfected with siRNA 1, in comparison to the 
Bcl-xL protein levels in non-transfected A549 cells. Densitometry analysis of the bands 
shows that cells transfected with siRNA 1 had 50.27 ± 4.11% Bcl-xL protein level in 
comparison to the 100.00 ± 0.01% protein level in non-transfected cells (Table 4.12).  
 
 
† Lo GC NC denotes cells transfected with low GC content negative controls 
‡ 
NTC denotes non-transfected cells 
 
Figure 4.19: Indication of significantly decreased Bcl-xL (30-kDa) protein levels in 
A549 cells transfected with siRNA 1. β-actin (45-kDa) was used as a normalization 
control to ensure equal protein concentrations across samples.  
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Figure 4.20:  Densitometry analysis of the Western blots using the ImageJ Analyst 
software. The results were standardized against the levels of β-actin and are presented 
as normalized intensities. All experiments were carried out in triplicates, and presented 
as mean  SD. 
 
Table 4.12: Densitometry analysis of the Western blots was carried out using the 
ImageJ Analyst software. Bcl-xL protein levels in cells transfected with siRNA 1 was 
50.27 ± 4.11% in comparison to the 100.00 ± 0.01% protein levels in non-transfected 
cells.  
Sample Bcl-xL Protein Level (%) ± SD p-Value 
siRNA 1 50.27 ± 4.11 0.0016 
Lo GC NC
†
 125.44 ± 3.50 0.0023 
NTC
‡
 100.00 ± 0.01 0.0001 
† Lo GC NC denotes cells transfected with low GC content negative controls 
‡ 
NTC denotes non-transfected cells 
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4.3 MTT Cell Viability Assay 
 
 The MTT assay is a colomrimetric assay that was used to assess the viability of 
A549 cells in response to siRNA-based silencing of the bcl-xL gene. Figure 4.21 
indicated that a knockdown of bcl-xL gene expression resulted in a reduction in cell 
viability after 48 hours post-transfection compared to non-transfected A549 cells. After 
48 hours of transfection, A549 cells transfected with siRNA had a 69.8 ± 2.2% cell 
viability compared to the 98.2 ± 2.2% seen in non-transfected A549 cells (Table 4.13). 
Results also indicated that NP-69 normal cells were not negatively affected by the 
knockdown of bcl-xL gene expression (Figure 4.21 and Table 4.13).    
 
 
Figure 4.21: Comparison of total viable cell count on NP-69 normal cell control and 
A549 lung adenocarcinoma cells after siRNA transfection over 48 hours.  
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Table 4.13: Table comparing total cell viability levels (%) as obtained from MTT 
assays at 12 hours, 24 hours and 48 hours in NP-69 and A549 cell lines. 
Cell Lines Treatment 
(100nM) 
Time (h) Cell Viability ± 
SD (%) 
NP-69 
NTC
†
 
12 101.47 ± 3.4 
24 100.92 ± 1.0 
48 101.75 ± 2.9 
siRNA 
12 102.58 ± 6.3 
24 101.48 ± 3.7 
48 103.19 ± 3.2 
Lo GC NC
‡
 
12 97.04 ± 1.6 
24 98.81 ± 3.4 
48 100.48 ± 1.4 
A549  
NT
†
 
12 103.5 ± 2.3 
24 97.5 ± 4.7 
48 98.2 ±3.2 
siRNA 
12 87.9 ± 1.6 
24 80.7 ± 1.0 
48 59.8 ± 1.7 
Lo GC NC
‡
 
12 104.1 ± 2.2 
24 93.7 ± 4.4 
48 95.3 ± 2.1 
† NTC denotes non-transfected cells  
‡ 
Lo GC NC denotes cells transfected with low GC content negative controls 
 
4.4 MiRNA Microarray 
 
4.4.1 MiRNA Microarray Analysis 
 
Once it was determined that the bcl-xL gene was successfully silenced in A549 
cells and subsequently decreased cell viability, to investigate which miRNA expressions 
was mediated by the presence of bcl-xL, a global miRNA expression profile in siRNA-
transfected and non-transfected A549 cells was performed using miRNA microarray 
analysis. This allowed for the elucidation of which miRNAs aid in enhancing the anti-
apoptotic ability of A549 cells in conjunction with Bcl-xL overexpression. Evaluation 
on miRNA expression changes following siRNA-based bcl-xL silencing was carried out 
in triplicates independently. 
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Total RNA from siRNA-transfected A549 and non-transfected A549 cells were 
labeled and hybridized onto the Affymetrix GeneChip
 
miRNA Arrays. The use of this 
array was coupled with the employment of the GeneChip
 
miRNA 2.0 Array 
(Affymetrix Inc., USA), which provides the most sensitive, accurate and complete 
measurement of small non-coding RNA transcripts involved in gene regulation. This 
chip has 100% miRBase v15 coverage of all 131 organisms, consisting of 15,644 probe 
sets, as well as 2,344 snoRNAs and scaRNAs, and 2,202 probe sets unique to pre-
miRNA hairpins. 
Using the GeneSpring
 
GX and Partek
 
Genomics Suite software, raw 
microarray images were analyzed and the average values of the replicate spots of each 
miRNA were background subtracted, normalized and subjected to further analysis. The 
microarray raw data were normalized using per chip median normalization method and 
the summarization algorithm Robust Multichip Average (RMA). The differentially 
expressed miRNAs were then filtered with p-value of ≤0.05 and fold change difference 
of more than 1.5.  Both software identified 10 miRNAs that were differentially 
expressed between the siRNA-transfected A549 cells and the non-transfected A549 
cells. Of these, 7 miRNAs were down-regulated while 3 were up-regulated (Figure 4.22 
and Table 4.14). 
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Figure 4.22: Hierarchical clustering heat map of 10 differentially expressed miRNAs in 
siRNA-transfected A549 cells versus non-transfected A549 cells. Up-regulated 
miRNAs are represented with red, while down-regulated miRNAs are represented with 
green.  
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Table 4.14: List of differentially expressed miRNAs filtered with at least a 1.5-fold 
change in expression and p0.05 using the GeneSpring GX and Partek Genomics 
Suite Software.  
MicroRNA 
Partek

 
Fold-
Change† 
Partek

 
p-value 
GeneSpring

 
Fold-
Change† 
GeneSpring

 
p-value 
hsa-mir-181a -3.37  1.85 0.006 -3.39  1.88 0.006 
hsa-mir-769-5p -2.42  0.91 0.007 -2.41  0.95 0.008 
hsa-mir-10b -1.76  0.51 0.015 -1.75  0.50 0.017 
hsa-mir-361-5p -1.55  0.42 0.036 -1.54  0.42 0.036 
hsa-mir-1304 -1.53  0.10 0.000 -1.53  0.11 0.000 
hsa-mir-328 -1.52  0.24 0.011 -1.53  0.29 0.010 
hsa-mir-99a -1.50  0.31 0.013 -1.50  0.31 0.014 
hsa-mir-130a 1.87  0.66 0.034 1.85  0.63 0.032 
hsa-mir-768-3p 2.02  0.27 0.005 2.02  0.26 0.005 
hsa-mir-608 2.38  0.31 0.001 2.38  0.38 0.002 
† Positive values denote up-regulation while negative values denote downregulation.  
 
4.4.2 MiRNA Microarray Validation 
 
4.4.2.1 Quantitative Real-Time Reverse Transcribe PCR (qRT-PCR) 
 
 Five representative differentially expressed miRNAs (hsa-miR-181a, hsa-miR-
769-5p, hsa-miR-361-5p, hsa-miR-1304, and hsa-miR-608) between siRNA-transfected 
and non-transfected A549 cells were then selected based upon fold-change and 
preliminary target prediction, and validated using qRT-PCR.  
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Figure 4.23: Quantitative real-time RT-PCR validation of five representatitve miRNAs. 
After normalization to the endogenous control (RNU6), the expression of miRNAs in 
siRNA-transfected A549 cells was expressed in comparison to the levels observed in 
non-transfected A549 cells. (n=3). 
 
Table 4.15: Fold-change of miRNA expression in siRNA-transfected A549 cells as 
compared to non-transfected A549 cells (p  0.05). 
MicroRNA Fold-Change† p-Value 
hsa-miR-181a -2.17  0.21 0.051 
hsa-miR-769-5p -2.43  0.18 0.035 
hsa-miR-361-5p -1.16  0.10 0.041 
hsa-miR-1304 -1.49  0.16 0.057 
hsa-miR-608 3.45  0.62 0.003 
† Positive values denote up-regulation while negative values denote downregulation.  
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Figure 4.24: Pearson correlation scatter plot between two variables, miRNA microarray 
fold-change and qRT-PCR fold-change, produced a correlation coefficient value of r = 
0.950 with an r
2
 = 0.903, indicating a strong positive association between both sets of 
data. 
 
4.4.3 MiRNA Putative Target 
 
 To understand the roles that the five representative miRNAs played in the anti-
apoptotic ability of A549 cells, the TargetScan Human v5.2 software was used to 
identify the putative miRNA targets of the miRNAs and predicted targets with total 
context score of <0 were then selected for gene-annotation enrichment analysis using 
DAVID v6.7. The putative miRNA targets were filtered based on the genes related to 
apoptosis, proliferation and angiogenesis. The list of putative target genes is 
summarized in Table 4.16. 
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Table 4.16: Summary of miRNA apoptosis-, proliferation- and angiogenesis-related 
putative gene targets.  
Gene 
Symbol 
Gene Description 
TargetScan Total Context Score 
hsa-miR-
181a 
hsa-miR-
769-5p 
hsa-miR-
361-5p 
hsa-miR-
1304 
hsa-miR-
608 
AKT2 
v-akt murine 
thymoma viral 
oncogene homolog 
2 
-0.21 -0.02 N/A N/A -0.17 
AKT3 
v-akt murine 
thymoma viral 
oncogene homolog 
3 
-0.25 -0.42 N/A N/A N/A 
APC2 
adenomatosis 
polyposis coli 2 
N/A 0.05 N/A -0.03 -0.33 
BCL2 
B-cell 
CLL/lymphoma 2 
N/A N/A N/A -0.15 N/A 
BCL2L BCL2-like 1 N/A N/A N/A N/A -0.59 
BCL2L11 BCL2-like 11 -0.36 N/A N/A N/A N/A 
BCR 
breakpoint cluster 
region 
-0.05 -0.05 N/A -0.14 -0.16 
BMF 
Bcl2 modifying 
factor 
-0.07 N/A N/A N/A N/A 
CASP3 
caspase 3, 
apoptosis-related 
cysteine peptidase 
N/A N/A N/A -0.12 N/A 
CASP9 
caspase 9, 
apoptosis-related 
cysteine peptidase 
N/A N/A N/A -0.21 -0.12 
CCDC6 
coiled-coil domain 
containing 6 
-0.2 N/A -0.06 N/A -0.14 
CCND1 cyclin D1 N/A N/A -0.12 N/A -0.31 
CCND2 cyclin D2 N/A N/A -0.11 N/A N/A 
CDK6 
cyclin-dependent 
kinase 6 
-0.04 N/A N/A -0.11 -0.16 
COL4A1 
collagen, type IV, 
alpha 1 
-0.25 N/A N/A   
COL4A2 
collagen, type IV, 
alpha 2 
N/A N/A -0.11  -0.08 
COL4A4 
collagen, type IV, 
alpha 4 
N/A N/A -0.38 -0.17  
CREBBP 
CREB binding 
protein 
N/A N/A -0.32 N/A -0.18 
CYCS 
cytochrome c, 
somatic 
N/A -0.07 N/A -0.16 N/A 
DAPK1 
death-associated 
protein kinase 1 
N/A N/A -0.17 N/A N/A 
DAPK2 
death-associated 
protein kinase 2 
N/A N/A N/A -0.41 N/A 
DVL3 
dishevelled, dsh 
homolog 3 
N/A 0.03 N/A N/A -0.51 
E2F2 
E2F transcription 
factor 2 
-0.03 0.06 N/A N/A -0.13 
EGFR 
epidermal growth 
factor receptor 
N/A N/A N/A N/A -0.56 
FADD 
Fas (TNFRSF6)-
associated via death 
domain 
N/A N/A -0.44 N/A N/A 
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Table 4.16, continued 
 
FAS 
Fas (TNF receptor 
superfamily, 
member 6) 
-0.44 N/A -0.32 -0.08 -0.19 
FASLG 
Fas ligand (TNF 
superfamily, 
member 6) 
-0.16 N/A N/A N/A N/A 
FGF1 
fibroblast growth 
factor 1 
N/A N/A -0.4 N/A N/A 
FGF11 
fibroblast growth 
factor 11 
N/A N/A N/A N/A -0.07 
FGF12 
fibroblast growth 
factor 12 
N/A N/A N/A -0.03 N/A 
FGF17 
fibroblast growth 
factor 17 
N/A N/A N/A -0.07 -0.21 
FGF23 
fibroblast growth 
factor 23 
N/A -0.08 N/A N/A N/A 
FGF5 
fibroblast growth 
factor 5 
N/A 0.01 -0.45 N/A -0.21 
FGF7 
fibroblast growth 
factor 7 
-0.19 N/A -0.5 -0.18 N/A 
FGFR3 
fibroblast growth 
factor receptor 3 
N/A 0.04 N/A N/A -0.06 
FLT3 
fms-related tyrosine 
kinase 3 
N/A N/A -0.14 N/A N/A 
FOS 
v-fos FBJ murine 
osteosarcoma viral 
oncogene homolog 
-0.16 N/A N/A -0.11 N/A 
FOXO1 forkhead box O1 N/A N/A -0.05 N/A N/A 
FZD1 frizzled homolog 1 N/A N/A N/A -0.15 N/A 
FZD10 
frizzled homolog 
10 
N/A N/A N/A N/A -0.12 
FZD3 frizzled homolog 3 N/A N/A -0.55 N/A N/A 
FZD4 frizzled homolog 4 N/A N/A -0.07 -0.04 -0.38 
FZD5 frizzled homolog 5 N/A -0.17 N/A N/A -0.13 
FZD7 
frizzled homolog 7 
(Drosophila) 
N/A N/A N/A N/A -0.25 
FZD8 frizzled homolog 8 N/A N/A N/A N/A -0.46 
HGF 
hepatocyte growth 
factor (hepapoietin 
A; scatter factor) 
N/A N/A N/A -0.19 N/A 
ITGA2 
integrin, alpha 2 
(CD49B, alpha 2 
subunit of VLA-2 
receptor) 
N/A N/A N/A N/A -0.11 
ITGA3 
integrin, alpha 3 
(antigen CD49C, 
alpha 3 subunit of 
VLA-3 receptor) 
-0.28 N/A N/A N/A -0.33 
ITGA6 integrin, alpha 6 -0.17 N/A N/A N/A -0.24 
JAK1 Janus kinase 1 N/A -0.23 N/A -0.15 N/A 
JAK2 Janus kinase 2 -0.15 N/A N/A N/A N/A 
KIT 
Proto-oncogene 
tyrosine-protein 
kinase Kit (c-kit) 
(CD117 antigen) 
N/A N/A N/A N/A -0.06 
KITLG KIT ligand -0.42 -0.28 N/A -0.03  
LAMC3 laminin, gamma 3 N/A -0.18 N/A N/A N/A 
LEF1 
lymphoid enhancer-
binding factor 1 
N/A N/A N/A N/A -0.08 
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Table 4.16, continued 
 
MAP2K1 
mitogen-activated 
protein kinase 
kinase 1 
-0.42 N/A N/A N/A N/A 
MAP2K2 
mitogen-activated 
protein kinase 
kinase 2 
N/A -0.03 N/A N/A N/A 
MAPK1 
mitogen-activated 
protein kinase 1 
N/A -0.26 -0.15 0.03 N/A 
MAX 
MYC associated 
factor X 
N/A N/A -0.09 N/A -0.18 
MDM2 
Mdm2 p53 binding 
protein homolog 
N/A N/A N/A -0.29 N/A 
MET 
met proto-oncogene 
(hepatocyte growth 
factor receptor) 
-0.19 N/A -0.61 N/A -0.1 
MMP1 
matrix 
metallopeptidase 1 
(interstitial 
collagenase) 
-0.16 N/A N/A N/A N/A 
MMP2 
matrix 
metallopeptidase 2 
(gelatinase A, 
72kDa gelatinase, 
72kDa type IV 
collagenase) 
N/A N/A N/A N/A -0.22 
MYC 
v-myc 
myelocytomatosis 
viral oncogene 
homolog 
N/A N/A N/A -0.46 N/A 
NFKB2 
nuclear factor of 
kappa light 
polypeptide gene 
enhancer in B-cells 
2 (p49/p100) 
N/A N/A N/A N/A -0.35 
NRAS 
neuroblastoma 
RAS viral (v-ras) 
oncogene homolog 
-0.22 N/A -0.2 -0.21 -0.29 
PDGFA 
platelet-derived 
growth factor alpha 
polypeptide 
N/A -0.21 N/A N/A N/A 
PDGFB 
platelet-derived 
growth factor beta 
polypeptide 
N/A -0.1 N/A N/A -0.18 
PDGFRA 
platelet-derived 
growth factor 
receptor, alpha 
polypeptide 
N/A N/A -0.11 N/A N/A 
PIK3R1 
phosphoinositide-3-
kinase, regulatory 
subunit 1 (alpha) 
-0.08 -0.04 -0.27 -0.05 -0.22 
PIK3R2 
phosphoinositide-3-
kinase, regulatory 
subunit 2 (beta) 
N/A N/A N/A N/A -0.34 
PIK3R3 
phosphoinositide-3-
kinase, regulatory 
subunit 3 (gamma) 
-0.5 N/A N/A N/A N/A 
PIK3R5 
phosphoinositide-3-
kinase, regulatory 
subunit 5 
N/A N/A N/A N/A -0.1 
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Table 4.16, continued 
 
PPARD 
peroxisome 
proliferator-
activated receptor 
delta 
N/A 0.08 N/A N/A -0.15 
PRKCA 
protein kinase C, 
alpha 
-0.04 -0.01 N/A -0.18 -0.17 
PTGS2 
prostaglandin-
endoperoxide 
synthase 2 
(prostaglandin G/H 
synthase and 
cyclooxygenase) 
-0.29 N/A N/A N/A N/A 
RAC1 
ras-related C3 
botulinum toxin 
substrate 1 (rho 
family, small GTP 
binding protein 
Rac1) 
N/A N/A -0.42 N/A N/A 
RB1 retinoblastoma 1 -0.1 N/A -0.35 N/A N/A 
RET ret proto-oncogene N/A N/A -0.18 N/A N/A 
SMAD2 
SMAD family 
member 2 
-0.26 -0.38 -0.44 N/A N/A 
SMAD3 
SMAD family 
member 3 
-0.24 -0.21 N/A N/A N/A 
SMAD4 
SMAD family 
member 4 
N/A N/A -0.14 N/A N/A 
SOS1 
son of sevenless 
homolog 1 
-0.28 N/A N/A N/A N/A 
SOS2 
son of sevenless 
homolog 2 
N/A N/A N/A N/A -0.17 
STAT3 
signal transducer 
and activator of 
transcription 3 
(acute-phase 
response factor) 
-0.16 -0.01 -0.2 N/A -0.13 
STAT5B 
signal transducer 
and activator of 
transcription 5B 
N/A N/A N/A -0.94 -0.27 
TCF7 
transcription factor 
7 (T-cell specific, 
HMG-box) 
N/A -0.06 N/A -0.18 N/A 
TCF7L2 
transcription factor 
7-like 2 (T-cell 
specific, HMG-
box) 
N/A N/A N/A N/A -0.15 
TGFA 
transforming 
growth factor, 
alpha 
-0.01 N/A -0.01 -0.18 N/A 
TGFBR1 
transforming 
growth factor, beta 
receptor 1 
N/A -0.15 -0.21 N/A N/A 
TGFBR2 
transforming 
growth factor, beta 
receptor II 
(70/80kDa) 
N/A -0.47 N/A N/A N/A 
TP53 tumor protein p53 N/A -0.15 N/A N/A -0.28 
TRAF2 
TNF receptor-
associated factor 2 
N/A -0.03 N/A N/A N/A 
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Table 4.16, continued 
 
TRAF3 
TNF receptor-
associated factor 3 
N/A N/A -0.3 N/A N/A 
TRAF5 
TNF receptor-
associated factor 5 
-0.17 N/A -0.26 N/A N/A 
TRAF6 
TNF receptor-
associated factor 6 
N/A N/A N/A N/A -0.16 
VEGFA 
vascular endothelial 
growth factor A 
N/A N/A -0.49 N/A N/A 
VEGFB 
vascular endothelial 
growth factor B 
N/A N/A -0.09 N/A N/A 
WNT1 
wingless-type 
MMTV integration 
site family, member 
1 
N/A N/A N/A 0.00 N/A 
WNT10B 
wingless-type 
MMTV integration 
site family, member 
10B 
N/A N/A N/A N/A -0.12 
WNT16 
wingless-type 
MMTV integration 
site family, member 
16 
-0.26 N/A N/A N/A N/A 
WNT3 
wingless-type 
MMTV integration 
site family, member 
3 
N/A N/A -0.12 N/A N/A 
WNT3A 
wingless-type 
MMTV integration 
site family, member 
3A 
N/A -0.03 N/A -0.39 -0.16 
WNT4 
wingless-type 
MMTV integration 
site family, member 
4 
N/A -0.05 N/A N/A -0.35 
WNT5A 
wingless-type 
MMTV integration 
site family, member 
5A 
N/A N/A N/A -0.17 N/A 
WNT5B 
wingless-type 
MMTV integration 
site family, member 
5B 
N/A N/A N/A N/A -0.09 
WNT7A 
wingless-type 
MMTV integration 
site family, member 
7A 
N/A N/A -0.6 N/A N/A 
XIAP 
X-linked inhibitor 
of apoptosis 
-0.24 N/A N/A N/A N/A 
TargetScan Total Context Score: N/A: (Not applicable) indicates that the gene is not a putative target of 
the miRNA.  
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4.4.3.1 Hypothetical Pathway Analysis 
 
The predicted targets of the five validated miRNAs were found to be associated 
with various signaling pathways; mainly the intrinsic and extrinsic apoptotic pathways, 
PI3K/AKT pathway, WNT pathway, TGF-β pathway and the MAPK pathway. The 
miRNAs were organized into a hypothetical pathway model (Figure 4.25) to illustrate 
the effects these miRNAs play on apoptosis as well as cell proliferation and 
angiogenesis. 
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CHAPTER 5: DISCUSSION 
 
5.1 Transient siRNA Based Bcl-xL Silencing in Lung Adenocarcinoma Cells 
(A549) 
 
 The anti-apoptotic proteins Bcl-2 and Bcl-xL are significantly expressed in solid 
tumors, including lung cancer, where they play a major role in cell survival (Gottschalk 
et al., 1994; Simonian et al., 1997). Expression of Bcl-2 is prominent in SCLC and in 
some squamous carcinomas, but is absent or lacks significant expression in lung 
adenocarcinomas (Dosaka-Akita et al., 1999; Jiang et al., 1995). Instead, lung 
adenocarcinomas have been found to express high levels of Bcl-xL (Reeve et al., 1996). 
In studies where Bcl-xL antisense treatment was carried out, a strong apoptotic response 
was induced in lung adenocarcinoma cells that lack the significant expression of Bcl-2 
(Leech et al., 2000). However, SCLC cells did not undergo apoptosis following Bcl-xL 
downregulation, most probably due to the protection of high levels of Bcl-2 present in 
these cells (Leech et al., 2000). These findings suggest that Bcl-xL is a more critical 
apoptosis repressor protein in lung adenocarcinoma cells than in SCLC cells (Leech et 
al., 2000; Reeve et al., 1996). This has led to studies to determine the effectiveness of 
use of antisense oligonucleotides inhibiting Bcl-xL expression as a means of therapy in 
various hyperproliferative diseases, including cancer (Zieglar et al., 1997). 
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5.1.1 siRNA Transfection in A549 Cells 
 
To determine which of the three was the most efficient in silencing bcl-xL, A549 
cells were transfected with each siRNA independently. BLOCK-iT
™
 Alexa Fluor
®
 Red
 
Fluorescent Oligo is a highly stable, fluorescein-labeled, non-targeted dsRNA 
compound that was used for the visual monitoring of transfection efficiency. After 24 
hours, transfection efficiency was assessed by visualizing uptake of BLOCK-iT
™
 Alexa 
Fluor
®
 Red
 
Fluorescent Oligo using fluorescence microscopy. Results indicated that for 
all three sets of siRNA had satisfactory transfection efficiency of 70% or above thus 
allowing for the silencing efficiency of the siRNAs to be determined using qRT-PCR.  
After normalization to endogenous -actin mRNA levels, the bcl-xL expression 
levels were lower for all siRNA-transfected A549 cells in comparison to the non-
transfected cells. As shown in Table 4.4, siRNA 1 had the highest negative fold 
induction at 4.42; followed by siRNA 2 and 3 with negative fold change of 2.62 and 
positive fold change of 1.70 respectively. The percentage of knockdown was also 
determined and it was found that, out of the three siRNAs, siRNA 1 had the greatest 
percentage of gene knockdown, with 75.19  8.32%, followed by siRNA 2 and 3 with a 
knockdown percentage of 55.52  4.32% and 39.29  8.58%, respectively (Table 4.5).  
To further confirm that bcl-xL was successfully silenced, Western blot analysis 
was carried out. Results show that the Bcl-xL protein levels decreased in A549 cells 
transfected with siRNA in comparison to the non-transfected A549 cells. Densitometry 
analysis of the Western bands, confirmed that cells transfected with siRNA 1 had a Bcl-
xL protein expression of 28.33 ± 6.79% compared to the 100.00 ± 0.48% protein 
expression seen in non-transfected cells (Figure 4.9). The Bcl-xL protein expression in 
siRNA 2 and 3 transfected A549 cells was 82.01  1.56% and 84.77  2.16% 
respectively (Figure 4.10). From our analysis, siRNA 1 was observed as the best 
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silencing among the siRNAs tested. Thus, siRNA 1 was chosen to be used for further 
downstream work. 
siRNA 1 has a low G/C content, while siRNA 2 and 3 had a high GC content. 
Previous work has shown that siRNAs that contain a high G/C content at the 3’ end of 
the antisense strand, and a lower G/C content at the 5’ end of the antisense strand, will 
result in a significantly higher gene-silencing rate (Elbashir et al., 2001; Holen et al., 
2002). In the cell, siRNAs unwind into 2 ssRNA strands, a passenger strand and a guide 
strand. The guide strand will be incorporated into the RISC and hybridize to the 
complementary target mRNA in the cell. The strand that is selected to be incorporated 
into RISC, is selected upon the basis of thermodynamic instability and weaker base 
pairing. siRNA strands with a high G/C content is more stable than an siRNA with a 
low G/C content, therefore, the siRNA with a lower G/C content at its 5’ end is 
preferentially loaded into RISC (Elbashir et al., 2001). 
 Theoretically, it can be assumed that siRNA 1 would have the greatest silencing 
efficiency, due to its low G/C content. However, as the company that provided the 
siRNA had only carried out in silico design and validation, it was necessary to perform 
a bench test to confirm which siRNA would provide the greatest silencing efficiency.  
Once it was confirmed that siRNA 1 had the greastest silencing effieicny, MTT 
viability assay was carried out to determine the viability of A549 cells in response to 
siRNA-based silencing of the bcl-xL gene. Results indicated that after 48 hours post-
transfection cell viability in siRNA-transfected cells was decreased to 69.8 ± 2.2% cell 
viability compared to the 98.2 ± 2.2% seen in non-transfected A549 cells (Table 4.13). 
This finding corresponds with the results of other Bcl-xL antisense treatments, as 
discussed previously, suggesting that Bcl-xL may be a critical apoptosis repressr protein 
in lung adenocarcinoma cell line A549.  
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5.2 MiRNAs Dysregulated in Response to Bcl-xL Silencing 
 
 Cancer cells have the ability to disrupt the balance between pro- and anti-
apoptotic factors to promote cell survival under the conditions of environmental stress. 
In terms of molecular events occurring in tumors, evasion of apoptosis is an important 
hallmark of tumor progression. Cell survival or death is determined by the competitive 
action of death agonists, such as Bcl-2 and Bcl-xL (Leech et al., 2000).  
MiRNAs play a role in a wide range of biological processes including cell 
proliferation (Hayashita et al., 2005), differentiation (Shivdasani, 2006), and apoptosis 
(Mott et al., 2007). Bioinformatics data have shown that miRNAs have the potential to 
regulate at least 20-30% of all human genes. A single miRNA has the ability to control 
hundreds of mRNA gene targets (Lewis et al., 2005). As miRNAs are an integral part of 
the regulatory networks in cells, a disturbed miRNA function or altered miRNA 
expression may disorganize cellular processes and eventually cause or contribute to 
diseases, including cancer (Weimer, 2007).  
MiRNAs are critical apoptosis regulator in tumorigenesis, and cancer cells are 
able to manipulate miRNAs to regulate cell survival in oncogenesis. For example, miR-
133 acts as a regulator of survival in cardiac cells by repressing caspase-9 expression at 
both the protein and mRNA levels (Xu et al., 2007), while the miR-17-92 cluster, which 
is amplified in B cell lymphomas, is capable of evading apoptosis by negatively 
regulating the tumor suppressor PTEN and the pro-apoptotic protein Bim (Xiao et al., 
2008).  
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To date, no studies have been conducted to identify miRNAs that are regulated 
or affected by the expression of the bcl-xL gene. Therefore, the identification of 
miRNAs whose expression are dysregulated in response to the silencing of Bcl-xL in 
A549 cells is important, as it will allow for further insight into the biological functions 
of miRNAs as well as the roles they may play in the mechanisms of pathogenesis in 
lung adenocarcinoma cells.  
 
5.2.1 MiRNA Microarray Analysis  
 
 A global miRNA expression profile was established using miRNA microarray, 
and compared between total RNA extracted from siRNA-transfected A549 cells and 
non-transfected cells to determine the miRNA expression changes that occur in 
response to bcl-xL gene silencing. Analysis of the microarray images using the 
GeneSpring

 GX and Partek

 Genomics Suite software led to the identification of 10 
miRNAs that were differentially expressed between the siRNA-transfected A549 cells 
and the non-transfected A549 cells. Of these, 7 miRNAs were down-regulated while 3 
were up-regulated, when compared to non-transfected A549 cells (Table 4.14 and 
Figure 4.22).  
 Previously, studies have been carried out which have implicated a number of the 
10 dysregulated miRNAs in a wide variety of cancers. For example, miR-181a is up-
regulated in thyroid papillary carcinomas (He et al., 2005), but down-regulated in 
glioblastomas (Shi et al., 2008), and oral squamous cell carcinoma (OSCC) (Shin et al., 
2011). In a study conducted by Shi and colleagues, it was found that miR-181a in 
human glioma cells function as a tumor suppressor, with the ability to induce apoptosis 
and inhibit division (Shi et al., 2008). Thus deregulation of miR-181a in glioma cells 
was found to play a critical role in the pathogenesis of gliomas (Shi et al., 2008). miR-
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181a was also found to elicit tumor suppressive activity in OSCC by down-regulating 
the K-ras oncogene (Shin et al., 2011). Activation of K-ras either through mutation or 
overexpression is an important molecular event that is required for the development and 
progression of OSCC (Shin et al., 2011). In non-small-cell-lung cancer cells, expression 
of miR-181a has been found to be down-regulated compared to normal lung cells. This 
downregulation was found to be negatively correlated with the survival time of the 
patients (Gao el al., 2010). Furthermore, miR-181a has been found to be a 
chemosensitizer, enhancing the lethality of various chemotherapeutic agents, such as 
cisplatin, carboplatin, and oxaliplatin, in several NSCLC, by stimulating Bax 
oligomerization and activation of the pro-apoptotic caspases (Galluzi et al., 2010).  
In a study carried out by Pan and colleagues in 2009, it was found that the 
expression of miR-328 was inversely related to the ATP-binding cassette, subfamily G, 
member 2 (ABCG2) in human breast cancer cells. The breast cancer resistance protein 
BCRP/ABCG2 is an ATP-binding cassette member transporter that is expressed in 
humans, and controls absorption, distribution and clearance of various xenobiotics, 
including pharmaceutical agents, dietary carcinogens and conjugated metabolites (Mao 
and Unadkat, 2005; van Herwaarden and Schinkel, 2006; Vore and Leggas, 2008). 
Overexpression of this ABCG2 represents an important mechanism for multidrug 
resistance (Pan et al., 2009). It has been found that miR-328 negatively regulates the 
expression of ABCG2, and thus significantly increases drug sensitivity in cancer cells 
(Pan et al., 2009).  
While many studies have been carried out linking the dysregulated miRNAs 
with various cancers, studies on association of these miRNAs with apoptosis in lung 
adenocarcinoma are still lacking. Therefore, this study is essential as it aims to develop 
a hypothetical pathway model that relates these miRNAs with the apoptotic pathways in 
the lung adenocarcinoma cell line. 
 128 
5.2.2 qRT-PCR Validation  
 
To warrant the accuracy of the microarray analysis, qRT-PCR validation with 
the same RNA preparations used in microarray analysis was carried out. Five 
representative miRNAs were selected to undergo qRT-PCR validation based upon the 
highest fold-change as well as preliminary putative cancer related targets identified 
using the TargetScan Human v5.2 database. These five miRNAs were miR-181a, miR-
769-5p, miR-361-5p, miR-1304 and miR-608. cDNA was first prepared by miRNA 
specific primers and then real-time quantification RT-PCR for these miRNAs and an 
endogenous control (RNU6B) were performed on the BioRad CFX96
™
 Real-Time PCR 
Detection System. RNU6B is a widely used endogenous reference RNA in miRNA 
quantification experiments because RNU6B is not affected under the experimental 
conditions and shows a constant level of expression and similar abundance to the target 
miRNA.  
 Results of the qRT-PCR indicated that miR-181a, miR-769-5p, miR-36105p 
were all down-regulated in siRNA-transfected A549 cells when compared to non-
transfected A549 cells, while miR-608 was up-regulated. The Pearson correlation plot 
was used to determine how well the miRNA microarray results correlated with the qRT-
PCR results. Pearson correlation coefficient measures the strength of the linear 
relationship between two random variables. The correlation coefficient takes on values 
between -1 and +1, ranging from being negatively correlation (-1) to uncorrelated (0) to 
positively correlated (+1) (Zuo et al., 2003).  These data from miRNA microarray and 
qRT-PCR had a correlation coefficient of +0.950 indicating that the two sets of data 
were strongly positively correlated  
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5.3 Hypothetical Pathway Analysis 
 
A bioinformatics analysis was then carried out on the five selected dysregulated 
miRNAs to determine their interaction with their putative gene targets. TargetScan 
Human v5.2 was used and predicted targets with total context score of <0 were then 
selected for gene-annotation enrichment analysis using DAVID v6.7. These miRNAs 
were found to be involved in various signaling pathways; primarily the intrinsic and 
extrinsic pathway, the PI3K/AKT pathway, the WNT pathway, the TGF- pathway and 
the MAPK pathway. Based on this, a hypothetical pathway illustrating the interactions 
between these miRNAs with their specific targets were generated describing the effects 
of bcl-xL silencing on initiation of apoptosis in A549 cells (Figure 4.25). If more than 
one miRNA targets a specific gene, the miRNA with the most favorable context score 
(the miRNA with the lowest number) was shown on the hypothetical pathway. 
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5.3.1 PI3K/Akt Pathway 
 
 
Figure 5.1: Hypothetical pathway model illustrating miRNA targets in the PI3K/Akt 
pathway. 
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The PI3K/Akt pathway is an important regulator of cell survival and 
proliferation in human cancers (Vivanco and Sawyers, 2002). An important target in 
this pathway is Akt, which plays a significant role in the activation of a number of 
processes critical for tumorigenesis including inhibition of apoptosis, aberrant cell 
proliferation, promotion of angiogenesis and tumor cell invasiveness (Testa and 
Bellacosa, 2001).  Akt exerts its anti-apoptotic properties through phosphorylation of 
Bad or caspase 9 (Cardone et al., 1998), which directly regulates the apoptotic 
machinery or substrates including the forkhead family members, or IκB kinases (Datta 
et al., 1997), which in turn can indirectly inhibit apoptosis (Kandasamy and Srivastava, 
2002).  
This study indicated that Akt was a target of two down-regulated miRNAs, hsa-
miR-769-5p and hsa-miR-181a. As miRNAs are negative gene regulators, genes 
targeted by down-regulated miRNAs would therefore be expected to increase in 
expression. PI3K, which activates AKT through phosphorylation, on the other hand was 
a target of up-regulated hsa-miR-608, thereby negatively regulating its expression levels 
and indirectly reducing the activation of Akt. Previously, phosphorylated Akt (p-Akt) 
was found to be overexpressed in clinical specimens of NSCLC leading to continued 
cell survival and proliferation (Tang et al., 2006). This increase in p-Akt expression was 
found to be significantly correlated with reduced patient survival (Tang et al., 2006; 
David et al., 2004). As Akt regulates the activity of various downstream transcription 
factors that control cell death genes (Brunet et al, 1999), the withdrawal of this survival 
factor, due to a decrease in PI3K levels, will lead to an increase in apoptosis. 
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For example, a dephosphorylated forkhead transcription factor (FKHR) targeted 
by down-regulated hsa-miR-361-5p, will now be able to translocate into the nucleus and 
induce target genes such as pro-apoptotic proteins Bim and Fas ligand to trigger 
apoptosis (Brunet et al., 1999). Similarly, dephosphorylation of murin double minute 2 
(Mdm2), a target of hsa-miR-1304, will inhibit its translocation into the nucleus thereby 
preventing degradation of tumor-suppressor p53 proteins (Honda and Yasuda, 2000; 
Kubbutat et al., 1997).  
However, pathway analysis also revealed that p53, which directly activates the 
pro-apoptotic gene Bax, was a target of up-regulated hsa-miR-608. A decrease in p53 
expression may affect the stabilization of the mitochondrial membrane (Amaral et al, 
2010). However, as the expression of other pro-apoptotic proteins such as Bak, were not 
found to be affected by miRNAs, cytochrome c can still be released leading to initiation 
of the caspase cascade (Cheng et al, 2001). 
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5.3.2 Intrinsic and Extrinsic Pathway 
 
 
Figure 5.2: Hypothetical pathway model illustrating miRNA targets in the intrinsic and 
extrinsic apoptotic pathway. 
 
The intrinsic apoptotic pathway, also termed mitochondrial pathway, is 
primarily regulated by the Bcl-2 family of proteins. The balance of expression of the 
various pro- and anti-apoptotic members of the Bcl-2 family is largely responsible for 
the apoptotic homeostasis in cells (Daniel and Smith, 2004). Previously, Bcl-xL 
overexpression in NSCLC was associated with an inhibition of apoptosis and poor 
prognosis in patients with this disease (Daniel and Smith, 2004; Soini et al., 1999). 
Antisense treatment targeting Bcl-xL in NSCLC cell has resulted result in apoptosis, 
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thus validating Bcl-xL as a potent target in cancer (Leech et al., 2000; Reeve et al., 
1996).  
Figure 5.2 illustrates the hypothetical network between the miRNAs and their 
gene targets in the intrinsic and extrinsic apoptotic pathway. Pathway analysis indicates 
that breakpoint cluster region/Abelson (BCR/Abl), STAT5 and Bcl-xL were all targeted 
by the up-regulated hsa-miR-608. BCR/Abl is an oncogene that is able to activate 
STAT5, which has been found to be increased in lung cancer cell lines, and was 
speculated to control the process of apoptosis through the upregulation of the anti-
apoptotic protein Bcl-xL (Gesbert and Griffin, 2000; Sánchez-Ceja et al., 2006). 
Therefore an inhibition of BCR/Abl, STAT5 and Bcl-xL by hsa-miR-608 would 
hypothetically lead to the reinforcement of apoptosis in A549 cells, through the release 
of cytochrome c and the activation of caspase 3, the main apoptosis effector. 
Furthermore, dephosphorylation of Akt as a result of decreased PI3K levels, will allow 
pro-apoptotic Bad to be released from Akt inhibition allowing it to form a heterodimer 
with anti-apoptotic Bcl-xL and Bcl-2, thus further promoting apoptosis (Datta et al., 
1997).  
In the extrinsic pathway, results reveal that all of the upstream genes that result 
in the activation of caspase 8 were exclusively targeted by down-regulated miRNAs 
(has-miR-181a and has-miR-79-5p), indicating an up-regulation in its expression. 
Active caspase-8 will result in downstream apoptotic processes that include the 
activation of pro-caspase-3 directly or amplification of its signal through Bid cleavage 
(Garrido et al., 2006). Truncated Bid will translocate into the mitochondria where it will 
promote the release of cytochrome c (Garrido et al., 2006), thus enabling an alternative 
pathway for apoptosis to occur in the A549 cells.  
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5.3.3 WNT Pathway 
 
 
Figure 5.3: Hypothetical pathway model illustrating miRNA targets in the WNT 
pathway. 
 
The WNT pathway mediates a variety of cellular processes including 
proliferation, differentiation, survival, apoptosis and cell motility (Willert and Jones, 
2006). The loss of regulation of any of these processes can lead to tumorigenesis, and 
the WNT pathway has been implicated in the development of various cancers including 
leukemia (Mikesch et al., 2007), colon (Jass et al., 2003), breast (Turashvili et al., 
2006), thyroid, prostate (Yardy and Brewster, 2005) and lung (Tennis et al., 2007). 
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Pathway analysis revealed that various members of the WNT pathway were also 
putative targets of the dysregulated miRNAs, including Wnt, frizzled (Fzd), dishevelled 
(Dsh) and adenomatous polyposis coli (APC) genes. Previously the overexpression of 
Dvl-3 has been found in NCLC tumors, leading to an activation of the WNT signaling 
in this disease (Uematsu et al., 2003; Mazieries et al., 2005; Tennis et al., 2007). An 
increase in the Dsh concentration results in β-catenin stabilization and accumulation in 
the cytoplasm. Accumulated β-catenin will translocate into the nucleus where it will 
bind with members of the TCF transcription family (Young et al., 1998), which will 
activate the transcription of various Wnt target genes including matrix 
metalloproteinases (MMP) (Tamamura et al., 2005), cyclin D1 (Shtutman et al., 1999), 
Cox-2 (Longo et al., 2002), c-Myc (He et al., 1998), c-Jun (Mann et al., 1999), VEGF 
(Zhang et al., 2001), and others. Thus, an increase in the β-catenin concentration will 
result in an increase in cell proliferation and growth, enhancing the tumorigenesis 
ability of the cell.  
An inhibition of Dsh and APC by up-regulated hsa-miR-608 will result in the 
subsequent inhibition of the glycogen synthase-kinase-3-beta (GSK-3β)/APC/Axin 
complex, which would prevent the phosphorylation of β-catenin and consequently 
decrease cell proliferation and cell growth in A549 cells.  Inhibition of Dsh will also 
lead to the obstruction of survivin activation, via inhibition of T-cell factor/lymphoid 
enhancer factor (TCF/LEF), thus allowing for caspase activation to proceed, reinstating 
the cell’s ability to carry out apoptosis (Uematsu et al., 2003; Mazieries et al., 2005; 
Tennis et al., 2007). Other targets of up-regulated hsa-miR-608 include the LEF, 
CDK4/6 and cyclin D1, further inhibiting the cells ability to proliferate through cell 
cycle arrest.   
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5.3.4 TGF-β Pathway 
 
 
Figure 5.4: Hypothetical pathway model illustrating miRNA targets in the TGF-β 
pathway. 
 
Alterations in the TGF-β signaling pathway have been linked to various human 
diseases including cancer. Studies have shown that the ligands along with its 
downstream elements, including its receptors and primary cytoplasmic signal 
transducers, as well as the Smad proteins are crucial for suppression of tumorigenesis in 
many tissue types (Markowitz and Roberts, 1996). In lung cancer studies, it has been 
found that TGF-β is frequently overexpressed, however the malignant transformation 
that occurs in lung cancer results in a loss of the tumor suppressor effects of TGF-β 
(Jeon and Jen, 2010). The loss of the tumor suppressor effects will promote cell 
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proliferation, tumor invasion and metastasis, and has therefore been strongly associated 
with tumor development or progression (Massagué 2008). Studies have also shown that 
in multiple lung cancer cell lines, in both small cell (Damstrup et al., 1992) and non-
small cell (Anumanthan et al., 2005), the expression of TGFBR 2 is reduced (Toonkel 
et al., 2010) allowing for the cancer cells to further circumvent the suppressive effects 
of TGF-β (Massagué, 2008). 
Referring to Figure 5.4 it can be seen that TGFBR 1/2, Smad 2/3/4 are all targets 
of down-regulated miRNAs (hsa-miR-181a, hsa-miR-769-5p and hsa-miR-361-5p) 
indicating that gene expression was increased thus allowing them to carry out their 
tumor suppressive activities.  Furthermore, with none of the p15 upstream proteins 
being inhibited by miRNAs, its presence will result in CDK inhibition and hypo-
phosphorylated retinoblastoma protein (pRb) accumulation, which is associated with 
early G1 phase arrest (Hannon and Beach, 1994; Reynisdottir et al., 1995; Hanahan and 
Weinberg, 2000). Therefore this would presumably inhibit lung cancer cells’ excessive 
proliferation and growth.  
Cell proliferation and growth activity would be further decreased by the 
inhibition of cyclin D, CDK4/6 and E2F by the up-regulated hsa-miR-608. Cell 
proliferation is regulated by protein complexes that are made up of cyclins and cyclin-
dependent kinases (CDKs) (Caputi et al., 1999). Cyclin D1 assembles with CDK4, and 
alternatively with CDK6, and this complex will enter the nucleus to phosphorylate 
retinoblastoma (Rb) proteins which would in turn promote the release of E2F 
transcription factors (Caputi et al., 1999; Kato et al., 1994). Cyclin D1 is involved in the 
regulation of the G1-to-S phase transition and is important for the restriction of cell 
growth (MacLachlan et al., 1995). Studies have shown that cyclin D1 is frequently 
amplified in lung carcinomas (Yang et al., 1996; Caputi et al., 1999), therefore an 
inhibition of this gene is thought to play a role in the decrease of cell proliferation and 
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tumorigenesis of lung cancer.    
 
5.3.5 MAPK Pathway 
 
 
Figure 5.5: Hypothetical pathway model illustrating miRNA targets in the MAPK 
pathway. 
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The ERK signaling pathway has been shown to play a role in several steps of 
tumor development. Mutations associated with cancer have been found in components 
of the ERK signaling pathway, mainly in Ras and B-Raf (Dhillon et al., 2007; Boutros 
et al., 2008). Mutations of K-Ras frequently occur in colon and lung cancer, mainly in 
adenocarcinoma (Graziano et al., 1999; Schubbert et al., 2007). K-Ras activation will 
lead to stimulation of various pathways, primarily the Raf-MEK-ERK pathway and the 
PI3K pathway, that consequently results in tumor cell growth and proliferation, 
apoptosis, metastasis, invasion and angiogenesis (Aviel-Ronen et al., 2006). Studies 
have shown that mutations in K-Ras have conferred poor prognosis and shorter overall 
survival in lung cancer patients (Slebos et al., 1990). 
K-Ras is activated when ligands bind to the receptor tyrosine kinases (RTKs) 
such as platelet-derived growth factor receptor (PDGFR), hepatocyte growth factor 
receptor (HGFR), and epidermal growth factor receptor (EGFR) (Molina and Adjei, 
2006). Mutations in EGFR have also been found to frequently occur in lung cancer, and 
have been associated with a worse prognosis in patients with NSCLC (Hynes and 
MacDonald, 2009). Activation of the receptors upon binding of ligands will trigger the 
signaling pathways through the Ras-MAPK, and PI3K/Akt pathway (Paez et al., 2004). 
Therefore a mutation in both EGFR and K-Ras will augment the tumorigenesis process 
in lung cancer cells. 
 Results indicate that both EGFR and Ras are targets of up-regulated hsa-miR-
608. Inhibition of EGFR may lead to a slight decrease in the activation of Grb, however 
there are other receptors that may still provide stimulation for Grb. Nonetheless, an 
inhibition of Ras by hsa-miR-608 would lead to a break in the activation of the ERK 
pathway, by preventing Raf activation, which in turn prevents the phosphorylation of 
MEK and ERK1/2 leading to a decrease in cell growth and proliferation. Even though 
MEK and ERK are targets of down-regulated miRNAs (hsa-miR-181a, hsa-miR-769-5p, 
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hsa-miR-361-5p and hsa-miR-1304), and assuming that their expression increased or 
did not change, they would not be able to carry out their tumorigenic functions, as 
upstream proteins would not be able to phosphorylate and activate them. Inhibition of 
EGFR by has-miR-608 would also prevent the activation of JAK thus disrupting 
angiogenesis in the lung cancer cells as well.   
 To further support the linkage between MAPK and Bcl-xL miRNA interactions, 
recent studies have revealed new mechanisms by which ERK1/2 pathway can control 
the activity of Bcl-2 family proteins to promote cell survival (Balmanno and Cook, 
2009). For example, ERK1/2 activation can repress the mRNA levels of the pro-
apoptotic protein BIM (Fu and Tindall, 2008). Therefore, coupled with repression of 
Ras, it can be assumed that the downstream proteins will no longer be activated, thus 
Bim degradation would be avoided, allowing it to carry out its functions which would 
hypothetically lead to the occurrence of apoptosis. 
 
5.4 Future Prospects 
 
MiRNAs are strongly associated with cancer development and progression and a 
deregulation of miRNA expression are often seen in cancer. Experimental studies have 
shown that targeting miRNA expression can modify cancer phenotypes, thus miRNAs 
have become targets of novel anticancer gene therapy. As the miRNA field continues to 
evolve and develop it is important to gain a better understanding of miRNA biogenesis 
and function, as it will certainly affect the development of these miRNA-based therapies. 
While miRNAs as a target for cancer treatment has great potential, there are many 
challenges that must still be overcome. Major challenges for developing miRNA-based 
therapeutics may include issues of delivery, potential off-target effects as well as long-
term safety concerns in humans (Garzon et al., 2010). The chemical design of the 
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antisense and miRNA mimics must be improved as well as developing new delivery 
methods to overcome issues such as cellular uptake of the synthetic oligonucleotides to 
achieve target inhibition. Pharmacokinetic and pharmacodynamics studies will also 
have to be carried out to ensure that the desired miRNA concentrations are achieved in 
tissues and that targets are down-regulated (Garzon et al., 2010). Generally, the idea of 
targeting miRNAs to reprogramme miRNA networks in cancer has a strong potential 
and chance for success.  
In summary, this study describes the successful determination of miRNAs 
dysregulated in response to bcl-xL silencing in A549 adenocarcinoma NSCLC cells, 
with the aim to elucidate the hypothetical pathway these dysregulated miRNAs may be 
involved in to affect the induction of apoptosis. The identification of 10 significantly 
dysregulated miRNAs were linked to several apoptotic signaling pathways, using the 
TargetScan software, including the PI3K/AKT, intrinsic and extrinsic, WNT, TGF-β, 
and ERK pathway, and were all implicated as those directly affected by bcl-xL levels. 
However as many drawbacks exist in using only one target prediction software, in the 
future a comparison should be carried out using other miRNA targeting softwares such 
as PicTar and miRANDA. Furthermore, studies should also be carried out in other types 
of lung adenocarcinoma cell lines to investigate the similarity in the pattern of 
expression of dysregulated miRNAs when bcl-xL expression has been ectopically 
suppressed.  
With further studies carried out to determine the specific functions of these 
dysregulated miRNAs, this study has provided a platform for antisense treatment 
whereby miRNA expression can be exploited to increase the apoptotic properties in 
lung adenocarcinoma cells.  
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CHAPTER 6: CONCLUSION 
 
The main purpose of this entire study was to determine miRNAs dysregulated in 
response to bcl-xL silencing in A549 cells, with the aim to elucidate the hypothetical 
pathway these dysregulated miRNAs may be involved in to affect the apoptotic 
properties in lung adenocarcinoma. siRNA transfection in A549 cells decreased the bcl-
xL expression at both the gene and protein levels and miRNA microarray analysis 
determined the differential miRNA expression profile between bcl-xL silenced and non-
silenced cells, with the identification of ten significantly dysregulated miRNAs (hsa-
miR-181a, hsa-miR-769-5p, hsa-miR-10b, hsa-miR-361-5p, hsa-miR-1304, hsa-miR-
328, hsa-miR-99a, hsa-miR-130a, hsa-miR-768-3p, and hsa-miR-608). These ten 
dysregulated miRNAs were linked to several apoptotic signaling pathways including the 
PI3K/AKT, intrinsic and extrinsic, WNT, TGF-β, and ERK, and all were implicated as 
those directly affected by bcl-xL levels. It was therefore concluded that these miRNAs 
may play a significant role in inducing apoptosis in lung adenocarcinoma cells and may 
potentially be used as an antisense treatment in lung adenocarcinomas. 
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APPENDICES 
 
Appendix 1: Solutions and Formulations 
 
i) Roswell Park Memorial Institute 1640 (RPMI 1640) 
 
To prepare 250ml of Roswell Park Memorial Institute 1640 (RPMI 1640) culture media 
supplemented with heat inactivated 10% (v/v) fetal bovine serum (FBS), 25mL of FBS 
was added into a sterile autoclaved bottle and mixed with 225ml of sterile RPMI 1640, 
and stored at 4°C.  
 
ii) 1Phosphate-Buffered Saline (PBS) 
 
To prepare 1 liter of 1×PBS solution (pH 7.4), 100ml of premixed 10× calcium- and 
magnesium-free (CMF) PBS (Mediatech, USA) was added to a sterile autoclaved bottle 
and topped up with distilled water to 1 liter.  The 1×PBS was then autoclaved at 121°C, 
15psi for 45 minutes and then stored at room temperature.  
 
iii) 0.1% (v/v) Trypsin-0.53mM EDTA 
 
98mg of ethylenediaminetetracetic acid (EDTA) (GibcoBRL, USA) was dissolved in 
500ml of 1×PBS to prepare 1×PBS-0.53mM EDTA. The solution was then autoclaved 
at 121°C, 15psi for 45 minutes and stored at room temperature. 100ml of 0.1% (v/v) of 
trypsin solution was prepared by mixing 4ml of 2.5% (v/v) trypsin (Sigma-Aldrich, 
USA) with 96ml of sterile 1×PBS-0.53mM EDTA, and then stored at room temperature.  
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iv) Diethyl pyrocarbonate (DEPC)-treated water 
 
1L of 0.1% (v/v) DEPC-treated water was prepared by adding 1ml of DEPC (Merck, 
Germany) to 1 liter of distilled water. The solution was mixed well by shaking and left 
at room temperature overnight prior to being autoclaved at 121°C, 15psi for 45 minutes, 
and then stored at room temperature.  
 
v) 1Tris/Borate/EDTA (TBE) electrophoresis buffer 
 
1L of 1×TBE was prepared by mixing 100ml of 10×Tris/Boric Acid/EDTA (Bio-Rad, 
USA) with 900ml of DEPC-treated water and was then stored at room temperature.  
 
vi) 1% (w/v) agarose gel 
 
A 1% (w/v) agarose gel was prepared by dissolving 400mg of agarose powder (Fisher 
Scientific, USA) in 40ml of 1×TBE electrophoresis buffer. The solution was boiled to 
allow for the solution to be completely dissolved.  The molten gel was poured into a 
casting tray with a comb and left at room temperature to allow for complete 
polymerization.  
 
vii) Ethidium bromide (EtBr) solution 
 
10mg/ml of stored EtBr (Sigma-Aldrich, USA) was diluted to 0.5μg/ml in DEPC-
treated water, and stored at room temperature.  
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viii) 2.0% (w/v) Bis-acrylamide 
 
2 grams of bisacrylamide powder (Promega, USA) was added to a sterile autoclaved 
bottle and topped up to 100ml with ultra-pure water.  
 
ix) 0.5M Tris-HCl, pH 6.8 
 
200ml of 0.5M Tris-HCl was prepared by dissolving 12.1 grams of Tris Base powder 
(Promega, USA) in 100ml of ultra-pure water. The pH of the solution was adjusted to 
6.8 with hydrogen chloride (HCl) and the total volume brought up to 200ml.  
 
x) 1.5M Tris-HCl, pH 8.8 
 
200ml of 1.5M Tris-HCl was prepared by dissolving 36.6 grams of Tris Base powder in 
100ml of Ultra-pure water. The pH of the solution was adjusted to 8.8 with HCl and the 
total volume brought up to 200ml.  
 
xi) 10% (w/v) Sodium Dodecyl Sulfate (SDS) 
 
10 grams of SDS powder (Promega, USA) was added to a sterile autoclaved bottle and 
topped up to 100ml with ultra-pure water, and then stored at room temperature.  
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xii) 10% (w/v) Ammonium Persulfate (APS) 
 
10% APS was prepared fresh each time in a microcentrifuge tube. 10mg APS (Pierce, 
USA) was dissolved in 100μl of distilled water. The solution was mixed well using a 
vortex.  
 
xiii) Transfer buffer (1TGS + 10% MeOH (v/v)) 
 
500ml of transfer buffer was prepared by mixing 100ml of methanol (Merck, Germany) 
with 40ml of premixed 10×TGS buffer (Merck, Germany) and topped up to 500ml with 
distilled H2O. 
 
xiv) 1Tris/Glycine/SDS (TGS) buffer 
 
1L of 1×TGS buffer was prepared by diluting 100ml of premixed 10×TGS buffer 
(Merck, Germany) with 900ml of distilled water.  
 
xv) Blocking buffer 
 
Blocking buffer for phosphorylated protein (blocking buffer A) consisted of 5.0% (w/v) 
non-fat skim milk powder (Merck, Germany), 0.05% (v/v) Tween20 (Promega, USA) in 
1×TBS. Blocking buffer for non-phosphorylated proteins (blocking buffer B) consisted 
of 5.0% Bovine Serum Albumin (BSA) (Calbiochem, USA), 0.05% Tween 20 and 
1×TBS.  
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xvi) 1Tris-buffered saline-0.05% (v/v) Tween20 (TBST) buffer 
 
To prepare 1L of 10×TBST buffer the following were mixed together: 12.11g of Tris 
Base powder, 87.66g of sodium chloride (NaCl) (Merck, Germany), 5.0ml of Tween20, 
and 800ml of distilled water. The solution was adjusted with 1N of HCl (Merck, 
Germany) to pH7.6 and then topped up with distilled water to 1L. 100ml of 10×TBST 
was diluted with 900ml of distilled water to prepare 1L of 1×TBST.  
 
xvii) 1Tris-buffered saline (TBS) buffer 
 
To prepare 1L of 10×TBS buffer the following were mixed together: 12.11g of Tris 
Base powder, 87.66g of NaCl, and 800ml of distilled water. The solution was adjusted 
with 1N of HCl to pH 7.6, and then topped up with distilled water to 1L. 100ml of 
10×TBS was diluted with 900ml of distilled water to prepare 1L of 1×TBS.  
 
xviii) MTT reagent 
 
MTT reagent was prepared by adding 50.0mg of MTT (Calbiochem, USA) to 10.0ml of 
1× CMF-PBS. The reagent was shaken vigorously and vortexed to ensure that the MTT 
granules were completely dissolved. MTT working solutions were stored in the dark at 
room temperature (25°C), and the MTT stock was stored in the dark at 4°C. The final 
concentration of MTT working solution in the MTT cell viability assay was 5mg/ml.  
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Appendix 2: Molecular Markers 
 
i) RNA Molecular Weight Marker - RiboRuler™ High Range RNA Ladder with 
200-6000 bases as reference sizes 
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ii) Protein Ladder 
 
Spectra™ Multicolor Broad Range Protein Ladder consisted of ten pre-stained sized 
recombinant proteins molecular weight 260, 135, 95, 72, 52, 42, 34, 26, 17 and 10kDa.  
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The Biotinylated Protein Ladder (Cell Signaling Technology, USA) consisted of 10 
proteins ranging in apparent molecular weights from 9 to 200kDa. 
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Appendix 3: siRNA Binding Site 
 
siRNA binding sites on Homo sapiens Bcl-xL, nuclear gene encoding mitochondrial 
protein, transcript variant 1, mRNA. The sequence identity of all three siRNAs to the 
bcl-xL mRNA was 100%. 
 
   1 ggaggaggaa gcaagcgagg gggctggttc ctgagcttcg caattcctgt gtcgccttct 
  61 gggctcccag cctgccgggt cgcatgatcc ctccggccgg agctggtttt tttgccagcc 
 121 accgcgaggc cggctgagtt accggcatcc ccgcagccac ctcctctccc gacctgtgat 
 181 acaaaagatc ttccgggggc tgcacctgcc tgcctttgcc taaggcggat ttgaatctct 
 241 ttctctccct tcagaatctt atcttggctt tggatcttag aagagaatca ctaaccagag 
 301 acgagactca gtgagtgagc aggtgttttg gacaatggac tggttgagcc catccctatt 
 361 ataaaaatgt ctcagagcaa ccgggagctg gtggttgact ttctctccta caagctttcc 
 421 cagaaaggat acagctggag tcagtttagt gatgtggaag agaacaggac tgaggcccca 
 481 gaagggactg aatcggagat ggagaccccc agtgccatca atggcaaccc atcctggcac 
 541 ctggcagaca gccccgcggt gaatggagcc actggccaca gcagcagttt ggatgcccgg 
 601 gaggtgatcc ccatggcagc agtaaagcaa gcgctgaggg aggcaggcga cgagtttgaa 
 661 ctgcggtacc ggcgggcatt cagtgacctg acatcccagc tccacatcac cccagggaca 
 721 gcatatcaga gctttgaaca ggtagtgaat gaactcttcc gggatggggt aaactggggt 
 781 cgcattgtgg cctttttctc cttcggcggg gcactgtgcg tggaaagcgt agacaaggag 
 841 atgcaggtat tggtgagtcg gatcgcagct tggatggcca cttacctgaa tgaccaccta 
 901 gagccttgga tccaggagaa cggcggctgg gatacttttg tggaactcta tgggaacaat 
 961 gcagcagccg agagccgaaa gggccaggaa cgcttcaacc gctggttcct gacgggcatg 
1021 actgtggccg gcgtggttct gctgggctca ctcttcagtc ggaaatgaccagacactgac 
1081 catccactct accctcccac ccccttctct gctccaccac atcctccgtccagccgccat 
1141 tgccaccagg agaaccacta catgcagccc atgcccacct gcccatcacagggttgggcc 
1201 cagatctggt cccttgcagc tagttttcta gaatttatca cacttctgtgagacccccac 
1261 acctcagttc ccttggcctc agaattcaca aaatttccac aaaatctgtccaaaggaggc 
1321 tggcaggtat ggaagggttt gtggctgggg gcaggagggc cctacctgattggtgcaacc 
1381 cttacccctt agcctccctg aaaatgtttt tctgccaggg agcttgaaagttttcagaac 
1441 ctcttcccca gaaaggagac tagattgcct ttgttttgat gtttgtggcctcagaattga 
1501 tcattttccc cccactctcc ccacactaac ctgggttccc tttccttccatccctacccc 
1561 ctaagagcca tttaggggcc acttttgact agggattcag gctgcttgggataaagatgc 
1621 aaggaccagg actccctcct cacctctgga ctggctagag tcctcactcccagtccaaat 
1681 gtcctccaga agcctctggc tagaggccag ccccacccag gagggagggggctatagcta 
1741 caggaagcac cccatgccaa agctagggtg gcccttgcag ttcagcaccaccctagtccc 
1801 ttcccctccc tggctcccat gaccatactg agggaccaac tgggcccaagacagatgccc 
1861 cagagctgtt tatggcctca gctgcctcac ttcctacaag agcagcctgtggcatctttg 
1921 ccttgggctg ctcctcatgg tgggttcagg ggactcagcc ctgaggtgaaagggagctat 
1981 caggaacagc tatgggagcc ccagggtctt ccctacctca ggcaggaagggcaggaagga 
2041 gagcctgctg catggggtgg ggtagggctg actagaaggg ccagtcctgcctggccaggc 
2101 agatctgtgc cccatgcctg tccagcctgg gcagccaggc tgccaaggccagagtggcct 
2161 ggccaggagc tcttcaggcc tccctctctc ttctgctcca cccttggcctgtctcatccc 
2221 caggggtccc agccaccccg ggctctctgc tgtacatatt tgagactagtttttattcct 
2281 tgtgaagatg atatactatt tttgttaagc gtgtctgtat ttatgtgtgaggagctgctg 
2341 gcttgcagtg cgcgtgcacg tggagagctg gtgcccggag attggacggcctgatgctcc 
2401 ctcccctgcc ctggtccagg gaagctggcc gagggtcctg gctcctgaggggcatctgcc 
2461 cctcccccaa cccccacccc acacttgttc cagctctttg aaatagtctgtgtgaaggtg 
2521 aaagtgcagt tcagtaataa actgtgttta ctcagtgaaa aaaaaaaaaa aaaaa 
 
 siRNA 1 – HSS141361  siRNA 2 – HSS141362  siRNA 3 – HSS141363 
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i) siRNA 1 transfection efficiency 
 
 
 
 
 
Appendix 4: siRNA Transfection Efficiency 
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ii) siRNA 2 transfection efficiency 
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iii) siRNA 3 transfection efficiency 
 
 
 
 
 
 
 
84.5% 
90.4% 
79.8% 
84.0% 
83.2% 
87.6% 
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iv) siRNA 1 biological replicate 1 transfection efficiency 
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v) siRNA 1 biological replicate 2 transfection efficiency 
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vi) siRNA 1 biological replicate 3 transfection efficiency 
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Appendix 5: qRT-PCR Melting Curve Analysis 
 
i) Melting curve analysis for target gene, bcl-xL, samples siRNA 1-3 
 
 No Transfection 
 Hi GC NC 
 Lo GC NC 
 siRNA 1 
 siRNA 2 
 siRNA 3 
 No Template 
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 ii) Melting curve analysis for normalizer gene, β-actin, samples siRNA 1-3. 
 
 No Transfection 
 Hi GC NC 
 Lo GC NC 
 siRNA 1 
 siRNA 2 
 siRNA 3 
 No Template 
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iii) Melting curve analysis for target gene, bcl-xL, sample siRNA 1 
 
 No Transfection 
 Lo GC NC 
 siRNA 
 No Template 
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iv) Melting curve analysis for normalizer gene, β-actin, samples siRNA 1 
 
 No Transfection 
 Lo GC NC 
 siRNA 
 No Template 
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Appendix 6: qRT-PCR Quantification Data 
 
i) qRT-PCR quantification data for siRNA 1-3 
 Replicate 
Experimental 
(Bcl-xL) 
Endogenous  
(β-actin) 
CT† CT† 
NTC 
1 22.4 16.82 
2 22.11 16.91 
3 21.48 16.52 
siRNA 1 
1 24.17 17.01 
2 23.97 16.72 
3 23.48 15.95 
siRNA 2 
1 22.4 15.73 
2 22.4 15.86 
3 23.24 17.19 
siRNA 3 
1 22.82 16.69 
2 22.77 16.61 
3 22.25 16.61 
Hi GC NC 
1 21.89 16.68 
2 21.44 16.4 
3 21.37 16.66 
Lo GC NC 
1 22.06 16.4 
2 21.65 16.37 
3 21.56 16.09 
† CT = Cycle Threshold 
 
ii) qRT-PCR quantification data for siRNA 1, replicates 1-3 
† CT = Cycle Threshold 
 
 
 Replicate 
Experimental 
(Bcl-xL) 
Endogenous  
(β-actin) 
CT† CT† 
NTC 
1 24.14 18.99 
2 24.06 18.79 
3 24.04 18.6 
siRNA 
1 21.45 13.8 
2 21.58 14.27 
3 21.44 13.55 
Lo GC NC 
1 19.91 14.32 
2 19.95 14.4 
3 19.66 13.86 
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iii) qRT-PCR quantification data for validated miRNAs 
MicroRNA Sample Replicate 
Experimental 
(MicroRNA) 
CT† 
Endogenous 
(U6) 
CT† 
Hsa-miR-181a 
siRNA-
Transfected 
1 30.03 32.36 
2 30.45 32.50 
3 30.21 32.25 
Non-
Transfected 
1 29.15 33.17 
2 29.55 32.53 
3 30.21 32.72 
Hsa-miR769-5p 
siRNA-
Transfected 
1 31.46 32.25 
2 31.63 32.36 
3 31.14 32.50 
Non-
Transfected 
1 31.13 32.53 
2 30.22 32.72 
3 30.58 33.17 
Hsa-miR-361-5p 
siRNA-
Transfected 
1 32.01 30.96 
2 31.63 30.40 
3 31.54 30.38 
Non-
Transfected 
1 31.33 30.42 
2 31.27 30.39 
3 31.23 30.23 
Hsa-miR1304 
siRNA-
Transfected 
1 35.64 30.96 
2 35.56 30.38 
3 35.26 30.40 
Non-
Transfected 
1 34.87 30.42 
2 34.64 30.39 
3 34.6 30.23 
Hsa-miR-608 
siRNA-
Transfected 
1 34.53 30.96 
2 34.28 30.40 
3 34.05 30.38 
Non-
Transfected 
1 36.05 30.42 
2 35.90 30.39 
3 35.53 30.23 
† CT = Cycle Threshold 
 
 
 
